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PROJECT SUMMARY 
Medication non-adherence and non-persistence in type 2 diabetes (T2D) are common and associated with poor 
outcomes. Medication attributes have a major influence on adherence in chronic disease but it is not clear which 
medication classes are associated with better adherence and persistence in T2D.  
A systematic review and cohort analyses of comparative adherence and persistence across medication classes 
in T2D was performed. MEDLINE, Embase, The Cochrane Library, The Cochrane Register of Controlled Trials, 
PsycINFO, and CINAHL were searched for studies comparing class adherence and persistence. Where n>5 studies 
provided the same comparison a meta-analysis was performed. Retrospective cohort analyses used the Royal 
College of General Practitioners Research and Surveillance database to compare adherence and persistence with 
oral medications. 
The systematic review synthesised 66 studies (38 in meta-analyses). Adherence was better with 
thiazolidinediones (TZDs) and sulphonylureas than metformin. TZDs had slightly better adherence than 
sulphonylureas. Limited data suggest low adherence with alpha-glucosidase inhibitors (AGIs) and meglitinides. 
Insulin analogues had longer persistence than GLP1 analogues and human insulins. There was little data on 
comparative persistence with oral medications and adherence with injectable medications. Adherence and 
persistence were measured in cohorts of 60,327 and 145,546 people with T2D respectively (55,728 and 76,593 
oral medications). After adjustment in regression models metformin and SGLT2 inhibitors had the longest 
persistence, AGIs and meglitinides the shortest. TZDs, DPP4 inhibitors, and SGLT2 inhibitors had the highest 
adherence, and metformin, AGIs and meglitinides the lowest. Sulphonylureas had intermediate adherence and 
persistence. Younger age, female gender, and non-white ethnicity were also associated with reduced 
persistence and adherence. 
Adherence and persistence vary considerable between classes of medication for T2D. Class switching may 
improve adherence in people with low adherence e.g. metformin to DPP4 inhibitors. Pre-emptive selection of 
classes which promote adherence in those with non-adherence risk factors may also improve outcomes. 
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EXTENDED SUMMARY 
BACKGROUND: 
There are a wide range of medications available for the management of type 2 diabetes (T2D); including two 
new classes of oral agent and one new class of injectable therapy. However, despite this array of treatment 
options many people with T2D fail to achieve glycaemic control targets resulting in the development of 
microvascular and other complications. Whilst the efficacy of available medications has been demonstrated in 
clinical trials clinical effectiveness may be limited by real-world factors. Adherence and persistence with 
medication are key components of clinical effectiveness and differ in the real-world setting compared with that 
of clinical trials; where non-adherence will often result in exclusion. Non-adherence is associated with worse 
diabetes outcomes and increased healthcare costs overall. Whilst multiple factors contribute to non-adherence, 
medication related factors are a major contributor. It has been reported that levels of medication adherence in 
T2D are low it is not clear which diabetes therapies have the highest levels of adherence. Knowledge of 
comparative medications adherence may facilitate class switching or initial selection and improve overall 
adherence. 
AIMS: 
Primary aim: 
• To compare adherence and persistence between different classes of diabetes medication 
Secondary aims: 
• To quantify adherence and persistence with diabetes medications in the real-world setting 
• To identify other predictors of non-adherence or persistence with therapies in the UK population 
DESIGN AND SETTING:  
This project consists of two strands: Firstly, a systematic review and meta-analysis of the existing literature on 
the comparative adherence and persistence to medications in people with T2D. Secondly, an exploration of a 
large real-world dataset to quantify medication adherence and persistence, provide a comparison of these 
across different medication classes, and to identify other predictors/associations with medication adherence (or 
non-adherence). Data from the Royal College of General Practitioners Research and Surveillance Centre (RCGP 
RSC) will provide the real-world evidence dataset. This comprises all coded clinical data from over 150 primary 
care practices across the UK: with data from over 2 million patients.  
METHOD: 
The systematic review was undertaken in accordance to the methods recommended by the Cochrane 
collaboration and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) and Meta-analysis Of Observational Studies in Epidemiology (MOOSE) reporting guidelines. 
Literature proving a comparison of medication adherence or persistence between two or more classes of 
medication in people with T2D was identified using a comprehensive prespecified search method. The databases 
searched comprised; MEDLINE, Embase, The Cochrane Library, The Cochrane Register of Controlled Trials, 
PsycINFO, and CINAHL. Data was extracted into a preformatted database. Where several studies (n≥5) provided 
the same comparison a meta-analysis was performed. Depending on the measure combined in the meta-
analyses the pooled results are reported as either the mean difference (MD) in the adherence estimate, odds 
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ratio (OR), or hazard ratio (HR) for adherence/non-persistence. Results of random effects meta-analysis are 
reported with 95% confidence intervals (CI). 
The comparative analysis of medication persistence and adherence was undertaken using a large cohort of 
people with T2D from the RCGP RSC. This cohort of people with T2D was identified for analysis using a clinical 
informatics ontology to correct for possible misdiagnosis, misclassification, and miscoding of diabetes. 
Medication non-persistence was defined as a prescription gap > 90 days. Medication adherence was defined 
using the proportion of days covered (PDC) during a one year period (2016). Medication directions are recorded 
in the database as free text. These directions were processed, to calculate the PDC, using an algorithm devised 
using an iterative process on a sample of 500 free text directions and manually verified on a further 200 
directions. Cox proportional hazards modelling was used to identify the differential impact of medication class 
on persistence after adjusting for known confounders of persistence. Linear and logistic regression models were 
used to identify the impact of medication class on the PDC (percentage of days) and the odds of adherence 
(PDC>80%) respectively, after adjusting for known confounders of adherence. Model selection was performed 
using backwards stepwise elimination of variables and model assumptions were tested using standard 
regression diagnostics. 
RESULTS: 
From 4,466 identified records, 66 studies were included in the systematic review with 38 suitable for meta-
analyses. Compared with metformin, mean adherence (%) was better for sulfonylureas (n=6; MD 14.8%; 95% CI 
8.0-21.7%; p<0.0001) and thiazolidinediones (TZDs) (n=7; MD 15.0%; 95% CI 2.8-27.3%; p=0.016). TZD mean 
adherence was marginally better than sulfonylureas (n=6; MD 1.68%; 95% CI 0.4-3.0%; p=0.012). When reported 
as the OR for non-adherence there were no significant differences between metformin, sulphonylureas, or TZDs. 
DPP4 inhibitors were almost universally reported to have better adherence than sulfonylureas and TZDs 
although meta-analysis was not possible. Limited data suggests meglitinides and alpha-glucosidase inhibitors 
(AGIs) have poor adherence and SGLT2 inhibitors have good persistence. GLP1 receptor agonists had lower 
adherence than DPP4 inhibitors and SGLT2 inhibitors and a higher OR for discontinuation compared with long 
acting analogue insulins (n=17; OR for discontinuation 1.81; 95% CI 1.41-2.33; p<0.0001). Long acting insulin 
analogues had better persistence than human insulins (n=5; HR for discontinuation 0.80; 95%CI 0.74-0.87; 
p<0.0001). Methods for defining adherence and persistence were highly variable with a high degree of 
heterogeneity in all meta-analyses. 
Two slightly different datasets were used for the analysis of medications persistence and adherence; extracted 
from the RCGP database in January 2016 and December 2016 respectively. For the persistence analysis 60,327 
adults with T2D were identified. The majority 42,810 (70.9%) of people had one or more oral medications 
prescribed. Persistence was measured with 55,728 oral medications. Metformin had the longest median 
persistence (3.04 years; 95% CI 2.94-3.12). The adjusted hazard ratios for non-persistence compared with 
metformin were: TZDs HR 1.71 (95% CI 1.64-1.77), sulfonylureas HR 1.20 (1.16-1.24), DPP4 inhibitors HR 1.43 
(1.38-1.49), SGLT2 inhibitors HR 1.04 (0.93-1.17), meglitinides HR 2.25 (1.97-2.58), and AGIs HR 2.45 (1.98-3.02). 
Other factors associated with reduced medication persistence included female gender, younger age, and non-
white ethnicity. The largest effect sizes were for age and medication class. 
For the adherence analysis 145,546 adults with T2D were identified. Adherence was calculated for 76,593 oral 
medications within this cohort over a year (2016). The median level of adherence (PDC) was 95.1% (interquartile 
range [IQR]: 78.9-100.0%). DPP4 inhibitors had the highest crude adherence; median PDC 97.0% (IQR: 84.4-
100.0%) and alpha-glucosidase inhibitors (AGIs) the lowest; median PCD 93.2% (IQR: 82.2-100.0%). After 
adjusting for confounders, the adherence (PDC>80%) was better than metformin for TZDs (OR 1.65; 95% CI 1.44 
to 1.88), sulphonylureas (1.15; 1.09 to 1.21), DPP4 inhibitors (1.43; 1.34 to 1.52), and SGLT2 inhibitors (1.47; 
1.31 to 1.66). There was no significant difference in adherence when compared with metformin for AGIs (1.32; 
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0.73 to 2.38) or meglitinides (1.05; 0.66 to 1.66). Other factors associated with reduced adherence included 
younger age, female gender, non-white ethnicity, and higher socioeconomic deprivation. Linear regression 
models showed the same adherence trends but failed regression diagnostic tests. The largest effect sizes were 
for age, ethnicity, and medication class. 
ACADEMIC OUTPUTS: 
This work has produced five peer review publications and six conference presentations, posters, and abstracts 
related to the primary outcomes of the project. Nine other related publications and 16 conference 
presentations, posters, and abstracts were also produced during the research tenure. Additional manuscripts 
are under peer review, in press or preparation at the time of writing. 
CONCLUSIONS: 
Medication adherence and persistence vary substantially between different medication classes. The between 
class effect size for persistence and adherence is large making medication class one of the key predictor of 
treatment adherence in T2D. For oral medications the best adherence rates were for TZDs, DPP4 inhibitors, and 
SGLT2 inhibitors and the longest persistence was with metformin, DPP4 inhibitors, and SGLT2 inhibitors (with 
limited duration data). The lowest adherence and persistence was seen with AGIs and meglitinides. Medication 
class switching in people who are non-adherent may improve adherence and therefore potentially improve long-
term outcomes. Pre-emptive selection of medications which promote higher adherence in people with risk 
factors for poor adherence (younger, female, or non-white ethnicity) may also lead to better adherence.
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1 BACKGROUND 
In this section I provide a rationale for exploration of medications non-adherence in type 2 diabetes (T2D) and, 
in particular, the importance of comparing medication adherence across the classes of therapies available to 
treat T2D. I initially describe the rapidly increasing global burden of T2D, the importance of glycaemic control 
and the current suboptimal levels of achievement of glycaemic targets. I then describe the widespread problem 
of medications non-adherence in chronic disease and T2D specifically regarding the impact of non-adherence 
on patient outcomes. I outline the factors associated with non-adherence and highlight the possible role of 
medication class switching as an option for improving adherence in T2D. This is done in the context of an 
established behaviour change framework; the behaviour change wheel. 
1.1 THE GLOBAL BURDEN OF DIABETES AND IMPORTANCE OF GLYCAEMIC CONTROL 
The proportion of people with diabetes has been increasing dramatically over the last three decades.1 The World 
Health Organisation (WHO) estimates there are now 422 million people globally with T2D.2 Most alarmingly, the 
current rate of increase has substantially outstripped estimates made just over a decade ago.3 The changes in 
diet and lifestyle resulting from globalisation are major factors driving these trends.4 5 Analysis during the 1970s 
of the Framingham study firmly demonstrated that T2D is a major risk factor for macrovascular disease (including 
myocardial infarction and stroke), and studies since have demonstrated that macrovascular risk increases with 
worsening glycaemic control.6 7 Diabetes is also associated with an increased risk of microvascular disease which 
includes diabetic retinopathy, neuropathy, and renal disease.8 This microvascular damage means that diabetes 
a leading cause of blindness in adults, and a major cause of end-stage renal disease.9 10 
The first large scale trial to investigate the role of glucose lowering on microvascular and macrovascular 
outcomes was the UK Prospective Diabetes Study (UKPDS).11 This randomised controlled trial of glucose lowering 
demonstrated both microvascular and macrovascular (after a substantial delay) risks can be reduced by glucose 
lowering.12 13 Subsequently, three trials were undertaken to explore the impact of further improvements in 
glycaemic control on cardiovascular outcomes; the Action to Control Cardiovascular Risk in Diabetes (ACCORD) 
trial, the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) 
trial, and the Veterans Affairs Diabetes Trial (VADT). All three trials randomised people to glycated haemoglobin 
(HbA1c) targets of <6.0% (<42.1mmol/mol) or <6.5% (<47.5mmol/mol). The ACCORD trial was terminated early 
due to an excess of deaths in the intensive control group.14 The ADVANCE trial and VADT both found no 
differences in cardiovascular events or death between the trial arms.15 16 A large observational study using the 
UK General Practice Research Database, of 47,970 people with T2D aged 50 and over, found a U-shaped 
relationship between HbA1c and all-cause mortality; both high and low HbA1c were associated with increased 
mortality.17  
Combined, these data suggest that aiming for a level of glycaemic control around 7.0% (53.0mmol/mol) is 
optimal for most people with diabetes. This is the primary target recommended in diabetes guidelines produced 
by the American Diabetes Association (ADA), the European Society for the Study of Diabetes (EASD), the National 
Institute for Health and Clinical Excellence (NICE).18-20 These guidelines also suggest that this target should be 
reduced in those with early disease, long life expectancy and no diabetes complications and increased in those 
who are elderly, have short life expectancy, or multiple established diabetes complications.18-20 
Other diabetes related complications have been demonstrated to be associated with glycaemic control, in 
addition to microvascular and macrovascular disease. Hyperglycaemia is associated with multiple infections 
types21 including pneumonia, skin and soft tissue infections, urinary tract infections, genital infections, and 
conjunctivitis.22-24 Hyperglycaemia is also associated with reduced cognitive performance, and dementia.25 26 
Improved glycaemic control may also have a beneficial impact on these conditions. 
MD thesis| Medication use and adherence in type 2 diabetes 
15 
 
1.2 FAILURE TO MEET GLYCAEMIC TARGETS GLOBALLY 
The benefits of glucose lowering have been identified. Optimum targets for glycaemic control have been 
determined by expert consensus, widely disseminated, and are supported by reasonably robust data.18-20 
However, glycaemic control remains suboptimal. A large pan-European study compared current diabetes care 
against the glycaemic targets produced by the ADA/EASD and found just over half (53.6%) of those with T2D 
achieved adequate glycaemic control, with considerable variation between countries.27 Similarly, a cross-
sectional series, conducted in the USA, of all people with diabetes (including a small proportion of people with 
type 1 diabetes [T1D]) from the National Health and Nutrition Examination Survey (NHANES) found that just 
over half (52.2%) achieve an HbA1c < 7.0% (53.0mmol/mol).28 Additional comparisons of glycaemic control when 
compared to guideline targets have been undertaken elsewhere in Europe (Poland29-31, Ireland32, Spain33 34, 
Germany35, Italy36), North America (USA37-42), the Middle East (Saudi Arabia43, Palestine44, Kuwait45, Qatar46), 
Asia (China47, the Philippines48, Bangladesh,49 Malaysia50, Thailand51), and Australasia (Australia52). These studies 
are summarised in Figure 1 which demonstrates that the global proportion of people achieving glycaemic targets 
is around 43% (95% confidence interval [CI] 38-48%). 
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Figure 1. A forest plot of studies comparing glycaemic control achievement against guidelines. 
All studies which compared the proportion of people achieving targets, compared against a guideline published in the last 10 years (since 
2016) are included. Search terms: “Type 2 diabetes” AND “Guideline” AND “Adherence”). 
 
MD thesis| Medication use and adherence in type 2 diabetes 
17 
 
1.3 TREATMENT OPTIONS FOR TYPE 2 DIABETES 
Both diet and exercise are the recommended first line treatments for people with T2D.18 19 However, only a third 
of people with T2D achieve the recommended levels of physical activity and very few follow dietary guidelines 
for fat or fruit and vegetable consumption.53 Our national unselected diabetes cohort demonstrates that the 
majority of people with identified T2D require medication as an intervention.54 
Many new glucose lowering agents have become available in recent years including three new classes of 
medication; dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon like peptide 1 (GLP1) receptor agonists, and 
sodium glucose co-transporter 2 (SGLT2) inhibitors. Whilst these additional classes of medication provide an 
improved variety of treatment options for patients and physicians they have also made the management of T2D 
more complex.19 55-57 With this broadening array of therapies available the importance of scrutinising clinical 
effectiveness of each different drug class becomes more evident.58 Selecting optimal second and third line 
glucose lowering therapies has become an increasingly difficult challenge for clinicians with limited evidence to 
support the use of one therapy over another in clinical practice.59 
Whilst these newer agents have demonstrated effectiveness in clinical trials60-63 additional evidence is needed 
to support their efficacy in the real-world setting. The trial environment differs substantially from the clinical 
environment.64 Increased monitoring frequency and patient support may contribute to improved compliance 
with therapies delivered within trials.65 Strict patient selection criteria for trials also reduce the applicability of 
results to the clinical situation; patients with multiple co-morbidities, complex disease needs, and polypharmacy 
are usually excluded from trials.66 Real world data is therefore needed to ensure trial efficacy translates into 
clinical effectiveness and to identify where extrapolation of trial evidence is valid.64 National audit data have 
already demonstrated disparities in clinical effectiveness and trial efficacy for a new GLP1 receptor agonist.67 
Adherence and persistence with therapies are important real-world factors which may contribute to reduced 
medication effectiveness.65 It has previously been demonstrated that, whilst clinically effective, a new SGLT2 
inhibitor showed substantially reduced persistence with therapy in practice than has been reported in all trials 
to date.68 
1.4 DEFINITIONS OF MEDICATION ADHERENCE 
Various nomenclature has been used to describe appropriate use of medications especially: adherence, 
compliance, concordance, and persistence.69 These terms describe two discrete patterns of medication uses; 
missed medication doses (described by the terms adherence, compliance, or concordance) and duration of use 
before discontinuation (persistence).70 Persistence with medication is the preferred term to refer to the duration 
of medication use.69 The term used to describe medication adherence is more contested. As described above 
the medication adherence was termed medication compliance in the early literature. This term is considered to 
imply a paternalistic approach to prescribing with the patient as a passive recipient of medical advice.71 72 With 
a growing focus on shared decision making, and reduction in the power inequities in the clinical consultation, 
this term has fallen out of favour and has been gradually replaced by the use of the term adherence in the 
medical literature.73 The term “Medication Adherence” was added as a MeSH term in 2009.73  
The WHO promotes the use of the term adherence which it defines as “the extent to which a person’s behaviour 
– taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed 
recommendations from a health care provider”.71  
There are multiple measures of medication adherence, with no consensus definition of which is the 
recommended measure.72 The methods for measuring adherence are generally subdivided into direct and 
indirect measures.74 Each method has unique advantages and disadvantages (Table 1). 
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Method Advantages Disadvantages 
Direct methods 
Directly observed therapy Accurate Time consuming, invasive 
Serum levels of medicine Objective 
Variations in metabolism, not 
available for many medications, 
costly 
Indirect methods 
Patient questionnaires/self-
reports 
Simple, inexpensive, achieve 
patient reflection 
Requires patient honesty and 
accurate recall 
Pill counts 
Objective, quantifiable, time 
consuming 
Can be altered by the patient 
Rates of prescription refills 
Objective, easy to obtain data, 
cheap 
Not equivalent to ingestion of 
medicine 
Assessment of clinical response Easy to perform, routinely done Other influencing factors 
Electronic medication monitors Precise and quantifiable 
Expensive and time consuming 
(data downloads, setup etc) 
Patient diaries Correct for poor recall 
Time consuming for patient, 
easily altered by patient 
Table 1. A comparison of different methods for measuring medication adherence. 
Adapted from Osterberg and Blaschke (2005).75 
 
With the growing availability of large healthcare datasets population level measures of adherence have become 
possible. The two most commonly used methods for calculating adherence on this population level are both 
measures of prescription refills: the medication possession ratio (MPR) and the proportion of days covered 
(PDC).76 The common formulae for calculating these measures are provided in Equations 1 and 2. 
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The subtle difference between these two formulae is the approach to overlapping prescriptions. As an example, 
a patient who receives a medication prescription prior to running out will have overlapping days. Using the MPR 
calculation this can lead to an MPR greater than 100%, with PDC the overlapping days are moved forwards to 
the first day that the patient would not have medication available from the previous prescription, hence with 
PDC a value greater than 100% is not possible. Whilst MPR is the more common measure in the current literature 
PDC is the method preferred by the Pharmacy Quality Alliance (a large not-for-profit multinational collaboration 
with the aim of promoting appropriate medications use and development of strategies for measuring 
appropriate medications use).76 
1.5 IMPORTANCE OF MEDICATION ADHERENCE 
Medication effectiveness is reduced where medications are not taken at all or not taken as directed. As 
mentioned already medication adherence in the real-world setting varies from that of the trial environment and 
may be a major factor which limits clinical effectiveness.64 
The problem of medication non-adherence has been long recognised. The first known report of medication non-
adherence was made by Hippocrates (460 – 370 BC) who warned his fellow practitioners that patients may 
conceal information about their medication taking (or non-taking) habits and may complain that their 
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medication was not working despite not taking it.77 The first mention of non-adherence in modern medicine was 
made by Robert Koch who identified a “careless and irresponsible” group of people with tuberculosis 
(“consumptives”) who failed to adhere to their prescribed medications.77 Despite recognition of the problem of 
non-adherence by these well-known physicians, systematic investigation into the problem of non-adherence 
didn’t begin in earnest until the 1970s. The groundwork for modern adherence research began with Sackett and 
Haynes who published a seminal book on the topic entitled “Compliance with Therapeutic Regimens” in 1970.77 
The term “Patient Compliance” was subsequently introduced as a Medical Subject Heading (MeSH) in 1975 and 
since this time the body of literature published on medication adherence has increased substantially.73 
Good medication adherence in chronic disease is associated with improved health outcomes and quality of life.78 
79 By comparison, poor adherence in chronic disease is associated with treatment failure, increased mortality 
and morbidity, and increased healthcare costs overall.75 Despite recognition of these negative outcomes it has 
been estimated that non-adherence has a prevalence of around 50% in those treated for chronic disease.80 In 
T2D poor adherence has been recognised as a global problem81-84 with a similarly high proportion people failing 
to take their medication as prescribed.85 86 A large meta-analysis of observational studies describing the 
proportion of people with T2D adherent to treatment has been recently published.86 This analysis considered 
studies undertaken in the preceding 10 years reporting adherence to oral medications in people with T2D, 13 
studies were included for meta-analysis. Studies, pooled using random effects models, demonstrated a mean 
MPR of 75.3% (95% CI 68.8-81.7%) and a proportion of people achieving an MPR>80% of 67.% (95% CI 59.6-
76.3%).86 The total proportion of medications actually taken is likely to be worse than measured by the MPR as 
this measure is calculated from prescription data rather than by a direct analysis of medication use Whilst the 
included studies were predominantly undertaken in the USA, several European studies were also included. These 
data demonstrate that poor medication adherence is a substantial problem in T2D. 
In people with T2D reduced adherence to medications has been associated with a number of negative outcomes 
including; worse glycaemic control,87-90 increased hospital admissions,91-94 increased healthcare costs,95-99 higher 
risk of cardiovascular events,100 101 and mortality.93 102 Similarly, medication non-persistence is associated with 
failing to achieve glycaemic targets.103 104 No systematic review has yet been published exploring these 
associations although one is currently underway.105 The searches and meta-analysis for this review have been 
completed and demonstrate a strong positive correlation between medications adherence and both all-cause 
mortality and hospitalisation (Prof Kamlesh Khunti, Leicester; personal communication). 
1.6 CAUSES OF NON-ADHERENCE 
A huge range of factors associated with non-adherence in chronic diseases have been described. A recent 
systematic review of systematic reviews of determinants of medications non-adherence in chronic diseases 
identified 51 reviews describing a total of 771 individual risk factors for non-adherence.106 The WHO groups 
factors which can lead to non-adherence into five main categories;107 patient related (e.g. age), socioeconomic 
(e.g. medication costs), condition related (e.g. presence of complications), health system related (e.g. level of 
continuity of care), and therapy related (e.g. adverse effects). Most of these domains have been well explored 
in the context of T2D; the list below demonstrates factors which are associated with reduced medication 
adherence in people with T2D, grouped by the five main categories of factors leading to non-adherence (These 
studies were identified using the literature search strategy outlined in Appendix 1): 
Patient related 
• Younger age82 102 108 109 
• Gender (female)82 102 108  
• Smoking102 
• Naïve to oral therapy110  
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• Non-seatbelt wearing and impulsiveness111  
• Ethnic minorities108 112 113 
Socioeconomic 
• Reduced affordability of medication/higher medication costs82 114 
• Lack of financial resources115  
• Location (mixed results): rural location112 urban location116 
• Lower education level108 117 
• Lower socioeconomic status109 118  
• Lack of family support119 
Condition related 
• Depression108 120-122 
• Presence of chronic diseases: heart failure,123 renal disease,124 hypercholesterolemia110 
• Fewer diabetes complications109 
• Shorter duration of diabetes109 125 
• Improved adherence with severe mental health illness 126 and with schizophrenia 127 
• Forgetfulness128  
• Higher body mass index (BMI)129 
Health system-related 
• Proximity to nearest pharmacy130 
• Improved adherence with behavioural support interventions130 
• Low level of trust in healthcare provider131 
• Variation by healthcare centre/clinic132 
• First medication prescribed by GP116 
• Lower continuity of care133 
• Filling prescriptions at a chain pharmacy vs independent pharmacy134 
Therapy-related 
• Concurrent medication use (mixed results): Greater number of concurrent medications,123 135 136 
number of medicines not correlated,137 fewer medications138 139 
• Hypoglycaemia (reduced persistence with sulphonylureas)140 
• Needle phobia (with insulin)115 
• Lack of confidence in benefits137 
• Number of tablets per day83 
• Presence of side effects137 141 
• Previous experience with oral antidiabetic medications130 
 
An alternative grouping of factors associated with medication adherence has been proposed using the using the 
Capability, Opportunity and Motivation model of Behaviour (COM-B) to enable a focus on intervention (Table 
2).142 The COM-B was developed to be a comprehensive model of behaviour change developed with an 
associated ‘behaviour change wheel’ (Figure 2) with the aim of providing a framework for the development of 
behaviour change interventions.143 Application of this behaviour change framework to factors which influence 
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medicines adherence facilitates adherence intervention.142 This approach demonstrates that alteration of the 
medication related factors (such as by a change of medication class) the opportunity for medication adherence 
can be modified. 
 
Figure 2. The behaviour change wheel. 
The central sources of behaviour are described by the COM-B framework where factors influencing behaviour change can be categorised as 
Capability factors (either psychological or physical), Motivation factors (either reflective of automatic), and Opportunity factors (either social 
or physical). Figure excerpted from Michie et al. (2011) with permission.143 
 
Capability Motivation Opportunity 
The individual’s physical and 
psychological capacity to engage 
in the behaviour 
All brain processes that energise 
and direct behaviour 
All factors lying outside the 
individual that make 
performance of the behaviour 
possible or prompt it 
Psychological Reflective Physical 
• Understanding of condition 
• Memory 
• Executive function 
• Perception of illness 
• Treatment beliefs 
• Expectations 
• Locus of control 
• Medication cost 
• Access to medication 
• Regimen complexity 
• Physical characteristics of the 
medication 
• Social support 
• Healthcare provider 
relationship 
Physical Automatic Social 
• Dexterity 
• Swallowing 
• Capability to adapt behaviour 
• Cues to action (associations 
with medication taking 
behaviour) 
• Depression/mood disorders 
 
• Religious/cultural beliefs 
• Stigma of disease 
Table 2. Factors which influence medications adherence structured within the COM-B framework. 
Table adapted from Jackson et al (2014).143 
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1.7 MEDICATION FACTORS AS DETERMINANTS OF NON-ADHERENCE 
Both the WHO and COM-B based structures consider medication related factors as a major determinant of 
adherence. This separate consideration of therapy related factors is an approach supported by the systematic 
review of reviews by Kardas et al. (2013) discussed earlier; of the 771 determinants of non-adherence in chronic 
disease they identified, over a fifth of these were therapy related factors.106 Whilst many of the determinants of 
medication adherence are not modifiable by physicians and other healthcare practitioners, the type of 
medication or medication class prescribed is potentially modifiable for a number of conditions where multiple 
therapeutic options are available. Chronic disease examples with multiple therapeutic options include 
hypertension and depression. A systematic review of adherence in hypertension has demonstrated that use of 
angiotensin receptor blockers (in preference over angiotensin converting enzyme inhibitors, calcium channel 
blockers, beta-blockers, and diuretics) in the treatment of hypertension is associated with improved medication 
persistence and is subsequently projected to improve cardiovascular outcomes.144 Similarly in depression, a 
meta-analysis of 62 randomised controlled trials comparing discontinuation rates with selective serotonin 
reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs), found better persistence with SSRIs.145 These 
data suggest drug class modification can be used as a method to improve medications adherence in chronic 
disease when alternative medication options are available. 
A comparative assessment of medication adherence across all available diabetes therapies, to assess the therapy 
related impact, has previously been performed. Identification of any substantial differences in adherence rates 
between medication classes used in diabetes is important to help guide prescribing, maximise treatment 
adherence, and hence minimise diabetes related complications. 
1.8 RESEARCH HYPOTHESIS 
It was hypothesised that adherence and persistence vary between medication classes in people with T2D. To 
the best of our knowledge there has been no previous extensive comparison of adherence or persistence 
between different diabetes therapies. Medications with the most frequent and troublesome side effects were 
hypothesised as the most likely to have the lowest rates of adherence and persistence. As described, a greater 
understanding of differential adherence across different therapeutic classes for the treatment of T2D may 
facilitate medication adherence; class switching or modified class selection may improve the opportunity factors 
associated with medications adherence. 
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2 METHODS 
AIMS: 
Primary aim: 
• To compare adherence and persistence between different classes of diabetes medication 
Secondary aims: 
• To quantify adherence and persistence with diabetes medications in the real-world setting 
• To identify other predictors of non-adherence or persistence with therapies in the UK population 
DESIGN AND SETTING:  
This project consists of two strands: Firstly, a systematic review and meta-analysis of the existing literature on 
the comparative adherence and persistence to medications in people with T2D. Secondly, an exploration of a 
large real-world dataset to quantify medication adherence and persistence, provide a comparison of these 
across different medication classes, and to identify other predictors/associations with medication adherence (or 
non-adherence). Data from the Royal College of General Practitioners Research and Surveillance Centre (RCGP 
RSC) will provide the real-world evidence dataset. This comprises all coded clinical data from over 150 primary 
care practices across the UK: with data from over 2 million patients.  
METHOD: 
The systematic review was undertaken in accordance to the methods recommended by the Cochrane 
collaboration and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) and Meta-analysis Of Observational Studies in Epidemiology (MOOSE) reporting guidelines. 
Literature proving a comparison of medication adherence or persistence between two or more classes of 
medication in people with T2D was identified using a comprehensive prespecified search method. The databases 
searched comprised; MEDLINE, Embase, The Cochrane Library, The Cochrane Register of Controlled Trials, 
PsycINFO, and CINAHL. Data was extracted into a preformatted database. Where several studies (n≥5) provided 
the same comparison a meta-analysis was performed. 
The comparative analysis of medication persistence and adherence was undertaken using a large cohort of 
people with T2D from the RCGP RSC. This cohort of people with T2D was identified for analysis using a clinical 
informatics ontology to correct for possible misdiagnosis, misclassification, and miscoding of diabetes. 
Medication non-persistence was defined as a prescription gap > 90 days. Medication adherence was defined 
using the proportion of days covered (PDC) during a one year period (2016). Medication directions are recorded 
in the database as free text. These directions were processed, to calculate the PDC, using an algorithm devised 
using an iterative process on a sample of 500 free text directions and manually verified on a further 200 
directions. Cox proportional hazards modelling was used to identify the differential impact of medication class 
on persistence after adjusting for known confounders of persistence. Linear and logistic regression models were 
used to identify the impact of medication class on the PDC (percentage of days) and the odds of adherence 
(PDC>80%) respectively, after adjusting for known confounders of adherence. 
This section describes the methodology for these two strands of investigation in more detail. 
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2.1 SYSTEMATIC REVIEW OF COMPARITIVE MEDICATIONS PERSISTENCE AND ADHERENCE 
The systematic review component aimed to summarise the existing literature on comparative medications 
adherence and persistence in T2D. The systematic review protocol was published in full in the journal BMJ 
Open146 and was subject to expert peer review. It was also registered with the international register of 
systematic reviews; PROSPERO (registration number: CRD42015027865) prior to initiation of searches. The 
review addresses the question: “Are there substantially different adherence and persistence rates between the 
different classes of therapies available for T2D?”146 
The method in brief comprised performing a systematic search of the major medical literature databases 
(MEDLINE, Embase, The Cochrane Library, The Cochrane Register of Controlled Trials, PsycINFO, and CINAHL) 
from January 1st, 2006 until November 5th, 2015 for interventional or observational studies which provide a 
comparison of medications adherence or persistence across two or more classes of diabetes therapy in an adult 
population with T2D. The search strings, inclusion and exclusion criteria, search process, data extraction process, 
and data analysis plan were prespecified in the published protocol and PROSPERO registration. The search 
strings for the MEDLINE database is provided in Appendix 1. These search strings were adapted for the other 
databases. Additional studies were identified by bibliographic searching of the included studies. After 
deduplication, two reviewers (AMcG and ZT) independently reviewed the titles and abstracts of all the articles 
identified by the search terms. Studies were excluded if both reviewers agreed that the study did not meet the 
required criteria. Where either reviewer considered the study of possible relevance the full text was sought. The 
same two reviewers then independently reviewed all full texts and decided on inclusion or exclusion. A third 
reviewer (MW) made a final decision to include or exclude papers where there were remaining discrepancies. 
We placed no restriction on the method of measurement for adherence or persistence. Studies were excluded 
if they considered people with T1D, gestational diabetes, or other types of diabetes other than T2D. Studies 
were also excluded if medications were administered in hospital or by another care provider. 
Data was extracted from included studies into a preformatted database. The extracted data included 
information on the study population, provenance, adherence or persistence measurement method and 
definition, adherence outcomes, and any reported reasons for interclass adherence differences. A meta-analysis 
was undertaken where five or more studies provided a comparison between the same two classes using a 
comparable outcome measure. Distinct outcome measures were defined as follows: For medication adherence; 
studies reporting the proportion of medication taken during the observation period (usually medication 
possession ratio [MPR] or proportion of days covered [PDC]), those reporting the proportion of people who were 
adherent/non-adherent, or studies reporting odds ratios (ORs) or adjusted ORs for adherence/non-adherence. 
For medication persistence outcomes were grouped into; those reporting a measure of persistence duration, 
those reporting the proportion of people persistent, and those reporting time to non-persistence events (usually 
as hazard ratios [HRs]). The main pooling method used was a random effects meta-analysis to account for the 
large inter-study variation in definitions of medication adherence and persistence within each outcome measure 
category, and other variations in study design. Fixed effects meta-analysis results are also reported for 
comparison. The meta-analyses were performed using the inverse-variance approach using the DerSimonian 
and Laird method.147 The pooled estimates are reported with 95% confidence intervals (95% CI). Interstudy 
heterogeneity was assessed using Chi2 and the associated p-value (for the likelihood of heterogeneity; assuming 
significance at p>0.1)148 is also reported. The heterogeneity was quantified using the I2 statistic149, also reported 
with 95% CI and tau value2 (using the DerSimonian and Laird approach). Possible publication bias risk (or other 
sources of data skewing) was assessed for all pooled analyses where the included number of studies was 10 or 
more150 using funnel plots and the Egger’s test for asymmetry.151 The statistical software R version 3.3.2 was 
used for all analyses and the R packages meta152 and metafor153 used for data synthesis. 
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Study quality of observational studies was assessed using the Newcastle-Ottowa scale (Appendix 3). This scale 
facilitates scoring (out of nine points) using three domains; selection quality (four points), comparability (two 
points), and outcomes (three points).154 155 The Cochrane risk assessment tool was used to assess the quality of 
clinical trials. 
2.2 REAL WORLD DATA ANALYSIS OF MEDICATIONS PERSISTENCE AND ADHERENCE 
2.2.1  THE REAL-WORLD EVIDENCE DATA SOURCE 
The real-world patient sample used here will comprise data collected as part of the Royal College of General 
Practitioners Research and Surveillance Centre (RCGP RSC) for analysis. The RCGP RSC, established in 1957, is 
the gold standard surveillance network for infectious disease surveillance in the UK with an emphasis on 
influenza surveillance.156 However, the dataset has been utilised for a large number of epidemiological studies 
looking at both infectious diseases and other conditions.156-159 Data from the electronic patient record (EPR) are 
automatically uploaded to the RSC database from all the included practices via regular data uploads. This dataset 
currently comprises data collected from a national sample of over 160 primary care practices distributed across 
England and Wales (Figure 3). We have published full details on the representativeness of this network.160 In 
summary, the network consists of a representative sample of the population of England in terms of 
demographics and the presence of chronic diseases with slight oversampling of non-white people, people aged 
25-44, and people of higher socio-economic status.  
The method of data extraction and governance procedure has been developed by the University of Surrey in 
partnership with RCGP RSC and Public Health England, using an approved provider; Apollo Medical Software 
Solutions Ltd. This provider extracts data using an automated extraction system. Data extracts from participating 
practices are uploaded on a weekly basis for the purposes or infectious diseases surveillance. More extensive 
bulk data (complete EPR data) uploads occur twice a year. The dataset which will be used in the final version of 
this these will comprise data uploaded in a bulk data upload from 164 GP practices on 1st January 2017.  
Figure 3. The distribution of GP practices included in the RCGP RSC network. 
Figure excerpted from Correa et al. (2016)160 with permission. 
  
MD thesis| Medication use and adherence in type 2 diabetes 
26 
 
Data extractions are conducted in accordance with the Clinical Informatics and Health Outcomes Research 
Group’s standard operating procedures in data extraction, pseudonymisation, and transfer. All data processing 
and analysis is conducted within the secure IT environment of the Research Group at the University of Surrey. 
Data was extracted only for patients without an opt-out code; this is a code that is recorded by a clinician 
whenever a patient opts out of allowing their practice to share their data. Nationally around 700,000 people are 
reported as having an opt-out code;161 based on an English population of 56 million, this would give an opt-out 
rate of 1.25%. At the point of data drop, the data are processed through a pseudonymisation package encrypting 
the National Health Service (NHS) number. Once extracted, the data is stored in a secured structured query 
language (SQL) database server at the University of Surrey. The data are managed and configured in SQL to 
produce aggregated tables which can then be extracted to a statistical package for analysis. 
Real world data has a number of limitations both in quality and completeness.162 The RCGP RSC dataset 
minimises these potential difficulties in a number of ways: the high quality of clinically coded data within the 
RCGP RSC network is assured by regular feedback to participating practices. The introduction of the Quality and 
Outcomes Framework (QOF) and pay for performance targets in 2004 across UK primary care has also greatly 
improved standardisation of diabetes and cardiovascular disease clinical coding,163 with practice funding 
provided based on analysis of clinically coded patient registers and outcome data. Since 2003 most practices 
have also had electronic links to their local chemical pathology laboratory enabling direct coding of laboratory 
data into the clinical record, hence improving data availability. Most people in the UK are registered with a 
general practitioner. The NHS structure precludes patients registering with more than one primary care centre 
and therefore prevents double-counting of patient data. With all these factors the RCGP RSC provides a world 
class research database in terms of both data quality and size and therefore provides an excellent platform for 
the investigation of real world diabetes management. 
As the RCGP RSC has recently undergone a considerable increase in the number of included practices a 
demonstration of the overall data quality of the dataset and population representativeness of the cohort is a 
required first step in the research process. The data quality within the diabetes population was also an initial 
requirement for assessment. These baseline analyses have comprised the initial component work undertaken 
here. 
2.2.2  THE DATASET 
Electronic health records in UK primary care are coded using Read codes. The Read code system enables 
recording of information regarding patient demographics, history and examination findings, diagnoses, test 
results, processes of care, and other healthcare related data.164 All data entered into the EPR is done so with an 
associated clinical Read code. Data coded using the Read coding system have a specified data format; there is a 
code for the clinical data item (e.g. disease, symptom, examination finding, investigation result, prescription, 
treatment, etc.), and number of associated fields. These associated fields include the date when the episode 
occurred (the event date), the recording date of the event, numerical values (HbA1c, cholesterol levels, etc.), 
sometimes a free text field, and other fields. Free text fields were not extracted for this study due to the 
possibility of inclusion of patient identifiable information. The remaining fields were extracted and available in 
the RCGP RSC SQL database for analysis. The majority of the big data research in UK primary care uses this 
approach.165 
There are two broadly adopted Read code schemes in use in UK general practice 5-byte version 2 and clinical 
terms version 3. These coding schemes are hierarchical. Read codes can be explored and identified using the 
Clinical Terminology Browser software (Figure 4). The presence of these codes along with associated numeric 
values is in the RCGP RSC dataset and available for analysis. 
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Figure 4. The Clinical Terminology Browser used to search Read codes. 
The Hierachical structure is demonstrated with a diagnosis of T2D seen as a child code of ‘Diabetes mellitus’ which is, in turn a child code of 
‘Other endocrine gland diseases’. 
2.2.3  DATA PROCESSING METHODS 
Identification of diseases and other entities (e.g. ethnicity) was performed using an ontological approach to case 
finding. This approach improves condition identification from the EPR.166 The approach is, in essence, a formal 
method of identifying a real-world entity from the EPR. Through this method real-world concepts relating to a 
condition are translated into clinical codes (in this case Read codes), which are then developed into a data 
extraction routine. Clinical entities can be identified using a simple list of relevant codes but this has a number 
of limitations. Whilst pay-for-performance targets in UK primary care based on clinical codes have improved 
clinical coding, difficulties in correct identification of cases from these codes remain. In diabetes, for example, 
people are often misdiagnosed, misclassified or miscoded in practice.167 168 An ontological approach to case 
finding and classification aims to overcome some of these issues. For example, people who are misclassified as 
having T1D could be identified by the prescription of multiple oral hypoglycaemic agents in their record, a high 
BMI, and an onset of disease late in life. People who have no formal diagnostic code for diabetes can be 
identified from multiple HbA1c values consistent with the diagnosis alongside the use of diabetes medications. 
The approach that was developed to optimise correct identification of people with T2D is described in the next 
section; and involves the use of diagnostic codes, process of care codes, test results, and medication codes. 
Diagnosis codes are also associated with term codes. These term codes usually provide synonyms for the 
diagnosis e.g. for T2D two term codes exist in the 5-byte version 2 system; Type 2 diabetes mellitus (term code 
MD thesis| Medication use and adherence in type 2 diabetes 
28 
 
00) and Type II diabetes mellitus (term code 11). Occasionally term codes are not completely synonymous and 
therefore care must be taken to ensure that only appropriate term codes are included in any disease definition. 
For numeric data captured with Read codes there is often associated unit information. This may be entered 
when data is uploaded via lab links, automatically through graphical user interface (GUI) templates or manually 
by the clinician. These multiple sources mean that unit information is recorded in various formats e.g. for HbA1c 
units are recorded in over 90 formats with the most common (more than 10,000 uses) being mmol/mol, %, per 
cent, IFCCmmol/mol, mM/M, % total Hb, DCCT %, % of Hb, % HB., and % (DCCT). Other numeric values have a 
similar number of different methods of recording units. These unit formats required manual sorting and 
assignment of conversion factors where required e.g. to convert HbA1c from DCCT to IFCC units*. 
In such a large dataset is it inevitable that there is erroneous data caused by data entry issues, particularly as 
there are a large number of clinicians manually entering data into the record. It is difficult to remove data errors 
where the value entered falls within the range of data values expected for the parameter, but data extremes 
can be identified and removed. These data can be clearly identified as erroneous and as extreme outliers may 
leverage regression models they are removed. For each numeric variable extreme data limits have been imposed 
to exclude these erroneous data (Table 3). These limits were selected using a combination of clinical experience 
and examination of the distribution of values for each parameter. The values selected were agreed by two 
clinicians (AMcG and NH) and where there was disagreement the opinion of a third clinician (JW) was sought. 
Additional data cleaning was subsequently performed where data outliers leverage statistical models. 
Variable Units Extreme lower limit Extreme upper limit 
Deprivation Score (IMD) N/A 0 100 
Body mass index kg/m2 5 90 
HbA1c mmol/mol 15 250 
Systolic blood pressure mmHg 60 280 
Diastolic blood pressure mmHg 20 160 
eGFR* ml/min/1.73m2 0 200 
Total Cholesterol mmol/L 1 15 
HDL Cholesterol mmol/L 0.1 7.0 
LDL Cholesterol mmol/L 0.1 10.0 
Table 3. Extreme data limits set for data extraction for the numeric variables using in the study. 
IMD: index of multiple deprivation, eGFR: estimated glomerular filtration rate. *eGFR data is almost universally truncated by the laboratory 
at 60 or 90 ml/min/1.73m2 although a small number of manually entered values exist.  
The extreme data cleaning limits were applied automatically when extracting data from the SQL database. The 
alternative method would be to extract the data into variables and then apply the cleaning limits. The advantage 
of direct application in SQL is that if the most time appropriate recording of a variable does not contain a realistic 
value a second value recorded at a different time can be sought for extraction. For example, when extracting 
the most recent HbA1c value prior to 1st January 2017, if a person has a data value recorded on 31st December 
2016 with a data entry value of 300 mmol/mol but a genuine value of 75 mmol/mol recorded on 15th November 
                                                                 
 
* All HbA1c measurement are converted from the old method of reporting (DCCT; Diabetes Control and 
Complications Trial) to the newer method (IFCC; International Federation of Clinical Chemistry). 
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2016 the SQL extraction routine can ignore the incorrect value in December and extract the correct value in 
November. This is not possible after the SQL stage of data extraction and therefore improves data completeness. 
2.2.4  STUDY COHORT 
The study cohort comprised adults with T2D as identified using algorithms developed and refined for correct 
identification of T2D. These have been published as part of this project.54 These use a two-step process to 
identify people with T2D. Initially all people with diabetes are identified using a combination of diagnostic codes, 
clinical investigations, and medication use. People are then categorised by diabetes type using a seven-step 
algorithm. Clinical characteristics of the cohort are also identified from data recorded in the EPR. We have used 
all available coded computerised medical record information prior to 1st January 2017 to identify the cohort. 
In the first step of the case finding method we included all people with diagnostic codes, test results, and 
medication codes consistent with a diagnosis of diabetes. The diagnostic codes also included some process of 
care codes which unambiguously record a clinical review of diabetes (Table 4). People who only had codes for 
gestational diabetes, steroid induced diabetes, or other forms of secondary diabetes were not included. 
Read Code (5-byte version 2) Description 
C10E and derivative codes Type 1 diabetes mellitus 
C10F and derivative codes (excluding C10F8; Reaven’s syndrome)  Type 2 diabetes mellitus 
C109 and derivative codes Non-insulin dependent diabetes 
66An. Diabetes type 1 review 
66Ao. Diabetes type 2 review 
Table 4. Diabetes diagnostic and process of care codes used to identify people with diabetes. 
 
Test results consistent with diabetes comprise blood glucose results and HbA1c. Blood glucose results were 
categorised by the test provenance (fasted, random, part of an oral glucose tolerance test, unknown 
provenance, or another known provenance). We have previously provided an in depth analysis of this method 
of categorising glucose provenance.169 The results of glucose measurements in each category were then 
classified as consistent with diabetes or not based on universally used diagnostic criteria (Table 5). Where the 
sample provenance was fasting, the diagnostic criteria for a fasted sample have been applied and similarly for 
oral glucose tolerance test results and random samples. Where the test provenance was unknown the (higher) 
diagnostic threshold for a random sample has been applied. We required two samples consistent with diabetes 
before inclusion. We have previously described the limitations of this method.169 In brief glucose provenance is 
not recorded in the majority of samples. However, samples with no provenance information have a results 
distribution which most closely resembles that of fasting samples, suggesting that almost all samples with no 
provenance information are fasted samples. Despite the apparent similarity between the two distributions they 
are statistically significantly different and therefore those with no provenance information cannot all be 
assumed to be fasting. This lack of provenance information means that the proportion of people with diabetes 
identified using blood glucose results alone will be an underestimate. The use of additional diabetes identifiers, 
and the trend in recent years to use HbA1c for diagnosis should limit the impact of this issue. 
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Test type Criteria for diabetes 
Fasting plasma glucose ≥ 7.0 mmol/l and diabetes symptoms 
(Impaired fasting glucose: 6.1 to 6.9 mmol/l) 
Plasma glucose concentration two hours 
after 75g anhydrous glucose in an OGTT 
≥ 11.1 mmol/l and diabetes symptoms 
(Impaired glucose tolerance: 7.8 to 11.0 mmol/l) 
Random venous plasma glucose ≥ 11.1 mmol/l and diabetes symptoms 
Serum HbA1c ≥ 48 mmol/mol (6.5%) in suspected type 2 diabetes and 
diabetes symptoms for longer than two months, 
Table 5. The diagnostic criteria for diabetes using serum glucose measurements. 
Two different test results on two different days, with values within the diabetes range are required to confirm a diagnosis of diabetes. OGTT: 
oral glucose tolerance test. 
  
As described HbA1c tests were categorised as Diabetes Control and Complications Trial (DCCT), International 
Federation of Clinical Chemistry and Laboratory Medicine (IFCC), or unknown measurements. Where the 
measurement unit was unknown values below 25 where assumed to have been reported using DCCT units and 
were converted into IFCC units. Similarly, all measurements known to be reported using DCCT were converted 
into IFCC. A diagnosis of diabetes, using HbA1c values, was only made where individuals had two or more 
measurements of glycated haemoglobin (HbA1c) above the diagnostic threshold; ≥ 48 mmol/mol (6.5%).170 
Finally, patients who had been issued two or more prescriptions for medication used to treat diabetes were also 
included for assessment of diabetes type. This excludes metformin use as there appears to be substantial 
amount of prescribing of metformin in people without diabetes within the dataset. 
2.2.5  IDENTIFICATION OF DIABETES TYPE 
Once identified as having diabetes we categorised people as either T1D or T2D using a seven-step algorithm 
(Figure 5). This categorisation algorithm allows overriding of diagnostic codes where clinical characteristics are 
highly likely to indicate a specific type of diabetes:  
Step 1: If insulin initiated before age 35 and no oral agent use ever recorded except metformin the person is 
assumed to have T1D.  
Step 2: On multiple oral hypoglycaemic agents – T2D. 
Step 3: On one or more oral hypoglycaemic agent, excluding metformin, for more than 12 months and no 
history of insulin use – T2D.  
Step 4: diagnostic codes with no evidence of conflict; if all clinically entered codes are consistent with either 
T1D or T2D then the person is categorised accordingly. If there are no recorded diagnostic codes or 
codes are conflicting then the algorithm proceeds to step 5. 
Step 5: no recorded use of insulin – T2D 
Step 6: On oral diabetes medications for longer than 12 months (excluding metformin alone) – T2D 
Step 7: If the patient is overweight then they are categorised as T2D. If the diabetes subtype is not identified 
by these steps then the type of diabetes is categorised as undetermined. 
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Figure 5. Seven-step algorithm for categorising diabetes subtype. 
OHA: oral hypoglycaemic agent, BMI: body mass index. 1excluding prescriptions for metformin. Figure reproduced from McGovern et al. 
(2016)54 with permission. 
We have previously compared the results to diabetes classification methods used by other authors using similar 
datasets171 and have found it to compare favourably. 
To ensure that only high quality data is used for analysis and that the results provide a contemporary view of 
diabetes practice only the most recent 10 years of data were included for analysis (1st January 2007 to 31st 
December 2016 inclusive). All people identified with T2D during this period were initially included for analysis. 
People were then excluded if they were under 18 at the time of diabetes diagnosis. 
People with T2D were included for analysis of medication persistence if they had an identifiable medication start 
date during the follow up period. For this they must have a first prescription of the medication more than six 
months after registration with their GP practice. This avoids the possibility that they had been previously 
prescribed the medication at a previous GP practice. 
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2.2.6  ADHERENCE AND PERSISTENCE RELATED VARIABLES 
As described in section 1.6 there are a large number of factors associated with medication adherence. Whilst 
many of these are not identifiable from the EPR (e.g. social support) we have attempted to identify as many of 
these as possible. These factors were then included in adherence regression models to identify the independent 
impact of medication class on medication adherence. Factors included comprise: age, gender, ethnicity, 
socioeconomic status, smoking status, alcohol intake, duration of diabetes, glycaemic control, presence of 
complications, presence of comorbidities, number of concurrent diabetes medications, and number of previous 
non-persistent diabetes medications, and diabetes medication class. 
Ethnicity was defined using the Office of National Statistics (ONS) official UK ethnicity categories: this defines 
five major ethnic categories; White, Mixed/Multiple ethnic groups, Asian (including Indian, Pakistani, 
Bangladeshi, and Chinese people), Black (including African, and Caribbean people), and Other (including Arab 
and other minority groups not classified elsewhere).172 Socioeconomic status was derived using the official 
national measure; Index of Multiple Deprivation (IMD) which is based on patient postcode. IMD scores provide 
a combined measure of household income, education, healthcare provision, and living environment for the UK 
at small spatial scales.173 
Smoking status and alcohol use were defined using the most recently recorded measure prior to the initiation 
of the medication (medication persistence) or prior to the follow up period (medication adherence). Duration of 
diabetes was defined as the time between the first recorded indicator of diabetes (diagnostic code, blood 
glucose measure consistent with diabetes, or medication) in the record and the time of initiation of the 
medication. BMI, and blood pressure were defined using the value most recently recorded prior to the initiation 
of the medication of interest. The presence of diabetes complication and comorbidities was determined by the 
presence of diagnosis codes or other codes specific for the diagnosis (e.g. Read code “6A9..” “Atrial fibrillation 
annual review” as a code to identify the presence of atrial fibrillation.). The diabetes complications identified 
comprised; amputation, peripheral neuropathy, retinopathy, and peripheral vascular disease. The comorbidities 
identified comprised; hypertension, atrial fibrillation, angina, stroke, myocardial infarction, congestive cardiac 
failure, transient ischaemic attack (a history of), coronary artery disease, chronic kidney disease (CKD stages 3-
5), renal replacement therapy (dialysis or transplant), dementia, depression, rheumatoid arthritis, and chronic 
liver disease (any cause). CKD was identified using eGFR measurements and diagnosis codes. The definitions of 
comorbidities and complications were mapped on to clinical trial definitions where there was no clear formal 
consensus on the definition of the condition e.g. angina.174 175 The baseline demographics and other key variables 
are reported for each cohort analysed. 
The primary outcome measures of medication use, adherence, and persistence were be grouped by medication 
class. These groups will include oral diabetes medications available in the UK; biguanides (metformin), 
thiazolidinediones (TZDs; “glitazones”), sulfonylureas, meglitinides (“glinides”), dipeptidyl peptidase-4 (DPP4) 
inhibitors (“gliptins”), alpha-glucosidase inhibitors (AGIs), amylin analogues, and sodium glucose cotransporter 
2 (SGLT2) inhibitors (“gliflozins”). 
2.2.7  MEASURE OF MEDICATION PERSISTENCE 
As described earlier there are multiple methods for measuring adherence and persistence. The primary methods 
for calculating medication adherence from large datasets are described in equations 1 and 2 (MPR and PDC).  
Here non-persistence was defined as a gap in prescriptions of ≥ 90 days for this analysis which is consistent with 
previous analyses.176-181 The duration of persistence was defined as the time interval between the first 
prescription and the last identified prescription consistent with persistence. People who had a final prescription 
for the medication within 90 days of the end of follow-up were categorised as having censored persistence and 
included for analysis. People were considered non-persistent if they switched medication within a class e.g. a 
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change from sitagliptin to linagliptin was considered non-persistence with sitagliptin – two persistence events 
are then included for analysis (one with sitagliptin and one with linagliptin). People who switched medication 
preparation (for example metformin standard release to metformin modified release) but remained on the same 
drug were considered persistent. We only consider primary persistence i.e. persistence from the first recorded 
prescription of each medication. 
2.2.8  MEASURE OF MEDICATION ADHRENCE 
Generating a measure of medication adherence from the UK EPR is substantially more difficult than generating 
a measure of persistence. Information about the number of days covered by each prescription is required to 
calculate both MPR and PDC. As PDC is the preferred measure of medication adherence from the EPR76 is it the 
measure used here calculated using equation 2. 
The duration of a prescription is not recorded directly in the EPR. Prescription records include the type of 
medication prescribed, the number of tablets dispensed, the directions for use. The directions for use are free 
text descriptions which are entered by the prescriber. Commonly used directions can be saved by users in several 
systems but the saved directions vary from GP practice to practice. The duration of each prescription can only 
be calculated by converting the free text directions into a dosing frequency and dividing the total number of 
tablets dispensed by this frequency. A sample of the large resulting variation in directions for metformin are 
shown in Table 6. 
Frequently occurring n Infrequently occurring n 
One To Be Taken Each Day With Breakfast And Then 
Increase Dose As Directed 
1,264 TAKE 2 TABLETS THREE TIMES A DAY WITH OR AFTER FOOD. 1 
Two To Be Taken Once A Day With Evening Meal 1,188 take 2 each morning, 1 at lunch, 2 at teatime 1 
One To Be Taken With Breakfast, Lunch And Evening Meal 1,018 TAKE 2 EVERY NIGHT 1 
One To Be Taken Each Day With Food 1,015 TAKE 2 IN EVEINING 1 
take one 3 times/day  592 Take 2 in morning and 1 evening 1 
2 TWICE A DAY 543 Take 2 in morning, 1 in evening with food 1 
One To Be Taken Once A Day With Evening Meal 513 TAKE 2 BD (FOR DIABETES) 1 
TAKE ONE TWICE A DAY 470 take 2 breakfast, 1 at lunch, 2 at teatime 1 
THREE TO BE TAKEN DAILY 389 TAKE 2 DAILY FOR 1 WEEK. THEN 3 DAILY 1 
two twice a day 372 TAKE 1 TABLET WITH OR AFTER BREAKFAST AND EVENING MEAL 1 
One To Be Taken With Breakfast And Evening Meal 367 TAKE 1 TABLET(S) A DAY FOR 1 WEEK THEN TAKE 1 TABLET(S) 
TWICE A DAY 
1 
two tablets to be taken twice a day 326 TAKE 1 TABLET(S) THREE TIMES A DAY IMMEDIATELY AFTER MEALS 1 
take one, twice daily 323 2 DAILY 20 MINS BEFORE MEAL 1 
take two twice daily 304 TAKE 1 TABLET WITH BREAKFAST AND TAKE 1 TABLET WITH 
MIDDAY MEAL2 
1 
two to be taken twice daily 293 TAKE 1 TABLET WITH BREAKFAST AND TAKE 2 TABLETS WITH 
EVEING MEAL 
1 
ONE THREE TIMES A DAY 289 TAKE 1 TABLET WITH BREAKFAST AND TAKE 2 TABLETS WITH 
EVEVING MEAL 
1 
2 bd 255 TAKE 1 TABLET WITH BREAKFAST DAILY 1 
Table 6. A sample of frequently used and infrequently used prescription directions for metformin. 
n refers to the number of times the exact directions string occurred in the RCGP database (December 31st 201g6 extraction) in prescriptions 
for metformin. 
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An algorithm for processing these free text directions was developed using an iterative process. A trial algorithm 
was run against a small sample of directions. The results were manually reviewed and the algorithm adjusted to 
correct any errors. The algorithm was then trialled on another batch of directions and further refined. This 
process was repeated until the algorithm had been run against 500 directions each had been manually checked 
against the final iteration of the algorithm. Where the duration of the prescription could not be determined the 
prescription was marked as such and any person with a prescription of indeterminate length during the 
observation period was excluded from the analysis. Examples of directions leading to this condition are those 
were a variable number of tablets per dose was prescribed e.g. “ONE to TWO to be taken TWICE daily”, where 
there was an indeterminate change in dosing e.g. “One To Be Taken Each Day With Breakfast And Then Increase 
Dose As Directed - to TDS” or where the instructions to the patient were unclear e.g. “HALF TABLE 1 WK”. The 
resulting algorithm derived by this iterative process is reported in the results section. 
During the process of creating the adherence measure algorithm it became apparent that the amount field 
associated with each prescription was handled differently by difference GP systems providers. Two IT systems 
allowed the GP user to enter an amount which was either a duration or total number of tablets to be dispensed. 
No units data is recorded with this number and therefore there was insufficient data available to reliably 
calculate the duration of the prescriptions for these systems. The majority of the GP practices providing data to 
the RSCP RSC use the IT system EMIS WEB. This system provides users with a prescription template which 
automatically calculates and records the prescription amount as the number of tablets. We therefore restricted 
our analyses to these practices. An added complication is that the predecessor system EMIS LV did not record 
data in this consistent way, and no information on the date of practice switch to ENMIS WEB was available in 
the RCGP RSC records. Support for the EMIS LV system was withdrawn in 2014. We therefore further restricted 
the adherence analysis to the most recent year of data to ensure that all analysed prescriptions were recorded 
using the EMIS WEB system. 
2.2.9  STATISTICAL METHODS 
All statistical analyses were performed using the statistics package R version 3.3.2 (“Sincere Pumpkin Patch”). 
This was used to derive descriptive statistics for all the primary outcome measures and cohort descriptors. 
Adherence and persistence prediction models were be developed using regression analysis. The type of 
regression used varied depending on the outcome variable: both linear and logistic models were built for the 
identification of predictors of adherence. Linear regression was used in models where the outcome variable was 
PDC (percentage of days covered during a one year follow-up period) and logistic regression where PDC was 
categorised as non-adherent (PDC ≤80% of days covered) or adherent (>80% of days covered). Cox regression 
analysis was used as the method for identification of predictors of persistence with the outcome defined as the 
time to a non-persistence event. Linear regression models were checked for heteroskedasticy and other 
properties which may violate the assumptions of linear regression. Logistic regression models and Cox models 
were similarly tested for validity. Model selection in all cases was performed using the approach described by 
Maindonald and Braun182; minimising the Bayesian information criterion using backward stepwise elimination – 
this was done automatically in R using the step() function. 
2.2.10  DATA LIMITATIONS 
Several limitations of using routine data are predictable. Incomplete data is one such major limitation. In many 
cases alternative routes of discovering the relevant information can be sought from the patient record to 
improve completeness. For example where hypertension is not coded using the hypertension diagnostic codes, 
recorded blood pressure values can be used, where these are not available hypertension may be inferred from 
the use of various antihypertensive medications in the absence of other explanatory conditions. Data such as 
ethnicity can often be accurately inferred from spoken language or use of a language interpreter.183 Where 
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possible we maximised data completeness via variable specific methods similar to those described above. Where 
this was not possible data was specifically coded as missing and included in regression models. Our previous 
experience has demonstrated that missing data in routine GP care can be associated with worse outcomes.184 
This data therefore should not be generated by imputation methods and categorisation into a specific “missing” 
category represents a more appropriate alternative. 
Collection of a drug prescription does not equate to use of that medication. This is an inherent limitation of this 
type of analysis, however previous data suggest regular collection of a prescription has a high correlation with 
use.185 If data on dispensed prescriptions can be linked to the existing dataset this could in future provide an 
additional step towards the true value of medication adherence; however these data were not available for this 
project. 
2.3 ETHICAL CONSIDERATIONS 
Formal ethical approval for the real-world analysis component of the project was granted by an NHS Research 
Ethics Committee (REC) (REC reference: 15/LO/1755). The study used pseudonymised RCGP RSC clinical data 
extracted from GP information systems; the data was routinely collected as part of clinical consultations in 
primary care. No patient identifiable information was available within the research datasets used. No ethical 
review was required for the systematic review component of this project. 
 
3 RESULTS 
3.1 RESEARCH OUTPUTS 
Multiple research outputs have been generated from this work. A summary of these outputs with publication 
details are provided in Appendix 3 (for publications directly applicable to the research question posed here) and 
Appendix 4 (for publications generated from related work) with the complete publications provided in Appendix 
5 (printed version only). 
3.2 SYSTEMATIC REVIEW OF COMPARITIVE MEDICATIONS PERSISTENCE AND ADHERENCE 
Database searching using the prespecified search strings yielded a total of 4,466 records for title and abstract 
review after deduplication (Figure 6). Bibliographic searching of included articles yielded an additional 13 records 
for title and abstract review. The inclusion criteria were met by 66 unique studies with a total population of over 
2.2 million people which are summarised in narrative form. Of these studies 29 made comparisons between oral 
therapies only (Table 7), 31 between injectable therapies only (Table 8), five between oral and injectable 
therapies (Table 9), and one compared an oral and inhaled agent186 (Table 10). The majority were conducted in 
North America (USA, 36; Canada, 1; and USA and Mexico, 1), with others in Europe (Germany, 5; UK, 4; Italy, 3; 
Ireland, 1; Sweden, 1; Netherlands, 1; Hungary, 1; France, 1; Multiple European countries 5), and elsewhere 
(Iran, 1; China, 1; Multiple countries 5). The characteristics, results, and strengths and limitations of these studies 
are detailed in Tables 7 to 10 below. Their results are then summarised in the subsequent sections. 
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Figure 6. A PRISMA flow diagram of study selection. 
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Study Study design and population Measure of adherence 
or persistence 
Sample size and 
characteristics 
Study results Strengths and limitations Adjustment for 
confounding 
Al-Arouj et al. 
(2013)187 
Prospective multicentre cohort study 
in the Middle East and Asia, of adults 
with T2D fasting during Ramadan, 
and taking vildagliptin or a SU as 
monotherapy or with metformin. 
1,315 people included. 
Mean number of missed 
doses during a 16 week 
observation period. 
684 people taking vildagliptin 
(mean age 48.0 years; SD 10.9; 
57.7% male) and 631 people 
taking SUs (mean age 51.3 
years; SD 10.7; 59.8% male). 
The mean number of missed doses 
was similar: vildagliptin 0.7 (SD 3.36) 
and SU 0.8 (SD 2.66) 
Prospective design may influence 
adherence. Specific setting 
limited generalisability of results 
outside patients fasting during 
Ramadan. 
None 
Balkrishnan et 
al. (2006)188 
Retrospective cohort study using a 
large USA claims database (North 
Carolina Medicaid) of adults with T2D 
initiated on a TZD, metformin, or SU 
between July 1, 2001 and December 
31, 2004. 3,191 people included. 
Adherence measured 
using MPR. Persistence 
duration (years). 
1,774 people started on a TZD, 
218 started on metformin, and 
1,199 started on a SU. 
Mean adherence rates: TZDs 0.49, 
metformin 0.07, SUs 0.43. Mean 
persistence: TZDs 0.69, metformin 
0.10, SUs 0.97. 
Precise definition of medication 
persistence and adherence rates 
are unclear. Comparisons used in 
multivariate analysis are unclear. 
Limited reporting of patient 
characteristics. 
None 
Barner et al. 
(2011)189 
Retrospective cohort study using a 
large USA claims database (Texas 
Medicaid) of adults (18-65) with T2D 
prescribed pioglitazone or metformin 
followed by fixed dose combination 
therapy between January 1, 2004 and 
August 31, 2007. 210 people from 
study met inclusion criteria for this 
analysis. 
Mean adherence (MPR) 
and proportion of people 
adherent (MPR ≥ 80%) 
62 people taking pioglitazone 
compared with 148 people 
taking metformin 
Mean adherence was lower with 
metformin (0.71) than pioglitazone 
(0.84). Similarly, the proportion of 
people adherent was lower with 
metformin (86.3%) than pioglitazone 
(91.2%). 
Small sample size. The study was 
primarily aimed at providing a 
comparison of fixed and loose 
dose combination therapies but 
this proportion of the analysis did 
not meet our study inclusion 
criteria. 
None 
Calip et al. 
(2015)178 
Retrospective cohort study from an 
existing breast cancer outcomes 
cohort with early stage breast cancer.  
Comparison of metformin and SU 
adherence during breast cancer 
treatment. 509 people included. 
Mean MPR and proportion 
with MPR ≥ 80%. 
Proportion of people 
persistent at 1 year 
(discontinuation defined 
as a gap of ≥ 90 days) 
149 people taking metformin 
during breast cancer 
treatment, 195 people taking 
Sus. 
During treatment for breast cancer 
more people were adherent to 
sulfonylurea treatment than 
metformin (39.0% vs 30.9%). No 
measure of significance provided. 
Small sample size and unadjusted 
MPR used. Addresses adherence 
in a very specific population. 
None 
Chong et al. 
(2014)190 
Retrospective cohort study, in Canada 
using health administration data 
between 1997 and 2006, of adults 
with T2D. Data from 167,243 people 
analysed. 
Proportion with PDC ≥ 80% Medication adherence 
compared across ethnic 
groups; 14,084 Chinese, 9,529 
South-Asian, 143,630 White 
people. 
Biguanides (BIG) had higher 
adherence across all ethnicity groups 
compared with SUs and TZDs: 
Chinese (MET; 57.5%, SU; 50.5%, TZD; 
46.0%), South-Asian (MET; 39.3%, SU; 
35.4%, TZD; 35.1%), White (MET; 
60.7%, SU; 53.6%, TZD; 55.6%). 
Large sample size with 
comparison across different 
ethnic groups. No other 
adjustment performed. 
Comparison across therapies not 
primary study outcome. 
Comparison within 
different ethnic 
groups 
Corrao et al. 
(2011)191 
Retrospective cohort study, in Italy 
using National Health Service data, of 
people age 40 to 90 with T2D 
initiated on metformin or SU 
monotherapy between 2001 and 
2003 (followed until 2007). Data from 
70,437 included. 
Proportion of people 
persistent at one year 
(defined as continued 
therapy without switching, 
combining with another 
agent, or discontinuation) 
21,810 people started on 
metformin (mean age 60.0 
years; SD 9.8; 53.0% male), 
48,627 people started on SUs 
(mean age 64.8 years; SD 10.5; 
54.4% male). 
At one year persistence was 35.5% 
with metformin and 44.5% with SUs. 
Large sample size comparing 
persistence with initial therapy. 
Composite measure of non-
persistence. 
None 
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Degli Esposti et 
al. (2014)192 
Retrospective cohort study, using a 
linked administrative databases in 
three Italian local health units, of 
adults with T2D initiated on SUs, 
TZDs, or sitagliptin between July 2008 
and June 2010 inclusive. 1,341 people 
included. 
Mean MPR and adjusted 
OR of adherence (MPR ≥ 
80%). 
928 people started on SUs 
(mean age 66.1 years; SD 11.4; 
52.2% male), 330 started on 
TZDs (mean age 63.2 years; SD 
10.1; 55.2% male), and 83 
started on sitagliptin (mean 
age 56.2 years; SD 9.8; 50.6% 
male). 
MPR was higher with sitaglitpin 
(79.5%) vs SUs or TZDs (53.9% and 
62.8%; p<0.001). Adjusted OR for 
adherence was lower than sitagliptin 
for SUs (0.36; 95% CI 0.20-0.64; 
p<0.001) and TZDs (0.51; 0.28-0.93; 
p=0.028). 
Careful measurement of MPR 
accounting for hospital 
dispensing. Small sample size. 
Multivariate 
adjustment for a 
broad range of 
confounders 
Farr et al. 
(2014)193 
Retrospective cohort study using the 
US MarketScan claims database of 
adults with T2D initiated on 
saxagliptin, a DPP4 inhibitor, an SU, 
or TZD between 1st January 2009 and 
31st January 2011 inclusive. 238,372 
people included. 
Adherence defined as PDC 
≥ 0.80 measured over one 
and two years. Adjusted 
OR of adherence reported. 
Discontinuation defined as 
60+ day gap in therapy 
during the first one and 
two years. Adjusted HR for 
discontinuation reported. 
61,399 people started on DPP4 
inhibitors (mean age 56.4 
years; SD 11.7; 51.2% male), 
134,961 started on SUs (mean 
age 57.2 years; SD 12.6; 57.2% 
male), and 42,012 started on 
TZDs (mean age 55.6 years; SD 
11.6; 55.6% male). 
The proportion of people adherent at 
one year was higher for DPP4 
inhibitors (47.3% and 55.0%) than SUs 
(41.2% and 47.8%) and TZDs (36.7% 
and 42.9%). Adjusted OR for 
adherence at one year was higher 
with DPP4 inhibitors compared with 
SUs (OR 1.68; 95% CI 1.63-1.73; 
p<0.001) and TZDs (OR 1.61; 1.56-
1.65; p<0.001). Adjusted HR for 
discontinuation within a year also 
favoured DPP4 inhibitors compared 
with SUs (HR 1.39; 1.36-1.41; 
p<0.001) and TZDs (HR 1.40; 1.38-
1.43; p<0.001). Similar trends were 
seen at two years. 
 
Large sample size. Sensitivity 
analysis comparing one year and 
two year outcomes. Also 
monotherapy and non-mail order 
patients considered separately 
with similar trends. Some 
predictor characteristics not 
available e.g. HbA1c, BMI, 
socioeconomic status. 
Multivariate 
adjustment for a 
broad range of 
confounders 
Farsaei et al. 
(2011)194 
Prospective cohort study of people 
35-75 with T2D enrolled from June to 
September 2007 currently taking 
metformin or glyburide. 
Adherence defined as ≥ 
90% and ≤ 105% of 
medication taken as 
measured by pill count and 
self-reporting. 248 
patients enrolled. 
204 people taking metformin 
and 167 people taking 
glyburide (including 123 
patients taking both 
medications). 
A higher proportion of people were 
found to be adherent to glyburide 
compared to metformin using pill 
counting (64.7% vs 60.3%) and self-
reported adherence (69.5% vs 
57.2%). Forgetting, confusion, and 
Ramadan were reported as the most 
common reasons for non-adherence. 
 
Prospective design with a 
considerable number of people 
included in both medication 
groups. No adjustment for 
confounders. Small sample size. 
Comparison with glyburide 
rather than other SUs. 
None 
Filozof et al. 
(2010)195 
RCT, 52 weeks of intervention, adults 
with T2D not controlled on 
metformin alone. Patients were 
randomised 1:1 to vildagliptin (50mg 
twice daily) or gliclazide (up to 320 
mg/day). 1,007 people started on 
treatment. 
 
Discontinuation for any 
reason during 52 week 
intervention period. 
512 people randomised to 
vildagliptin (mean age 59.2 
years; SD 9.9; 52.2% male), 494 
people randomised to 
gliclazide (mean age 59.7 
years; SD 10.2; 52.8% male). 
Discontinuation during follow up; 
vildagliptin 20.6%, gliclazide 16.6%. 
Adverse events cited as the most 
common reason for discontinuation 
in both groups. 
No measure of treatment 
adherence. Reasons for 
discontinuation reported. 
Treatment 
randomisation 
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Göke et al. 
(2010)196 
RCT, 52 weeks of intervention, adults 
with T2D not controlled on 
metformin alone. Patients were 
randomised 1:1 to saxagliptin (5mg 
daily) or glipizide (up to 20mg/day). 
858 people randomised. 
Discontinuation due to 
adverse events during the 
52-week intervention 
period. 
428 people randomised to 
saxagliptin (mean age 57.5 
years; SD 10.3; 49.5% male), 
430 people randomised to 
glipizide (mean age 57.6 years; 
SD 10.4; 54.0% male). 
Discontinuation for adverse events 
during follow up; saxagliptin 2.3%, 
glipizide 1.6%. 
No measure of clear measure of 
adherence. A large proportion of 
participants discontinued as no 
longer meeting study criteria. 
Treatment 
randomisation 
Grimes et al. 
(2015)197 
Retrospective cohort study using an 
Irish pharmacy claims database (Irish 
Health Services Primary Care 
Reimbursement Services database) 
people with T2D (≥40 years) with 
initial diabetes treatment with 
metformin or an SU. 8,995 people 
included in persistence analysis. 
Number of people 
remaining persistent at 12 
months. Non-persistence 
defined as a 12-week 
prescribing gap. 
7,539 people had initial 
therapy with metformin and 
1,456 people with SUs. 
Treatment persistence was lower 
with SUs (68.9%) compared with 
metformin (79.0%). Adjusted HR for 
non-persistence with sulfonylureas 
was 1.49 (95% CI 1.36-1.64; 
p<0.0001). 
Large population size. 
Comparison of first diabetes 
therapy in both groups. Only a 
limited number of factors 
adjusted for. 
Multivariate 
adjustment for age, 
gender, insurance 
scheme, and 
therapy type. 
Hanif et al. 
(2013)44 
Prospective cohort study of adult 
Muslims with T2D currently taking an 
SU or vildagliptin as add on to 
metformin intending to fast during 
Ramadan. Followed for up to 16 
weeks including observation before 
and during Ramadan. 72 people 
enrolled. 
Medication adherence was 
measured using patient 
reporting of missed doses 
(using a patient held 
diary). Total proportion of 
missed doses and 
proportion of patients 
missing more than 20% of 
doses reported. 
23 people taking liraglutide 
(mean age 58.3 years; SD 13.1; 
52.2% male), 36 people taking 
SUs (mean age 57.3 years; SD 
11.0; 58.3% male). 
Patients were more adherent to 
vildagliptin than SUs; total missed 
doses 0.2% vs 10.4% (p=0.0292), 
patients missing > 20% of doses 0% vs 
19.4% (p=0.0358). Authors speculate 
that differences were due to fear of 
hypoglycaemia with SUs. 
Small sample size. Self-reported 
measure of missing doses. Very 
specific scenario. Comparison of 
two different population groups. 
Prospective data collection may 
alter adherence. 
None 
Hansen et al. 
(2010)198 
Retrospective cohort study using the 
US MarketScan claims database of 
adults with T2D on monotherapy with 
metformin, pioglitazone, or an SU 
during 2003. 108,592 people 
included. 
Adherence was reported 
as the mean MPR and 
proportion adherent (MPR 
≥ 80%). 
52,156 people taking 
metformin, 11,520 taking 
pioglitazone, and 44,916 taking 
an SU. Demographic 
differences between the 
cohorts reported. 
Patients were less adherent to 
metformin (56.7% of patients) than 
pioglitazone (59.3%; P<0.001) or SUs 
(61.3%; P<0.001). Mean MPR; 
metformin 70.9%, pioglitazone 
73.8%, SUs 73.8%. 
Very large sample size with 
comparison across several groups 
of medication. Contained a 
mixture of current and new 
medication users with no 
adjustment for treatment 
duration. 
None 
Haupt et al. 
(2009)199 
Retrospective cohort study using the 
Swedish prescribed drug register 
(analysis of the complete population 
of Sweden). Adults with T2D and no 
hospital admissions on oral 
medications between 1st December 
2005 and 30 November 2006 
included. 171,220 people included. 
Adherence reported as 
mean MPR 
People currently on 
monotherapy with metformin 
(75,125), glibenclamide 
(20,347), glipizide (7,176), 
glimepiride (2,791), fixed dose 
combination with metformin 
and rosiglitazone (1,534), 
acarbose (508), rosiglitazone 
(878), pioglitazone (626), 
repaglinide (3,647), and 
nateglinide (166). An additional 
36,560 people analysed taking 
dual therapy. 
Adherence (mean MPR) over 12 
months; metformin 88.6%, 
glibenclamide 90.6%, glipizide 91.1%, 
glimepiride 90.8%, fixed dose 
combination with metformin and 
rosiglitazone 87.9%, acarbose 81.1%, 
rosiglitazone 92.8%, pioglitazone 
92.3%, repaglinide 86.4%, and 
nateglinide 81.3%. Trends were 
similar in those on dual therapy. 
Whole population study. 
Differentiation between 
medication use in mono and dual 
therapy. Analysis over a wide 
range of oral therapies. No 
adjustment for confounders. No 
differentiation between new and 
established therapy. 
None 
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Jariwala et al. 
(2010)200 
Retrospective cohort study in the 
USA, using the Mississippi Medicaid 
claims database from 2002 to 2004. 
Adults with T2D, initiating 
monotherapy with SUs, metformin, 
or TZDs therapies were included.  
6,206 people included. 
 
Medication persistence 
(refill gap > twice duration 
of supply) at 1 year. Mean 
adherence (PDC) in first 90 
days and 90-180 days. 
3,041 people started on SUs, 
1,800 on metformin and 993 
on TZDS 
Persistence at one year was similar: 
SUs 46%, metformin 42%, and TZDs 
45%. Mean PDC in the first 90 days of 
therapy was; SUs 82%, metformin 
68%, and TZD 85%. 
Comparison of monotherapy 
only. Comparison of adherence 
and persistence at multiple end 
points. Unusual definition of 
medication discontinuation. 
None 
Jermendy et al., 
(2012)201 
Retrospective cohort study using the 
Hungarian National Health Insurance 
Fund Administration database of 
adults with T2D initiated on mono or 
dual therapy with metformin or/and 
SUs between 1st January 2007 and 
31st March 2009. 256,384 people 
included. Those on a combination of 
metformin and SUs are excluded here 
as this group as the definition of 
persistence in the group was not 
clear. 
 
Proportion of people 
persistent at one year. 
Non-persistence defined 
as no repeat prescription 
within 180 days of the last 
date covered by the 
previous prescription. 
115,426 people started on 
metformin monotherapy, and 
125,362 people started on SU 
monotherapy. 
A higher proportion of people were 
found to be persistent at one year 
with metformin 47.7% (95% CI 47.4-
48.0) than with SUs 45.4% (45.1-
45.7). 
Large population analysis of 
initial therapy only. No 
adjustment for confounders. 
Unusual definition of medication 
persistence used. 
None 
Nauck et al. 
(2014)202 
RCT, 52 weeks of intervention, adults 
with T2D not controlled on 
metformin and one other oral 
therapy. Patients were randomised 
1:1 to dapagliflozin or glipizide once 
daily. 801 people randomised to 
treatment. 
 
Discontinuation for any 
reason during 2 week 
intervention period. 
400 people randomised to 
dapagliflozin, 401 people 
randomised to glipizide. 
Discontinuation due to inadequate 
glycaemic control was more common 
in those treated with glipizide than 
dapagliflozin (difference -3.6%; 95%CI 
-5.3 to -1.5). Discontinuation due to 
adverse events was similar; 
dapagliflozin 9.1%, glipizide 5.9%. 
No measure of treatment 
adherence. Short duration of 
study. 
None 
Patel et al. 
(2009)203 
Retrospective cohort study, in the 
USA, using Medicaid data on adults 
with T2D on oral antidiabetic 
medication between July 2001 and 
June 2002. 3,169 people included. 
Relative adherence rates 
(measured using MPR) 
adjusted for confounders 
The number of people initiated 
on metformin and SUs not 
reported. Age reported by age 
groups; 681 people aged 18-
44, 2,327 aged 45-64, and 161 
aged 65+.  
Metformin adherence was lower than 
SUs (adjusted difference in MPR 
34.5%, p < 0.05). 
Small sample size. Incomplete 
reporting of patient 
characteristics. 
Multivariate 
adjustment. 
Incomplete 
reporting of factors 
adjusted for 
Patel et al. 
(2010)204 
Retrospective cohort study, in the 
USA, using the North Carolina 
Medicaid database, of adults with 
T2D initiated on monotherapy with 
metformin, an SUs, or TZD. 3,169 
people included. 
 
Adjusted coefficient of 
MPR using multiple linear 
regression 
216 people initiated on 
metformin, 1,179 on TZDs, and 
1,774 on SUs. 
Compared to Sus, TZDs had better 
adherence (MPR adjusted estimated 
coefficient 0.024; 95% CI 0.008 to 
0.040), metformin had lower 
adherence (-0.345; -0.366 to -0.324). 
Duration of follow-up unclear. 
Limited number of factors 
adjusted for. No reporting of 
unadjusted adherence rate. 
Multivariate 
adjustment for age 
group, gender, 
ethnicity, and 
healthcare costs. 
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Plat et al. 
(2009)205 
Retrospective cohort study, in the 
Netherlands, using the PHARMO 
Record Linkage System, of adults with 
T2D initiated on metformin, SUs, or 
TZDs from 1999-2004. 33,463 people 
included here (those on 
monotherapy). 
Proportion of people 
discontinuing therapy 
within a year. 
Discontinuation was 
defined as less than 365 
days of continuous use. 
14,277 people initiated on 
monotherapy with metformin, 
18,876 on SUs, and 310 on 
TZDs. 
After 1 year discontinuation was 
16.1% with metformin, 20.1% with 
SUs, and TZDs 25.1%. 
Large sample size, except with 
TZDs. Long study period with 
changing guidelines within the 
study period. 
None 
Quillam et al. 
(2013)206 
Retrospective cohort study in the USA 
using the Medstat MarketScan 
database of adults with T2D initiated 
monotherapy with metformin, SUs, 
or TZDs between 2004 and 2008. 
93,156 people included for analysis. 
Proportion of people 
adherent (MPR ≥ 80%) 
during 12 months of follow 
up. People switching 
therapy excluded. 
55,043 people initiated on 
metformin monotherapy, 
9,817 on SUs, and 8,962 on 
TZDs. 
The proportion of people adherent 
was; metformin 70.4%, SUs 75.3%, 
and TZDs 76.4%. 
Large sample size. No sensitivity 
analysis. Only six month baseline 
period to determine no previous 
use - some of those included may 
not be true new users. 
None 
Rathmann et al. 
(2013)207 
Retrospective cohort study, in 
Germany, using the Disease Analyzer 
database of adults with T2D with 
initiating an SU or DPP4 inhibitor. 
50,294 people included. 
Proportion of people non-
persistent with initial 
therapy at 2 years. Non-
persistence defined as 
therapy switching. 
19,184 people initiated on 
DPP4 inhibitors (mean age 64.3 
years; SD 10.9; 56.2% male), 
31,110 people initiated on SUs 
(mean age 69.2 years; SD 11.7; 
50.8% male). 
The proportion of people persisting 
with DPP4 inhibitors (61%) was higher 
than with SUs (51%). After 
adjustment discontinuation was less 
common with DPP4 inhibitors (HR 
0.74; 95% CI 0.71-0.76) 
Large sample size, adjustment for 
a wide range of factors. No 
sensitivity analysis performed. 
Multivariate 
adjustment for a 
broad range of 
confounders 
Rex et al. 
(2012)208 
Retrospective cohort study, in 
Germany and France, using a primary 
care database (Disease Analyser 
Database) of adults with T2D initiated 
on SUs or DPP4 inhibitors between 
April 2007 and August 2011. 67,519 
people included. 
Proportion of people 
persistent with therapy 
(non-persistence defined 
as a prescribing gap of ≥90 
days) and adjusted HR for 
non-persistence. Reported 
separately for Germany 
and France. 
17,312 people in Germany and 
8,675 in France started on 
DPP4 inhibitors, and 30,382 
people in Germany and 11,150 
people in France started on 
SUs. 
At 2 years persistence was higher for 
DPP4 inhibitors (61% in Germany, 
59% in France) compared with SUs 
(51% in both countries). Risk of 
discontinuation was lower with DPP4 
inhibitors (Germany; HR 0.74; 95%CI 
0.71-0.76, France; HR 0.79; 95% CI 
0.75-0.83). 
Large sample size across two 
countries. Non-adjustment for 
concurrent therapies. 
Demographic information not 
reported in abstract. 
Multivariate 
adjustment 
Rozenfeld et al.  
(2008)90 
Retrospective cohort study in the USA 
using the Providence Primary Care 
Research Network database in 
Oregon of adults with T2D initiated 
monotherapy with metformin, 
sulfonylureas, TZDs, meglitinides or 
AGIs between 2001 and 2004. 2,471 
people included for analysis. 
Adherence reported as 
mean PDC and proportion 
of people with PDC ≥ 80%. 
1,274 people initiated on 
metformin (mean age 53.0 
years; SD 11.0; 46.0% male), 
1,081 on SUs (mean age 55.0 
years; SD 12.0; 51.0% male), 
and 337 taking TZDs (mean age 
52.0 years; SD 11.0; 49.0% 
male). Other groups not 
reported. 
Adherence was not significantly 
different between classes for either 
measure (mean PDC; proportion with 
PDC ≥ 80%); metformin (80.7%; 
63.9%), SUs (81.8%; 65.8%), TZDs 
(82.0%; 69.4%). P values not 
reported. 
Small sample size with no 
adjustment for differences 
between groups. Attempt to 
compare all available classes at 
the time of analysis although 
insufficient data for AGIs and 
meglitinides. 
None 
Shenolikar et al. 
(2006)113 
Retrospective cohort study in the USA 
using the North Carolina Medicaid 
program database of adults with T2D 
initiated on metformin, SUs, or TZDs 
between July 2001 and June 2002 
inclusive. 3,169 people included for 
analysis. 
Mean MPR 216 people initiating 
metformin, 1,179 initiating 
SUs, and 1,774 initiating TZDs 
Adherence was lowest for metformin 
(MPR 22%) compared with SUs (57%) 
and TZDs (60%). 
Primary comparison was racial 
differences in adherence. 
Characteristics of each 
medication group not reported. 
Trends in adherence by class 
examined across racial groups 
with same pattern identified. 
Stratification by race 
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Tunceli et al. 
(2014)209 
Retrospective cohort study, in the 
USA, using a claims database 
(MarketScan) of adults with T2D 
initiated on a SU or sitagliptin as add-
on to metformin between 2009 and 
2011. 14,886 pairs matched. 
Medication persistence 
(median time to 
discontinuation, and HR 
for discontinuation event 
during the 1 year follow 
up). OR for adherence 
(PDC≥80%). 
14,886 people started on 
sitagliptin (mean age 56.2 
years; SD 10.6; 54.7% male), 
matched with 14,886 people 
started on sulfonylureas (mean 
age 56.2 years; SD 10.6; 54.7% 
male). 
Median time to discontinuation was 
longer for sitagliptin (984 days) than 
SUs (885 days) with a reduced hazard 
for discontinuation (HR 0.84; 95% CI 
0.81-0.88). Sitagliptin also had higher 
adherence (OR 1.39 95% CI 1.29-
1.50). 
Large sample size. Propensity 
score matching included 
matching on adherence to 
metformin in baseline period. 
Study available only in abstract 
form. Definition of non-
persistence not reported.  
Propensity score 
matched groups 
Valensi et al. 
(2014)210 
Prospective cohort study using data 
from enrolled general practitioners in 
France. Adults with T2D initiated on 
SUs or sitagliptin between July 2009 
and December 2010 inclusive. 2,607 
people included for analysis. 
Median treatment 
duration (time to addition, 
switching, or withdrawal 
of therapy) 
733 people started on SUs 
(mean age 64.2 years; SD 11.5; 
57.6% male), 1,874 people 
started on sitagliptin (mean 
age 62.4 years; SD 10.8; 59.4% 
male). 
Median discontinuation or treatment 
switching occurred at 20.2 months 
(95% CI 17.0-25.1) in the SU group 
and 43.2 months (95% CI 41.4-non-
estimable; p<0.0001) in the sitagliptin 
group. 
Large sample size. 
Discontinuation events included 
addition of other treatments 
making study comparison 
difficult. Median discontinuation 
was only just achieved at the end 
of follow up in the sitagliptin 
group making estimate 
inaccurate. 
Propensity score 
matched groups 
White et al. 
(2012)211 
Prospective cohort study recruiting 
people in 2001 with T2D currently 
using oral hypoglycaemic agents, 
from a single large general practice in 
England. 60 patients recruited. 
Proportion of people 
taking ≥ 90% of prescribed 
doses and proportion of 
people taking prescribed 
doses on ≥ 90% of days. 
Measured using the 
Medication Event 
Monitoring System 
(MEMS). 
32 people taking metformin 
and 28 people taking an SU.  
Metformin adherence was lower than 
SUs with both measures (≥90% doses 
taken: 28/32 vs 28/28 and ≥90% days 
adherent: 17/32 vs 25/28). 
More direct measure of 
medication use. Single centre 
study (with high quality diabetes 
care) and small sample size limit 
generalisability. 
None 
Table 7. Studies which provide a comparison between different classes of oral therapy. 
AGI: alpha-glucosidase inhibitor, BMI: body mass index, CI: confidence interval, DPP4: dipeptidyl peptidase-4, HR: hazard ratio, MPR: medication possession ratio, OR: odds ratio, PDC: proportion of days covered, RCT: 
randomised controlled trial, SD: standard deviation, SU: sulfonylurea, TZD: thiazolidinedione. 
 
Study Study design and population Measure of adherence 
or persistence 
Sample size and 
characteristics 
Study results Strengths and limitations Adjustment for 
confounding 
Curkendall et 
al. (2013)179 
Retrospective cohort study using two 
large USA claims databases of adults 
with T2D initiated on saxagliptin, a 
GLP1 receptor agonist, an SU, or TZD 
between August 2009 and January 
2011 inclusive. 117,702 people 
included. 
Adjusted OR of adherence 
(PDC ≥ 80%). Persistence 
duration. 
8,383 people initiated on 
saxagliptin, 13,908 people 
initiated on GLP1 analogues, 
65,709 people initiated on SUs, 
and 29,702 people started on 
TZDs. 
Adjusted OR for adherence compared 
with saxagliptin was; GLP1 0.40 (95% 
CI 0.37-0.42), SUs 0.49 (0.46-0.52), 
and TZDs 0.54 (0.51-0.57). 
Persistence was significantly shorter 
with GLP1s, SUs, and TZDs than 
saxagliptin (data presented 
graphically) 
Very large sample size with 
comparison across several groups 
of medication. DPP4 inhibitor 
inclusion was limited to 
saxagliptin only. 
Multivariate adjustment 
for a broad range of 
confounders 
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Diels et al. 
(2015)212 
Retrospective cohort study, in the 
USA, from two administrative claims 
databases (OptumInsight and Truven) 
of adults with T2D initiating 
canagliflozin, a DPP4 inhibitor, or a 
GLP1 agonist. 66,206 people 
included. 
Medication persistence 
(treatment gap 90 days 
[sensitivity analysis 30 and 
60 days]) at one year. 
66,206 people included (mean 
age 52.6 years, 50% male). 
Number started on each 
medication not reported. 
The proportion of people persistent 
at one year was higher for 
canagliflozin (100mg; 64.0%, 300mg; 
65.0%) than DPP4 inhibitors 
(linagliptin; 30.2% to sitagliptin; 
50.1%) and GLP1 analogues 
(exenatide; 24.3% to liraglutide; 
43.0%). HRs for discontinuation were 
also lower with canagliflozin.  
Large sample size. Sensitivity 
analyses for definition of 
persistence. Study only available 
in abstract form. 
Multivariate adjustment 
for a broad range of 
confounders 
Garber et al. 
(2009)213 
RCT, 52 weeks of intervention, adults 
with T2D with no previous medication 
or up to half maximum dose single 
agent. Patients were randomised 
1:1:1 to monotherapy with daily 
liraglutide 1.2mg or 1.8mg or 
glimepiride (8mg). 746 people 
randomised. 
Discontinuation for any 
reason during 52-week 
intervention period. Non-
compliance (not defined in 
the trial manuscript). 
251 people randomised to 
liraglutide 1.2mg (mean age 
53.7 years; SD 11.0; 47.0% 
male), 247 to liraglutide 1.8mg 
(mean age 52.0 years; SD 10.8; 
49.0% male), and 248 to 
glimepiride 8mg (mean age 
53.4 years; SD 10.9; 54.0% 
male). 
Discontinuation during follow up; 
liraglutide 1.2mg 35.5%, liraglutide 
1.8mg 21.4%, glimepiride 38.7%. 
Adverse events were the most 
common reason for discontinuation 
in the liraglutide groups, ineffective 
therapy in the glimepiride group. 
Non-compliance more common in the 
liraglutide groups (4.4% and 4.4%) 
than glimepiride group (2.0%). 
Number of people non-compliant 
reported. Reasons for 
discontinuation reported. 
Treatment 
randomisation 
Koro et al. 
(2013)214  
Retrospective cohort study in the USA 
using the Thomson Reuters 
commercial health insurance 
database (2005-2011). Adults (18-64) 
with T2D using GLP1 analogues, DPP4 
inhibitors, and others medications 
(not separated) were included. 
333,608 people using GLP1 analogues 
and DPP4 inhibitors included. 
Proportion with adherence 
(MPR) ≥80%. Proportion 
non-persistent (add-on 
therapy, switch, 
discontinuation). 
208,683 people started on a 
DPP4 inhibitor and 124,925 
people started on a GLP1 
analogue. 
The proportion with MPR ≥ 80% was 
high in both classes; DPP4 inhibitors 
94.5%, GLP1 analogues 90.2%. 
Persistence was lower with GLP1 
analogues (18.7%) than DPP4 
inhibitors (31.5%). 
No information provide on 
duration of follow-up. Exact 
method for calculating 
adherence not reported. Large 
population size. 
None 
Montilla et al. 
(2014)215  
Retrospective cohort study in Italy 
using of patients enrolled into the 
Italian AIFA Anti-diabetics Monitoring 
Registry. Those taking exenatide, 
sitagliptin or vildagliptin and 
registered between February 2008 
and August 2010 included. 75,283 
people included. 
Medication persistence 
reported as the proportion 
of people discontinuing for 
treatment failure during 
30 months of follow-up 
after excluding loss to 
follow-up. 
21,064 people taking exenatide 
(mean age 58.9 years; SD 9.9; 
48.0% male), 38,811 taking 
sitagliptin (mean age 61.7 
years; SD 10.4; 52.7% male), 
and 17,989 taking vildagliptin 
(mean age 61.9 years; SD 10.4; 
54.1% male). 
During 30 months discontinuation for 
treatment failure occurred; exenatide 
7.7%, sitagliptin 3.8%, and vildagliptin 
4.1%. 
Large registry based analysis. No 
clear definition of treatment 
failure provided. A high 
proportion of loss to follow-up 
which will skew discontinuation 
rates. 
None although factors 
associated with 
discontinuation was 
explored for each 
medication 
Table 8. Studies which provide a comparison between oral therapies and injectable therapies. 
Some of these studies also compared multiple classes of oral therapies. CI: confidence interval, DPP4: dipeptidyl peptidase-4, MPR: medication possession ratio, OR: odds ratio, PDC: proportion of days covered, RCT: 
randomised controlled trial, SD: standard deviation, SU: sulfonylurea, TZD: thiazolidinedione. 
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Study Study design and population Measure of adherence 
or persistence 
Sample size and 
characteristics 
Study results Strengths and limitations Adjustment for 
confounding 
Baser et al. 
(2011)216 
Retrospective case-matched study, in 
the USA, using IMPACT® claims 
database of adults with T2D initiated 
on glargine or exenatide in 2007 or 
2008. 2,339 people met the inclusion 
criteria, 626 people matched. 
Proportion of people 
persisting with medication 
at one year and average 
persistence during one 
year follow-up. 
Medications were 
considered discontinued if 
the prescription was not 
refilled within the 
expected time of 
medication coverage. 
313 people initiated on insulin 
glargine (mean age 54.2 years; 
SD 10.2; 53.0% male) and 313 
matched people initiated on 
exenatide (mean age 54.5 
years; SD 8.8; 56.5% male) 
At one year persistence was 48% with 
glargine and 15% with exenatide; 
p<0.0001. Average persistence (days) 
was 253 with glargine and 144 with 
exenatide; p<0.0001. Better 
glycaemic control achieved with 
glargine (HbAc1 reduction 1.23% vs 
0.92%; p=0.0384). 
Both study groups well matched 
for potential confounders 
including Charlson comorbidity 
index. Duration of diabetes was 
not available. Only 26.8% of 
people meeting in the selection 
criteria could be matched for 
inclusion. 
Case-matching using 
propensity scores 
Baser et al. 
(2013)217 
Retrospective case-matched study, in 
the USA, using IMPACT® claims 
database of adults with T2D initiated 
on glargine or a premixed insulin 
analogue from 2001 to 2009. 2,502 
people met the included. 
Proportion of people 
persisting with medication 
at one year and average 
persistence during one 
year follow-up. 
Medications were 
considered discontinued if 
the prescription was not 
refilled within the 
expected time of 
medication coverage. 
Average MPR and adjusted 
MPR. 
834 people initiated on 
premixed analogue insulin 
(mean age 55.9 years; SD 11.1; 
52.6% male) and 1,668 
matched people initiated on 
glargine insulin (mean age 55.6 
years; SD 11.6; 52.2% male) 
At one year persistence was 45.4% 
with premixed analogue insulin and 
55.9% with glargine; p<0.0001. 
Average persistence (days) was 254 
with premixed and 280 with glargine 
p<0.0001. Adjusted MPR were 
similar, 0.64 premixed; 0.66 glargine; 
p=0.19. No difference in glycaemic 
control, hypoglycaemic events, or 
healthcare costs. 
Both study groups well matched 
for potential confounders 
including Charlson comorbidity 
index. Duration of diabetes was 
not available. Not reported how 
many people meeting the 
selection criteria could not be 
matched. 
Case-matching using 
propensity scores 
Bergenstal 
et al. 
(2009)218 
RCT, 24-weeks duration, in the USA, 
including people with T2D for longer 
than 6 months. Patients were 
randomised 1:1:1 to exenatide twice 
daily, biphasic insulin aspart 70/30 
once daily, or biphasic insulin aspart 
70/30 twice daily. 372 people started 
on treatment. 
Discontinuation for any 
reason during 24-week 
intervention period. 
124 people randomised to 
exenatide (mean age 52.5 
years; SD 10.6; 48.4% male), 
124 people randomised to 
biphasic insulin aspart once 
daily (mean age 51.8 years; SD 
10.9; 48.4% male), and 124 
people randomised to biphasic 
insulin aspart twice daily 
(mean age 53.4 years; SD 10.0; 
47.6% male) 
Discontinuation during follow up; 
exenatide 29.8%, insulin aspart once 
daily 16.1%, insulin aspart twice daily 
19.4%. Nausea was cited as the most 
common reason for discontinuation 
in the exenatide group. 
Excluded patients with NYHA 
class III or IV heart failure, 
hepatic or renal insufficiency. 
Study staff monitored subjects 
for medication compliance. 
Treatment 
randomisation 
Bhushan et 
al. (2009)219 
Retrospective cohort study, in the 
USA, using 47 health plan databases, 
of adults with T2D initiated on 
glargine or exenatide between May 
2005 and Sept 2007. 37,211 people 
included. 
Proportion persistent with 
treatment at 9 months and 
at 1 year. 
21,516 people stared on 
glargine insulin (mean age 54.0 
years; 57.0% male), and 17,312 
people started on exenatide 
(mean age 53.0 years; 46.0% 
male). 
At 1 year persistence was 63% for 
glargine and 50% for exenatide 
(p<0.001). 
Large sample size. Definition of 
non-persistence not reported. 
Two treatment groups reported 
as having substantially different 
characteristics with no 
adjustment method used. 
None 
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Bonafede 
et al. 
(2011)177 
Retrospective cohort study, in the 
USA, from two Thompson Reuters 
MarketScan® research databases of 
adults with T2D with mealtime insulin 
newly added to basal insulin therapy. 
4,752 people included. 
Multivariate analysis of 
ORs for insulin persistence 
at one year. Two non-
persistence definitions 
used. Measure 1: a 90-day 
gap in claims, measure 2: 
failure to make an insulin 
claim in three-month 
period. 
1,903 people started on meal-
time short acting human 
insulins, 2,849 people started 
on mealtime rapid acting 
insulin analogues. 
Adjusted OR for persistence with 
short acting human insulin compared 
to rapid acting analogues - measure 
1: OR 0.80 (95% CI 0.68-0.95; p=0.01), 
measure 2: OR 0.77 (0.67-0.87; 
p<0.0001). 
Demographics of each insulin 
group not individually reported. 
Adjustment for a comprehensive 
range of patient characteristics 
Multivariate adjustment 
for age, gender, region, 
rural/urban location, 
health insurance, 
injection device, 
Charlson comorbidity 
index, admissions, 
diabetes complications, 
mental health disorders, 
and insulin co-payments. 
Buysman 
et al. 
(2011)220 
Retrospective cohort study from a 
USA large claims database of adults 
with T2D initiated on Levemir FlexPen 
or NPH Vial insulin. 1,876 people 
included. 
Univariate and 
multivariate analysis of 
adjusted MPR (≥80%) and 
adjusted persistence (time 
to discontinuation defined 
by a medication gap 
greater than the 80th 
percentile of time 
between claims in the 
parent population). 
1,082 people started on 
Levemir FlexPen (mean age 
54.1 years; SD 10.1; 55.6% 
male), 794 people started on 
NPH Vial insulin (mean age 
53.1 years; SD 15.1; 45.5% 
male). 
Adjusted MPR was higher with 
Levemir (0.58 vs 0.38; p<0.001). Time 
to adjusted discontinuation gap was 
longer with Levemir (167 vs 123 days; 
p<0.001). Multivariate odds of 
adherence higher with Levemir (OR 
1.39; 95% CI 1.04-1.85). Multivariate 
HR for discontinuation lower with 
Levemir (HR 0.62; 95% CI 0.55-0.70) 
Multivariate adjustment for a 
wide range of potential 
confounders. No sensitivity 
analysis performed on the impact 
of adjustment for differences in 
frequency of claims. Number of 
non-persistence and non-
adherence events not reported. 
Multivariate adjustment 
for age, gender, region, 
Charlson comorbidity 
index, prescribing 
physician, HbA1c test 
frequency, other 
medication use, and 
costs. 
Cooke et 
al. (2010)221 
Retrospective cohort study using a 
large USA claims database of adults 
with T2D initiated on glargine, 
detemir, exenatide, or NPH Vial 
insulin. 1,769 people included. 
Duration of medication 
persistence 
(discontinuation gap 
defined as 60 days after 
the prescription supply 
duration) and adjusted 
survival analysis for 
persistence duration. 
785 people started on glargine 
(mean age 53.0 years; SD 13.2; 
52.2% male), 30 people started 
on detemir insulin (mean age 
53.4 years; SD 11.9; 56.7% 
male), 738 people started on 
exenatide (mean age 54.6 
years; SD 10.3; 45.9% male), 
216 people started on NPH 
insulin (mean age 49.2 years; 
SD 15.5; 33.3% male). 
Mean persistence duration was 
similar for glargine (7.4 months SD 
4.4), detemir (7.8 SD 4.1), and 
exenatide (7.6 SD 4.4), but shorter for 
NPH insulin (5.6 SD 4.5). In survival 
analysis persistence with NPH insulin 
was significantly shorter than with 
glargine (p=0.01), there was no 
significant difference between 
glargine and detemir or exenatide. 
Multivariate adjustment for 
several potential confounders. 
Small number of people in the 
detemir group. Unable to exclude 
people with gestational diabetes 
only. 
Multivariate adjustment 
for age, gender, co-
payments, and number 
of oral antidiabetic 
agents at index date. 
Davies et 
al. (2013)222 
RCT, 26-weeks of intervention, adults 
with T2D not controlled on 
metformin alone or in combination 
with an SU. Patients were 
randomised 1:1 to exenatide weekly 
or detemir insulin once/twice daily. 
216 people started on treatment. 
Discontinuation for any 
reason during 26-week 
intervention period. 
111 people randomised to 
exenatide (mean age 59.0 
years; SD 10.0; 64.0% male), 
105 people randomised to 
detemir insulin (mean age 58.0 
years; SD 10.0; 69.0% male). 
Discontinuation during follow up; 
exenatide 17%, detemir 6%. Adverse 
events cited as the most common 
reason for discontinuation in the 
exenatide group (12/19). 
No measure of treatment 
adherence. Short duration of 
study. Open-label design.  
Treatment 
randomisation although 
this was dependant on 
baseline HbA1c and 
sulfonylurea use. 
Diamant et 
al. (2010)223 
RCT, 26-weeks of intervention, adults 
with T2D not controlled on 
metformin alone or in combination 
with a SUs. Patients were randomised 
1:1 to exenatide weekly or glargine 
Discontinuation for any 
reason during 26-week 
intervention period. 
233 people randomised to 
exenatide (mean age 58.0 
years; SD 10.0; 52.0% male), 
223 people randomised to 
glargine insulin (mean age 58.0 
years; SD 9.0; 55.0% male). 
Discontinuation during follow up; 
exenatide 10.3%, glargine 6.3%. 
Adverse events cited as the most 
common reason for discontinuation 
in the exenatide group (12/24). 
No measure of treatment 
adherence. Short duration of 
study. Open-label design. 
Treatment 
randomisation 
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insulin once daily. 456 people started 
on treatment. 
Divino et 
al. (2013)224 
Retrospective cohort study, in the UK 
and Germany, from the IMS LifeLink™ 
EMR-EU databases between 2010 and 
2012 of adults with T2D initiating 
exenatide twice-daily or once weekly, 
liraglutide or glargine. 7,213 people 
included. 
Treatment modification 
(discontinuation, switch, 
or augmentation) during 
180-day period 
542 people started on twice 
daily exenatide, 114 people 
started on once weekly 
exenatide, 1,212 people 
started on liraglutide, and 
5,278 people started on 
glargine insulin (mean age 67.0 
years). Mean age for GLP1 
initiators 57.6 (not separately 
reported). 
Over 180-day period, treatment 
modification varied by treatment and 
country (Germany/UK %); exenatide 
twice daily (58.0/41.4), exenatide 
once weekly (40.8/no patients), 
liraglutide (54.1/39.2), and glargine 
(13.7/29.2). 
Large population size in two 
countries. No adjustment for 
confounding. Data available as 
conference abstract only; very 
limited description of the cohorts 
analysed. 
None 
Fabunmi et 
al. (2009)180 
Retrospective cohort study, in the 
USA, using HealthCore Integrated 
Research Database™ research 
databases of adults with T2D initiated 
on exenatide or glargine insulin. 
6,300 people included. 
Mean MPR over 1 year 
post initiation of therapy 
and proportion of people 
with MPR ≥ 80%. Duration 
of medication persistence 
(discontinuation gap 
defined as 60 or 90-days 
after the prescription 
supply duration) and 
adjusted survival analysis 
for persistence duration. 
Annual discontinuation 
rate. 
 
3,262 people started on 
exenatide (mean age 53.0 
years; SD 10.0; 46.0% male), 
3,038 people started on 
glargine insulin (mean age 56.0 
years; SD 12.0; 59.0% male). 
MPR was higher with exenatide (0.68 
vs 0.29; p<0.001). The proportion of 
people adherence (MPR ≥ 80%) was 
higher with exenatide (47% vs 29%; 
p<0.001). More people in the glargine 
group discontinued therapy using 
both 60-day and 90-day 
discontinuation gap definitions 
(p<0.001). 
Substantial and significant 
differences reported between 
groups particularly with gender 
and comorbidities which may 
explain observed differences.  
None 
Gaebler et 
al. (2011)225 
Retrospective cohort study in the 
USA, using administrative claims 
databases from May 2005 to 
December 2008. People over 60 with 
T2D, initiating glargine insulin or 
twice daily exenatide were included.  
6,526 people case matched. 
 
OR for medication 
discontinuation (gap of 60 
days between 
prescriptions) and OR for 
MPR ≥ 80%. 
3,263 people started on twice 
daily exenatide, matched with 
3,263 people started on 
glargine insulin. Mean cohort 
age 65 years (SD 4.9); 52% 
male. 
People taking exenatide twice daily 
were more likely to have a MPR ≥ 
80% (OR 1.93; 95% CI 1.72-2.17); and 
less likely to discontinue (OR 0.28; 
95% 0.25-0.31). 
Relatively large propensity 
matched cohorts. No sensitivity 
analysis of measurement of 
adherence/persistence. Only 
data from abstract available. 
Case-matching using 
propensity scores 
Gallwitz et 
al. (2011)226 
RCT in Germany, 26 weeks of 
intervention, adults with T2D not 
controlled on metformin alone or in 
combination with an SU or 
meglitininde. Patients were 
randomised to exenatide twice daily 
or premixed insulin aspart twice daily. 
354 people started on treatment. 
 
Discontinuation due to 
adverse events during 26 
week intervention period. 
181 people randomised to 
exenatide (mean age 57.0 
years; SD 10.0; 59.7% male), 
173 people randomised to 
premixed insulin aspart (mean 
age 57.0 years; SD 9.9; 55.5% 
male). 
Discontinuation during follow up due 
to adverse events; exenatide 7.2%, 
premixed insulin aspart 0.6%; p = 
0.0014. 
Total number of participants 
discontinuing for any reason not 
reported. No measure of 
adherence. Open-label design. 
Treatment 
randomisation 
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Gordon et 
al. (2010)227 
Retrospective cohort study using a 
large UK primary care database (The 
Health Improvement Network; THIN) 
people with T2D (≥35 years) initiated 
on NPH, detemir, glargine, or premix 
insulin. 8,009 people included. 
Primary outcome measure was 
change in HbA1c. 
Number of people 
remaining persistent at 12, 
24, and 36 months 
included as a secondary 
outcome. 
357 people started on detemir 
(mean age 58.9 years; SD 12.1; 
47.0% male), 2,197 people 
started on glargine (mean age 
61.1 years; SD 12.2; 45.0% 
male), and 1,463 people 
started on NPH insulin (mean 
age 60.7 years; SD 12.3; 46.0% 
male) 
Persistence at 12 months was: 
detemir 78%, glargine 83%, NPH 75%. 
At 36 months persistence was highest 
with glargine and lowest with NPH (p 
< 0.001). No 36 month data was 
available for detemir as it was 
licensed in mid-2004. 
Large population size. No 
adjustment for confounders. 
Exclusion of people switching 
insulin may bias sample. 
Definition of non-persistence not 
clear. 
None 
Grabner et 
al. (2012)228 
Retrospective cohort study in the 
USA, using OptumInsight™ and 
HealthCore® administrative claims 
databases during 2010. Adults with 
T2D, initiating liraglutide or glargine 
insulin were included and propensity 
score matched 1:1.  640 people case 
matched. 
Proportion of people 
remaining persistent with 
medication during 9 
months of follow up. 
320 people started on 
liraglutide, matched with 320 
people started on glargine 
insulin. Baseline characteristics 
reported as being well 
matched. 
Persistence at 9 months in the 
OptumInsight™ database was 
liraglutide vs glargine (56.0% vs 
63.4%; p=0.213) and HealthCore® 
(47.6% vs 68.3%; p<0.001). No 
difference in A1c reduction was 
reported. 
Small sample size. Limited 
reporting of patient 
characteristics, Definition of non-
persistence not reported. 
Case-matching using 
propensity scores 
He et al. 
(2015)176 
Retrospective cohort study in China, 
using Tianjin Urban Employee Basic 
Medical Insurance database from 
2008 to 2011. Adults with T2D, 
initiating insulin were included and 
grouped by insulin type. 24,192 
people included. 
OR for MPR ≥ 80% during 
12 month of follow up and 
HR for persistence with 
medication (non-
persistence defined as a 
medication gap ≥ 90 days) 
9,459 people started on 
analogue insulin, 12,556 
people started on human 
insulin, 2,177 people started 
on animal insulin (adherence 
not reported). Mean cohort 
age 58.9 years; 50.5% male. 
People prescribed analogue insulin 
(vs human insulin) were more likely 
to have a MPR ≥ 80% (OR 1.07; 95% 
CI 1.01-1.14); and less likely to 
discontinue (HR 0.88; 95% 0.84-0.91). 
Large sample size. No reporting 
of characteristics of each group 
available. Study on available in 
abstract form. Unclear what was 
adjusted for in regression 
models. 
Multivariate adjustment 
Holman et 
al., 
(2007)229 
RCT in the UK and Ireland, 1 year of 
intervention, adults with T2D not 
controlled on metformin and a SU. 
Patients were randomised to insulin 
aspart 30 twice daily, prandial insulin 
aspart thrice daily, or insulin detemir 
once or twice daily. 708 people 
randomised to treatment. 
Discontinuation for any 
reason during 1 year 
intervention period. 
235 people started on 
NovoMix 30 (mean age 61.7 
years; SD 8.9; 67.7% male), 239 
people started on NovoRapid 
(mean age 61.6 years; SD 10.5; 
63.6% male), 234 people 
started on Levemir (mean age 
61.9 years; SD 10.0; 61.1% 
male) 
Discontinuation during follow up; 
NovoMix 30 5.5% (13/235), 
NovoRapid 7.2% (17/239), Levemir 
4.3 (10/234).  Withdrawal of 
participation was more common 
reason on those on prandial 
NovoRapid insulin (13), vs biphasic 
NovoMix (4) or basal Levemir insulin 
(3). 
Only discontinuation reported. 
Open-label design. 
Treatment 
randomisation 
Levin et al. 
(2012a)230 
Retrospective cohort study, in the 
USA, using a national insurance 
claims database (the Integrated 
Health Care Information Services 
Impact database), of adults with T2D 
initiated on exenatide and glargine 
insulin, either in succession or 
simultaneously. 453 people included. 
Proportion of people 
remaining persistent at 1 
year (discontinuation 
defined as a prescribing 
gap longer than the 90th 
percentile of the time 
between the first and 
second prescriptions). 
Mean duration of 
persistence. 
281 people started on glargine 
followed by exenatide (mean 
age 53.9 years; SD 8.7; 52.3% 
male), 141 people started on 
exenatide then glargine (mean 
age 54.2 years; SD 8.4; 58.2% 
male). 
Persistence at 12 months was: 
glargine before exenatide 68% (mean 
duration 298; SD 99 days), glargine 
after exenatide 65% (310; SD 85 
days), exenatide before glargine 39% 
(257; SD 111 days), exenatide after 
glargine 45% (237; SD 121 days). 
Study groups were well 
characterised. Sensitivity analysis 
of discontinuation definition 
performed.  
Comparison within the 
same population 
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Levin et al. 
(2012b)231 
Retrospective cohort study, in the 
USA, using a large claims database 
(IHCIS) of adults with T2D initiated on 
glargine or liraglutide between April 
1, 2010 and March 31, 2012. 336 
people case matched. 
Proportion persistent with 
treatment at 1 year 
168 people started on glargine 
insulin matched with 168 
people started on liraglutide. 
Mean cohort age 53 years; 55% 
male. 
At 1 year persistence was 51.7% for 
glargine and 47.6% for liraglutide (p 
reported as non-significant). 
Small sample size. Limited 
reporting of patient 
characteristics, Definition of non-
persistence not reported. 
Case-matching using 
propensity scores 
Levin et al. 
(2014)232 
Retrospective cohort study, in the 
USA, using a large claims database of 
adults with T2D initiated on glargine 
or liraglutide between April 1, 2010 
and March 31, 2012. 4,490 people 
included. 
 
Proportion persistent with 
treatment at 1 year 
2,116 people started on 
glargine insulin (mean age 53.3 
years; 57.7% male), 2,374 
people started on liraglutide 
(mean age 52.3 years; 51.6% 
male). 
At 1 year persistence was 64.0% for 
glargine and 49.4% for liraglutide. 
Two database sources compared. 
Definition of persistence not 
available. Significant differences 
in baseline characteristics not 
adjusted for. 
None 
Lin et al. 
(2012)233 
Retrospective case-matched study, in 
the USA, using IMPACT® claims 
database of adults with T2D initiated 
on glargine or liraglutide between 
January and June 2010. 967 people 
included. 
 
Proportion persistent with 
treatment at 1 year 
557 people started on glargine 
insulin (10.7% ≥ 65 years; 
56.1% male), and 410 people 
started on liraglutide (6.5% ≥ 
65 years; 47.1% male). 
At 1 year persistence was 52.0% for 
glargine and 43.6% for liraglutide (no 
significance level reported). 
Small sample size. Substantial 
differences between groups with 
no adjustment or matching. 
Definition of non-persistence not 
reported. 
None 
Miao et al. 
(2013)234 
Retrospective case-matched study, in 
the USA, using IMPACT® claims 
database of adults with T2D 
previously on glargine and initiated 
on rapid acting insulin analogues or 
switched to pre-mixed insulin 
analogues. 2,012 patients were 
eligible, 746 included. 
Proportion of patients 
persisting with therapy at 
one year (discontinuation 
defined as a refill gap 
longer than the 90th 
percentile of the time 
between first and second 
prescriptions). MPR and 
adjusted MPR. 
 
373 people initiated on insulin 
glargine (mean age 56.7 years; 
SD 10.1; 56.8% male) and 373 
matched people initiated on 
premixed analogue insulin 
(mean age 56.1 years; SD 10.0; 
58.7% male) 
At one year persistence was 45.4% 
with premixed analogue insulin and 
55.9% with glargine; p<0.0001. 
Average persistence (days) was 254 
with premixed and 280 with glargine 
p<0.0001. Adjusted MPR was lower 
with premixed (0.66) than glargine 
(0.77); p<0.0001. 
Propensity score matching of 
groups. No measure of 
adherence or persistence with 
rapid acting insulin performed. 
Case-matching using 
propensity scores 
Pawaskar 
et al. 
(2013)181 
Retrospective cohort study, in the 
USA, from a Thompson Reuters 
MarketScan® research database of 
adults with T2D initiating exenatide 
twice daily or glargine insulin. 13,696 
people met inclusion criteria. 7,548 
people matched. 
Average time to 
discontinuation 
(discontinuation defined 
as a 90-day gap in 
prescription claims). 
Proportion of people 
modifying treatment by 18 
months and average time 
to treatment modification. 
3,774 people initiated on 
exenatide (mean age 57 years; 
SD 10; 54.4% male) and 3,774 
matched people initiated on 
glargine insulin (mean age 57 
years; SD 12; 54.3% male) 
At 18 months treatment modification 
had occurred in 69.1% with exenatide 
and 76.0% with glargine insulin; 
p<0.0001. Treatment discontinuation 
had occurred in 38.3% with exenatide 
and 40.0% with glargine; p=0.14. 
Average time to modification (days) 
was 159 with exenatide and 123 with 
glargine p<0.0001. Average time to 
discontinuation (days) was 156 with 
exenatide and 105 with glargine 
p<0.0001. 
 
Propensity score matching of 
groups. Large sample size. 
Comparison of treatment 
discontinuation with treatment 
modification. No sensitivity 
analysis performed on definition 
of discontinuation. 
Case-matching using 
propensity scores 
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Pscherer et 
al. (2015)235 
Retrospective cohort study, in 
Germany, from The Disease Analyzer 
database (IMS Health) of adults with 
T2D initiating glargine, basal 
supported oral therapy (BOT), or 
intensified conventional therapy (ICT, 
or NPH insulin as either part of BOT, 
or ICT. 5,736 people included. 
Average time to 
discontinuation 
(discontinuation defined 
as prescription of a new 
insulin type). Proportion of 
people remaining 
persistent at two years. 
In the BOT group: 1,398 people 
started on glargine (mean age 
67.7 years; SD 11.3; 54.2% 
male), 292 people started on 
detemir (mean age 66.4 years; 
SD 11.4; 54.8% male), and 874 
people started on NPH insulin 
(mean age 65.0 years; SD 11.1; 
54.9% male). In the ICT group 
866 people started on glargine 
(mean age 63.8 years; SD 12.8; 
57.4% male), 512 people 
started on detemir (mean age 
60.4 years; SD 12.9; 53.7% 
male), and 1,794 people 
started on NPH insulin (mean 
age 63.9 years; SD 11.9; 53.8% 
male). 
Persistence in the ICT group (median 
days; IQR): glargine (421; 252-574), 
detemir (361; 185-560), NPH (483; 
288-683) and in the BOT group: 
glargine (371; 203-524), detemir (323; 
196-447), NPH (334; 195-542). 
Proportion persistent after 24 months 
in the ICT group: glargine 84.3%, 
detemir 85.4%, NPH 85.6% (Log rank 
p = 0.536) and in the BOT group: 
glargine 64.5%, detemir 52.7%, NPH 
59.2% (Log rank p<0.001). Adjusted 
HR for discontinuation versus glargine 
in BOT group: detemir 1.56 (95% CI 
1.31-1.87), NPH 1.22 (1.07-1.38). No 
significant difference in HR for 
discontinuation between insulins in 
ICT group. 
Adjustment for potential 
confounders. Unusual definition 
of discontinuation. Prescribing 
gap not included as a marker for 
discontinuation. 
Multivariate adjustment 
for age, gender, diabetes 
duration >5 years, 
diabetologist care, 
health insurance and 
other medication use. 
Quinzler et 
al. (2012)236 
Retrospective cohort study, in 
Germany, using claims data from the 
German Statutory Health Insurance 
scheme of adults with T2D with 
initiating glargine, or NPH insulin as 
part of BOT. 97,998 people included. 
Proportion of people non-
persistent with initial 
therapy at 1 year. Non-
persistence defined as 
therapy switching. 
61,070 people initiated on 
glargine and 36,928 people 
initiated on NPH insulin as part 
of BOT. 
The annual rate of switching was 
higher with NPH insulin (24.6 per 100 
patients) than glargine insulin (16.8 
per 100 patients). Adjusted HR for 
switching 1.22 (95% CI 1.18 - 1.27). 
Large sample size with sensitivity 
analysis of persistence definition. 
Limited adjustment for 
confounders. No reporting or 
adjustment for patient 
demographics. 
Multivariate adjustment 
for treatment switching 
with adjustment for 
provider type, insurance, 
and number of previous 
oral medications. 
Raparla et 
al. (2012)237 
Retrospective cohort study, in the 
USA, using a claims database 
(HealthCore Integrated Research 
Database) of adults with T2D initiated 
on glargine or liraglutide between 
January and June 2010. 1,709 people 
included. 
Proportion persistent with 
treatment at 1 year and 
mean persistence 
duration. 
1,188 people stared on 
glargine insulin (mean age 56.9 
years; 57.7% male), and 521 
people started on liraglutide 
(mean age 53.2 years; 47.8% 
male). 
At 1 year persistence was 60.2% for 
glargine and 50.9% for liraglutide. The 
mean persistence duration was 221 
days for glargine and 165 days for 
liraglutide (no significance level 
reported). 
Definition of non-persistence not 
reported. Two treatment groups 
reported as having substantially 
different characteristics with no 
adjustment method used. 
None 
Russell-
Jones et al. 
(2009)238 
RCT, 26 weeks of intervention, adults 
with T2D not controlled on oral 
therapies. Patients were randomised 
2:1:2 to liraglutide once daily, 
placebo, or glargine insulin once 
daily. 581 people randomised to 
treatment. 
Discontinuation for any 
reason during 26-week 
intervention period. 
230 people randomised to 
liraglutide (mean age 57.6 
years; SD 9.5; 57.0% male), 232 
people randomised to glargine 
insulin (mean age 57.5 years; 
SD 10.5; 60.0% male). 
Discontinuation during follow up; 
liraglutide 10.0%, glargine 5.6%. 
Adverse events cited as the most 
common reason for discontinuation 
in the exenatide group (11/23). 
No measure of treatment 
adherence. Short duration of 
study. No breakdown of which 
adverse events lead to 
discontinuation. Open-label 
design for insulin with blinding to 
placebo or liraglutide. 
Treatment 
randomisation 
Thayer et 
al. (2012)239 
Retrospective cohort study, in the 
USA, using a claims database 
(OptumInsight™ Database) of adults 
with T2D initiated on glargine or 
liraglutide between January and July 
2010. 975 people included. 
Proportion persistent with 
treatment at 9 months. 
365 people stared on glargine 
insulin (mean age 56.2 years; 
57.5% male), and 1,798 people 
started on liraglutide (mean 
age 52.8 years; 50.7% male). 
At 9 months persistence was 63.1% 
for glargine and 52.1% for liraglutide 
(no significance level reported). 
Definition of non-persistence not 
reported. Two treatment groups 
reported as having substantially 
different characteristics with no 
adjustment method used. 
None 
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Walker et 
al. (2012)240 
Retrospective cohort study, in the 
USA, using two claims database 
(OptumInsight™ and HealthCore®) of 
adults with T2D initiated on glargine 
or liraglutide between January and 
July 2010. 975 people included. 
Proportion persistent with 
treatment at 9 months and 
at 1 year. 
886 people stared on glargine 
insulin (mean age 56.0 years), 
and 14,886 people started on 
liraglutide (mean age 53.0 
years). 
At 9 months persistence was 63.1% 
for glargine and 52.1% for liraglutide 
and at 12 months 60.2% for glargine 
and 50.9% for liraglutide (no 
significance level reported). 
Definition of non-persistence not 
reported. Two treatment groups 
reported as having substantially 
different characteristics with no 
adjustment method used. 
None 
Wang et al. 
(2013)241 
Retrospective cohort study, in the 
USA, from a MarketScan Commercial 
Claims and Encounters Database 
2003-2009 of adults with T2D 
initiating glargine insulin or NPH 
insulin. 2,454 people met inclusion 
criteria. 534 people case matched. 
Medication persistence 
(discontinuation gap 
defined as a gap longer 
than the 90th percentile 
gap between 1st and 2nd 
claims for each medication 
or medication switching). 
Adherence defined as MPR 
and adjusted MPR over the 
first year. 
356 people started on glargine 
insulin (mean age 49.0 years; 
SD 10.0; 57.1% male), matched 
with 178 people started on 
NPH insulin (mean age 49.0 
years; SD 10.0; 54.5% male). 
At one year persistence was 54.5% 
with insulin glargine and 43.8% with 
NPH insulin; p=0.0225. Average 
persistence (days) was 284 with 
glargine and 262 with NPH p=0.0178. 
MPR; 0.50 glargine, 0.45 NPH; 
p=0.0418.  Adjusted MPR; 0.67, 
glargine 0.61 NPH; p=0.0380.  
Propensity score matching of 
groups.  Adjusted and unadjusted 
measures of MPR reported. 
Sensitivity analysis of propensity 
matching method conducted. 
Case-matching using 
propensity scores 
Xie et al. 
(2013)242 
Retrospective cohort study, in the 
USA, from two administrative claims 
databases (OptumInsight™ and 
HealthCore®) in 2010 of adults with 
T2D initiating glargine insulin or 
liraglutide.  1,392 people met 
inclusion criteria. 824 people case 
matched. 
Medication persistence 
(discontinuation gap 
defined as a gap longer 
than the 90th percentile 
gap between 1st and 2nd 
claims for each medication 
or medication switching). 
412 people started on glargine 
insulin (59.7% male), matched 
with 412 people started on 
liraglutide (57.0% male). 
At nine months persistence was 
64.3% with insulin glargine and 51.9% 
with liraglutide; p=0.0003. Average 
persistence (days) was 239 with 
glargine and 207 with glargine 
p<0.0001. 
Propensity score matching of 
groups. Sensitivity analysis 
treatment persistence with 75 
centile and 95 centile of 
treatment gaps also analysed 
(similar outcome difference 
identified). Relatively small 
sample size. Selection process 
may have biased sample to 
include more compliant patients. 
Case-matching using 
propensity scores 
Table 9. Studies which provide a comparison between different classes of injectable therapy. 
BOT: basal supported oral therapy, CI: confidence interval, GLP1: glucagon-like peptide-1, HR: hazard ratio, ICT: intensified conventional therapy, IQR: interquartile range, MPR: medication possession ratio, NPH: 
neutral protamine Hagedorn, NYHA: New York Heart Association, OR: odds ratio, RCT: randomised controlled trial, SD: standard deviation. 
  
A COMPARISON OF MEDICATION ADHERENCE AND PERSISTENCE across drug classes IN PEOPLE WITH TYPE 2 DIABETES 
51 
 
Study Study design and population Measure of adherence 
or persistence 
Sample size and 
characteristics 
Study results Strengths and limitations Adjustment for 
confounding 
Barnett et al. 
(2007)186  
RCTs, 104 weeks of intervention, 
adults (35-80) with T2D not 
controlled on monotherapy with 
either metformin (study 1) or SU 
(study 2). Patients were randomised 
to inhaled insulin (Exhubera) or 
glibenclamide (study 2) or metformin 
(study 1). 922 people started on 
treatment. 
Discontinuation for any 
reason during the trial 
period 
In study 1: 235 people 
randomised to inhaled insulin 
and 211 to metformin. In study 
2: 243 people randomised to 
inhaled insulin and 233 to 
glibenclamide. 
Discontinuations were similar across 
the groups. Study 1: inhaled insulin 
31, SU 39. Study 2: inhaled insulin 40, 
metformin 43. 
No measure of medication 
adherence or duration of 
persistence. Open-label study 
design. 
Randomisation 
Table 10. Studies which provide a comparison between oral therapies and inhaled therapies. 
Only one study was found which met the review inclusion criteria. RCT: randomised controlled trial, SU: sulfonylurea
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3.2.1  COMPARISONS BETWEEN ORAL THERAPIES 
Thirty-one studies compared multiple oral agents (29 studies providing only comparisons between oral 
medications and two further studies which compared multiple oral agents and an injectable agent). Only the 
comparisons between oral medications are discussed here with the injectable-oral comparisons described in 
section 3.2.2. The majority of these studies were observational (23 retrospective cohort studies and five 
prospective cohort studies) and the remaining three studies were randomised controlled trials (RCTs). 
The largest number of class comparisons was made by Haupt et al. in a large Swedish study (n=171,220); six 
medication classes (metformin, TZDs, sulfonylureas, meglitinides, AGIs, and a fixed dose combination 
[metformin and rosiglitazone]) were compared.199 The highest adherence (mean MPR) was found with TZDs 
(rosiglitazone 92.8% and pioglitazone 92.3%) and the lowest with meglitinides and AGIs (repaglinide 86.4%, 
nateglinide 81.3%, and acarbose 81.1%). No other study provided a comparison with meglitinides or AGIs. 
Studies comparing DPP4 inhibitors with TZDs found better adherence (n=3)179 192 193 and better persistence (n=2) 
with DPP4 inhibitors.179 193 Numerous studies also compared DPP4 inhibitors with sulfonylureas (persistence n=8, 
and adherence n=6), however, no outcome type was reported by five or more studies precluding meta-analysis. 
Overall, in the observational studies, DPP4 inhibitors were reported to have better adherence179 192 193 209 and 
longer persistence179 193 207-210 than sulfonylureas. Two trials reported the proportion of discontinuations and 
found no significant difference between DPP4 inhibitors and sulfonylureas.195 196 Two studies compared 
adherence during Ramadan.44 187 These two prospective cohort studies compared adherence to vildagliptin with 
sulfonylureas using number of missed doses as the measure of adherence. Al-Arouj et al. found no difference in 
mean number of missed doses between groups, whereas Hanif et al. found lower adherence to sulfonylureas in 
their substantially smaller study (study sizes n= 1,315 and n=72 respectively).44 187 Only one study included an 
SGLT2 inhibitor (canagliflozin) which had better persistence than DPP4 inhibitors.212 
Meta-analysis was possible (n>5 studies) for several comparisons: A comparison of mean adherence (% 
measured using MPR or PDC) between metformin and sulfonylureas (n=6), metformin and TZDs (n=7), and 
sulfonylureas and TZDs (n=7). Sulfonylureas had better adherence than metformin; mean difference (MD) 
14.84% (95%CI 8.03 to 21.65%; p<0.0001) (Figure 7), as did TZDs; MD 15.03% (95%CI 2.78 to 27.29%; p=0.016) 
(Figure 8). Sulfonylureas had marginally lower adherence than TZDs; MD -1.68 % (95%CI -3.00 to -0.36 %; 
p=0.012) (Figure 9). 
 
Figure 7. A forest plot of mean difference in adherence (%) comparing metformin to sulfonylureas.  
Adherence was measured using MPR or PDC. Both fixed and random effect pooled estimates favour sulfonylureas. MD: mean difference. 
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Figure 8. A forest plot of mean difference in adherence (%) comparing metformin to thiazolidinediones. 
Adherence was measured using MPR or PDC. Both fixed and random effect pooled estimates favour TZDs. MD: mean difference, TZD: 
thiazolidinediones. 
 
 
Figure 9. A forest plot of mean difference in adherence (%) comparing sulfonylureas to thiazolidinediones. 
Adherence was measured using MPR or PDC. Both fixed and random effect pooled estimates favour sulphonylureas. MD: mean difference, 
TZD: thiazolidinediones. 
 
There were sufficient studies to compare the proportion of people considered adherent between metformin 
and sulfonylureas (n=7) and between metformin and TZDs (n=5). There was no significant difference in the 
proportion of people adherent in either comparison when results were combined using random effects models, 
with considerable study heterogeneity (Figure 10 and Figure 11). For treatment persistence only one comparison 
was possible; comparison of the proportion non-persistent between metformin and sulfonylureas (n=5). There 
was no difference between classes in the random effects model and again there was considerable study 
heterogeneity (Figure 12). 
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Figure 10. A forest plot of odds ratio for non-adherence comparing metformin to sulfonylureas. 
Random effect pooled estimates suggest no difference between medication classes. OR: odds ratio, NA: non-adherence. 
 
 
Figure 11. A forest plot of odds ratio for non-adherence comparing metformin to thiazolidinediones. 
Random effect pooled estimates suggest no difference between medication classes. OR: odds ratio, NA: non-adherence, TZD: 
thiazolidinediones. 
 
 
Figure 12. A forest plot of odds ratio for non-persistence comparing metformin to sulfonylureas. 
Random effect pooled estimates suggest no difference between medication classes. OR: odds ratio, NP: non-persistence. 
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3.2.2  COMPARISONS BEWEEN ORAL AND INJECTABLE THERAPIES  
Five studies compared oral and injectable therapies (Table 8), all of which were comparisons with GLP1 receptor 
agonists. These demonstrated shorter persistence with GLP1 receptor agonists than DPP4 inhibitors179 214 215 and 
SGLT2 inhibitors212, and lower adherence than with the sulfonylurea glimepiride213 and DPP4 inhibitors214. No 
meta-analysis was possible for any comparison. 
3.2.3  COMPARISONS BETWEEN INJECTABLE THERAPIES 
Of the 31 studies included which compared multiple injectable therapies (Table 9), 24 were observational studies 
(all retrospective) and the remaining five were RCTs. 
Only one study analysed prandial insulins. This study compared persistence between short acting human insulins 
and rapid acting analogue insulins when added to basal insulin, and found better persistence with analogue 
insulins.177 In an RCT, patients randomised to a three times daily prandial insulin analogue were more likely to 
withdraw from the study than those randomised to premixed twice daily or basal once daily insulins.229 Two 
observational studies compared both adherence and persistence in mixed insulins with long acting analogue 
insulins.217 234 Both studies found longer persistence with analogue insulins, however only Miao et al.234 found a 
difference in adherence (lower for premixed insulin). 
Several studies (n=6) compared insulin analogues with human insulins. Persistence was universally longer with 
analogue insulins although not all results were significant. We identified a total of five studies which reported 
data sufficient to compare the HR for non-persistence with long acting insulin analogues compared to human 
insulins. In the pooled sample (random effect model) non-persistence was less frequent with analogue insulins; 
HR 0.83 (95%CI 0.81-0.85; p<0.0001) (Figure 13). The results showed considerable heterogeneity (Tau²=0.086%; 
I²=87.6% [95%CI 73.5-94.2%]). 
 
Figure 13. A forest plot of the hazard ratio for treatment non-persistence comparing long-acting analogue insulins to human insulins. 
Both fixed and random effect pooled estimates favour analogue insulins. BOT; basal supported oral therapy, HR; hazard ratio, ICT; intensified 
conventional therapy, TE; Estimate of treatment effect, seTE; Standard error of treatment estimate. 
 
The most numerous comparisons were made between GLP1 receptor agonists and insulin (19 studies). Adverse 
events (predominantly nausea and injection site reactions) were the main reported determinant of this higher 
discontinuation rate (Table 9). For comparisons between GLP1 receptor agonists and long acting insulin 
analogues, there were sufficient studies to compare mean persistence duration (n=6) and OR for non-
persistence/treatment discontinuation (n=18). In the pooled samples persistence was shorter with GLP1 
receptor agonists; MD -33.83 days (95%CI -65.06 to -2.59 days; p=0.034) (Figure 14) and they also had a higher 
chance of non-persistence; OR 1.81 (95%CI 1.41 to 2.33; p<0.0001) (Figure 15).  
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Figure 14. A forest plot of the mean difference of treatment duration (days) comparing GLP 1 receptor agonists with long-acting analogue 
insulins. 
Both fixed and random effect pooled estimates favour persistence with analogue insulins. MD mean difference, SD; standard deviation.  
 
 
Figure 15. A forest plot of the odds ratio for treatment non-persistence comparing GLP1 receptor agonists with long-acting analogue 
insulins. 
Both fixed and random effect pooled estimates favour analogue insulins. NP; non-persistence, OR; odds ratio 
3.2.4  INHALED INSULIN COMPARISONS 
One paper described two RCTs where inhaled insulin was compared to metformin and the sulfonylurea 
glibenclamide (Table 10).186  All cause discontinuation during the two year trial period was reported and no 
difference was found between inhaled insulin and either oral therapies.  
3.2.5  QUALITY OF INCLUDED STUDIES 
When assessed using the Newcastle-Ottawa scale the quality of observational studies was found to be generally 
good, although a large proportion of studies did not adjust for potential confounders (Table 11). The risk of bias 
in randomised controlled trials was moderate with the main limitation being the lack of treatment concealment 
(open-label design) in almost all studies which contained one or more injectable therapies (Table 12).  
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Study Selection 
(4 max) 
Comparability 
(2 max) 
Outcome 
(3 max) 
Total 
(9 max) 
Studies comparing oral therapies only 
Al-Arouj et al. (2013)187 2 0 2 4 
Balkrishnan et al. (2006)188 4 0 3 7 
Barner et al. (2011)189 4 0 3 7 
Calip et al. (2015)178 2 0 3 5 
Chong et al. (2014)190 3 1 3 7 
Corrao et al. (2011)191 4 0 3 7 
Degli Esposti et al. (2014)192 4 2 3 9 
Farr et al. (2014)193 4 2 3 9 
Farsaei et al. (2011)194 3 0 3 6 
Grimes et al. (2015)197 4 2 3 9 
Hanif et al. (2013)44 2 0 2 4 
Hansen et al. (2010)198 3 0 3 6 
Haupt et al. (2009)199 3 0 3 6 
Jariwala et al. (2010)200 4 0 2 6 
Jermendy et al., (2012)201 4 0 3 7 
Patel et al. (2009)203 2 1 2 5 
Patel et al. (2010)204 3 2 2 7 
Plat et al. (2009)205 4 0 3 7 
Quillam et al. (2013)206 4 0 3 7 
Rathmann et al. (2013)207 4 2 3 9 
Rex et al. (2012)208 4 2 3 9 
Rozenfeld et al.  (2008)90 4 0 3 7 
Shenolikar et al. (2006)113 4 1 3 8 
Tunceli et al. (2014)209 4 2 3 9 
Valensi et al. (2014)210 3 2 3 9 
White et al. (2012)211 3 0 3 6 
Studies including a comparison of oral and injectable therapies 
Curkendall et al. (2013)179 4 2 1 7 
Diels et al. (2015)212 4 2 3 9 
Koro et al. (2013)214  3 0 1 4 
Montilla et al. (2014)215  3 0 3 6 
Studies comparing injectable therapies only 
Baser et al. (2011)216 4 2 3 9 
Baser et al. (2013)217 4 2 3 9 
Bhushan et al. (2009)219 4 0 2 6 
Bonafede et al. (2011)177 4 2 3 9 
Buysman et al. (2011)220 4 2 3 9 
Cooke et al. (2010)221 4 2 3 9 
Divino et al. (2013)224 4 0 2 6 
Fabunmi et al. (2009)180 4 0 3 7 
Gaebler et al. (2011)225 4 2 3 9 
Gordon et al. (2010)227 4 0 3 7 
Grabner et al. (2012)228 4 2 2 8 
He et al. (2015)176 4 1 2 7 
Levin et al. (2012a)230 4 1 3 8 
Levin et al. (2012b)231 4 2 3 9 
Levin et al. (2014)232 4 0 3 7 
Lin et al. (2012)233 4 0 3 7 
Miao et al. (2013)234 4 2 3 9 
Pawaskar et al. (2013)181 4 2 3 9 
Pscherer et al. (2015)235 4 2 3 9 
Quinzler et al. (2012)236 4 1 3 8 
Raparla et al. (2012)237 4 0 3 7 
Thayer et al. (2012)239 4 0 2 6 
Walker et al. (2012)240 4 0 3 7 
Wang et al. (2013)241 4 2 3 9 
Xie et al. (2013)242 4 2 2 8 
Table 11. The quality of observational studies assessed using the Newcastle-Ottawa scale. 
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Studies comparing oral therapies 
Filozof et al. (2010) ? ? L L L ? L 
Göke et al. (2010) L L L L L L L 
Hauck et al. (2014) L L L L L L L 
Studies comparing oral and injectable therapies 
Garber et al. (2009) L L L L L L L 
Studies comparing injectable therapies 
Bergenstal et al. (2009) L H H H L L L 
Davies et al. (2013) ? H H H L L L 
Diamant et al. (2010) L H H H L L L 
Gallwitz et al. (2011) ? H H H ? L L 
Holman et al., (2007) L H H H L L L 
Russell-Jones et al. (2009) L H H H L L L 
Studies comparing oral and inhaled therapies 
Barnett et al. (2007) L H H H L ? L 
Table 12. The quality of randomised controlled trials assessed using the Cochrane risk of bias assessment tool. 
L – Low risk of bias; ? – Unknown risk of bias; H – high risk of bias. 
 
3.2.6  RISK OF PUBLICATION BIAS 
There were sufficient studies (n≥10) reporting the comparison of odds ratio for treatment non-persistence 
comparing GLP1 receptor agonists with long-acting analogue insulins to assess publication bias. There was no 
viable funnel plot asymmetry (Figure 16) and no asymmetry detected Egger’s test (p=0.6766) in these studies. 
There were insufficient studies to reliable examine for publication bias with any other comparison. 
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Figure 16. A funnel plot studies reporting the odds ratio for treatment non-persistence comparing GLP 1 receptor agonists with long-
acting analogue insulins. 
Egger’s test for asymmetry in the included studies did not suggest significant asymmetry (p=0.6766). 
 
3.2.7  DEFINITIONS OF ADHERENCE AND PERSISTENCE  
Definitions of adherence varied considerably across studies with medication adherence reported as; mean 
number of missed doses, proportion of people taking ≥ 90% of doses, mean or median MPR or PDC, proportion 
of people with a MPR or PDC ≥ 80%, or odds ratio for adherence. MPR was frequently adjusted, to account for 
differing refill sizes between products, using a predefined centile of refill time between the first and second 
prescription. Only one identified RCT reported medication adherence.213 
Definitions of medication persistence were even more varied. Persistence was reported as mean time to a non-
persistence event, the proportion of people remaining persistent at a given time after initiation (commonly 9 
months, 1 year, or 2 years), or the OR or HR of non-persistence. A non-persistence event was defined as a fixed 
gap between medication refills (commonly 60 or 90 days), as an adjusted gap based using a predefined centile 
of refill time between the first and second prescription. Time to treatment modification (discontinuation, 
switching or augmentation) was also reported in some studies, and again definitions were very variable. 
3.3 REAL-WORLD DATA ANALYSIS OF MEDICATIONS PERSISTENCE AND ADHERENCE 
3.3.1  MEDICATION PERSISTENCE 
From an early upload of the RCGP RSC cohort (1st January 2016) a comparative analysis of medication persistence 
was performed. This dataset comprised 1,238,909 people from 128 primary care practices, with 64,909 (5.2%) 
people identified as having diabetes. Of these 60,327 (92.9%) were categorised as T2D; a crude prevalence of 
6.05% T2D in adults. The age-gender direct standardised prevalence for T2D in the cohort was 6.25% (95% CI 
6.20 – 6.30%), compared to the 2011 UK census. In the T2D population the mean age was 66.1 (SD 13.8) years, 
and 26,792 (41.3%) were female (Table 13). 
  
A COMPARISON OF MEDICATION ADHERENCE AND PERSISTENCE across drug classes IN PEOPLE WITH TYPE 2 
DIABETES 
60 
 
Characteristic n (%) or 
mean (SD) 
Characteristic n (%) or 
mean (SD) 
Age recorded 60,327 (100.0) HbA1c measured 57,159 (94.7) 
Age (years) 66.1 (13.8)  HbA1c (mmol/mol)† 61.9 (22.4) 
Gender recorded 60,327 (100.0) BMI measured 59,043 (97.9) 
Female 26,792 (44.4)  BMI (kg.m-2) 30.7 (6.4) 
Ethnicity recorded 51,747 (85.8) Blood pressure measured 60,106 
 White 42,284 (70.1)  SBP (mmHg) 132.0 (14.7) 
 Asian 5,706 (9.5)  DBP (mmHg) 75.0 (9.6) 
 Black 2,648 (4.4) Amputation 488 (0.8) 
 Mixed 552 (0.9) Peripheral neuropathy 3,845 (6.4) 
 Other 557 (0.9) Retinopathy 21,408 (35.5) 
IMD recorded 59,830 (99.2) Peripheral vascular disease 2,191 (3.6) 
 IMD score* 21.0 (16.3) Hypertension 35,657 (59.1) 
Smoking status recorded 60,067 (99.6) Atrial fibrillation 5,302 (8.8) 
 Never 20,227 (33.5) Angina 4,970 (8.2) 
 Current 7,932 (13.1) Stroke 2,605 (4.3) 
 Ex-smoker 31,908 (52.9) Myocardial infarction 2,886 (4.8) 
Alcohol use recorded 54,768 (90.8) Congestive cardiac failure 3,427 (5.7) 
 None 18,469 (30.6) Transient ischaemic attack 1,960 (3.2) 
 Within limits 12,489 (20.7) Coronary artery disease‡ 5,374 (8.9) 
 Excess 23,810 (39.5) Chronic kidney disease§ 11,164 (18.5) 
Duration of diabetes recorded 60,327 (100.0) Renal replacement therapy 335 (0.6) 
 <4 years 18,864 (31.3) Dementia 2,218 (3.7) 
 4≤ x <7 years 12,066 (20.0) Depression 7,366 (12.2) 
 7≤ x <10 years 10,994 (18.2) Rheumatoid arthritis 1,074 (1.8) 
 ≥10 years 18,403 (30.5) Chronic liver disease 3,231 (5.4) 
Table 13. The characteristics of an early cohort of adults with T2D (n=60,327). 
SD = standard deviation. IMD = index of multiple deprivation, BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood 
pressure, LDL = low- density lipoprotein, eGFR = estimated Glomerular Filtration Rate. *A higher score equates to a higher level or 
deprivation although the scale is non-linear. †HbA1c value at the ame of diagnosis. ‡A composite of myocardial infarction, revascularisation 
procedures, and acute cardiac syndrome. §Chronic kidney disease includes stages 3 to 5 only. 
 
The median duration of follow-up was 6.6 (IQR 3.17-10.9) years. During the follow-up period, the majority 42,810 
(70.9%) of people had one or more oral medications prescribed. Metformin was the most commonly prescribed 
medication, followed by sulfonylureas (Table 14). 
 
Medication class Number of people prescribed 
medication in class 
n (%) 
Number of medication 
persistence events 
n 
Metformin 41,317 (68.5) 30,156 
Thiazolidinediones 6,084 (10.1) 4,308 
Sulfonylureas 20,819 (34.5) 11,347 
Meglitinides 602 (1.0) 244 
Alpha-glucosidase inhibitors 370 (0.6) 109 
DPP4 inhibitors 9,614 (15.9) 8,125 
SGLT2 inhibitors 1,642 (2.7) 1,439 
Table 14. The number of people with T2D (n=60,327) prescribed medication during the follow-up period. 
The number of medication persistence events can include several medications within the same class taken by a single person where two 
new prescriptions were identified during the follow up period. 
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We measured persistence with 55,728 oral medications (Table 14). Non-persistence was identified in 38,169 
(68.5%) of these during follow-up. The remaining 17,559 medications had ongoing persistence at the end of 
follow-up. The median persistence duration overall was 2.25 (95% CI 2.20-2.30) years. Metformin had the 
longest crude persistence and AGIs had the shortest (Table 15). 
Medication class Median 
persistence 
years (95% CI) 
Persistence at 6 
months 
% (95% CI) 
Persistence at 1 
year 
%(95% CI) 
Persistence at 2 
year 
% (95% CI) 
Persistence at 5 
year 
% (95% CI) 
Metformin 3.04 (2.94-3.12) 80.5 (80.9-80.0) 70.1 (70.6-69.6) 58.0 (58.6-57.4) 39.6 (40.2-39.0) 
Thiazolidinediones 1.55 (1.48-1.64) 75.6 (76.8-74.2) 61.2 (62.7-59.8) 43.0 (44.5-41.5) 15.7 (16.8-14.5) 
Sulfonylureas 2.12 (2.03-2.23) 76.6 (77.4-75.8) 64.8 (65.7-63.9) 51.3 (52.3-50.3) 31.6 (32.7-30.6) 
Meglitinides 0.81 (0.58-1.08) 58.4 (64.3-51.8) 45.1 (51.3-38.7) 28.8 (34.7-23.0) 7.5 (11.9-4.3) 
Alpha-glucosidase 
inhibitors 
0.64 (0.27-0.85) 52.0 (61.0-42.0) 35.3 (44.6-26.2) 26.3 (35.4-18.0) 13.7 (22.2-7.2) 
DPP4 inhibitors 1.69 (1.62-1.78) 76.1 (77.0-75.1) 62.2 (63.3-61.0) 45.5 (46.8-44.2) 23.0 (24.5-21.5) 
SGLT2 inhibitors NA 79.5 (81.7-76.9) 69.5 (72.5-66.2) 54.8 (60.8-48.2) NA 
Table 15. Medication persistence duration by medication class.  
Median medication persistence durations and number of people remaining persistent with medication at 6 months, 1 year, 2 years, and 5 
years are shown. 
  
Figure 17. Kaplan-Meier plot of medication persistence in T2D by ethnicity. 
Primary medication persistence with all oral medications for T2D is shown. 
 
Unadjusted analysis using Kaplan-Meier plots demonstrated crude differences in medication persistence with 
age, gender, ethnicity (Figure 17), IMD quintile, alcohol use, glycaemic control, and duration of diabetes. 
In Cox regression analyses (Table 16) factors associated with improved medication persistence include older age, 
male gender, white ethnicity, HbA1c 42-60 mmol/mol, presence of hypertension, and no previous glucose 
lowering medication use. Factors associated with non-persistence include presence of neuropathy, history of 
myocardial infarction, heart failure, dementia, depression, and chronic liver disease. All medication classes had 
higher adjusted hazard ratios for non-persistence than metformin except SGLT2 inhibitors. Variables not 
associated with persistence (and therefore removed from the model) were smoking status, BMI, previous 
amputations, retinopathy, atrial fibrillation, angina, previous stroke or transient ischaemic attack (TIA), and use 
of renal replacement therapy. 
White ethnicity  
Mixed ethnicity  
Asian ethnicity  
Black ethnicity  
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Characteristic n (%)* HR (95% CI) P value 
Age 
  ≤ 30 years 373 (0.7) 1.66 (1.46-1.87) <0.001 
  31 to 50 years 8,912 (16.0) 1.00 [reference]  
  51 to 60 years 13,571 (24.4) 0.83 (0.80-0.86) <0.001 
  61 to 75 years 23,375 (41.9) 0.76 (0.73-0.78) <0.001 
  > 75 years 9,497 (17.0) 0.75 (0.71-0.78) <0.001 
Male 32,162 (57.7) 0.93 (0.91-0.95) <0.001 
Ethnicity 
  White 40,540 (72.7) 1.00 [reference]  
  Asian 4,871 (8.7) 1.53 (1.47-1.59) <0.001 
  Black 2,016 (3.6) 1.83 (1.73-1.93) <0.001 
  Mixed 453 (0.8) 1.29 (1.15-1.45) <0.001 
  Other 470 (0.8) 1.58 (1.41-1.77) <0.001 
  Not Recorded 7,378 (13.2) 0.99 (0.96-1.02) 0.598 
IMD quintile 
  1 (most deprived) 11,228 (20.1) 1.00 [reference]  
  2 9,669 (17.4) 1.05 (1.02-1.09) 0.004 
  3 9,315 (16.7) 1.01 (0.97-1.05) 0.614 
  4 12,111 (21.7) 0.97 (0.94-1.01) 0.123 
  5 (least deprived) 13,041 (23.4) 0.93 (0.90-0.96) <0.001 
  Not Recorded 364 (0.7) 1.06 (0.92-1.21) 0.429 
Alcohol intake 
  None 17,697 (31.8) 1.00 [reference]  
  Within recommended limits 11,327 (20.3) 1.02 (0.99-1.05) 0.232 
  Over recommended limits 21,849 (39.2) 1.00 (0.97-1.03) 0.958 
  Alcoholic 1,642 (2.9) 1.09 (1.02-1.16) 0.016 
  Not Recorded 3,213 (5.8) 1.13 (1.07-1.18) <0.001 
HbA1c (mmol/mol) 
  x<42 1,070 (1.9) 1.13 (1.04-1.22) 0.004 
  42≤x<50 5,139 (9.2) 1.00 [reference]  
  50≤x<60 13,428 (24.1) 0.95 (0.92-1.00) 0.030 
  60≤x<70 13,922 (25.0) 0.99 (0.95-1.03) 0.696 
  70≤x<100 15,902 (28.5) 1.10 (1.06-1.15) <0.001 
  ≥100 4,103 (7.4) 1.16 (1.10-1.23) <0.001 
Not Measured 2,164 (3.9) 1.16 (1.09-1.24) <0.001 
Duration of diabetes 
  1-3 years 24,922 (44.7) 1.00 [reference]  
  4-6 years 13,063 (23.4) 0.98 (0.95-1.01) 0.166 
  7-9 years 10,309 (18.5) 0.96 (0.93-0.99) 0.013 
  ≥10 years 7,434 (13.3) 0.95 (0.91-0.99) 0.012 
Complications 
  Peripheral neuropathy 4,604 (8.3) 1.08 (1.04-1.12) <0.001 
Comorbidities 
  Hypertension 34,060 (61.1) 0.96 (0.93-0.98) <0.001 
  Myocardial infarction 2,678 (4.8) 1.07 (1.02-1.12) 0.011 
  Congestive cardiac failure 3,254 (5.8) 1.08 (1.03-1.13) 0.002 
  CKD stages 3-5 10,647 (19.1) 1.09 (1.06-1.12) <0.001 
  Dementia 1,599 (2.9) 1.07 (1.01-1.14) 0.027 
  Depression 7,286 (13.1) 1.08 (1.05-1.12) <0.001 
  Chronic liver disease 3,492 (6.3) 1.12 (1.07-1.17) <0.001 
Number of previous oral glucose lowering medications 
  None 39,986 (71.8) 1.00 [reference]  
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  One 10,156 (18.2) 1.06 (1.03-1.10) <0.001 
  Two 3,731 (6.7) 1.13 (1.08-1.18) <0.001 
  Three or more 1,855 (3.3) 1.13 (1.06-1.21) <0.001 
Number of concurrent oral glucose lowering medications 
  None 13,164 (23.6) 1.00 [reference]  
  One 20,686 (37.1) 1.08 (1.04-1.12) <0.001 
  Two or more 21,878 (39.3) 0.93 (0.90-0.97) <0.001 
Medication class 
  Metformin 30,156 (54.1) 1.00 [reference]  
  Thiazolidinediones 4,308 (7.7) 1.71 (1.64-1.77) <0.001 
  Sulfonylureas 11,347 (20.4) 1.20 (1.16-1.24) <0.001 
  Meglitinides 244 (0.4) 2.25 (1.97-2.58) <0.001 
  Alpha-glucosidase inhibitors 109 (0.2) 2.45 (1.98-3.02) <0.001 
  DPP4 inhibitors 8,125 (14.6) 1.43 (1.38-1.49) <0.001 
  SGLT2 inhibitors 1,439 (2.6) 1.04 (0.93-1.17) 0.458 
Table 16. Cox regression analysis of factors associated with medication persistence. 
Hazard ratios (HR) for non-persistence are shown. Number of medications included = 55,728. Model R2 = 0.061. 
 
3.3.2  MEDICATION ADHERENCE 
Data from a recent extract of the RCGP RSC cohort (31st December 2016) was used for the comparative analysis 
of medication adherence. This dataset comprised 2,994,914 people from 164 primary care practices. This data 
extract included historic data on patients no longer registered with their RCGP RSC practice, hence the larger 
population size than the dataset used for the analysis of medication persistence. From this dataset 145,546 
people with T2D were identified. Prescription directions for all oral diabetes medications were extracted from 
this group. 
After several iterations on a sample of 500 unique prescription directions the processing algorithm shown in 
Figure 18 was generated. This was manually validated against a further 200 prescription directions and found to 
have an accuracy of 95%. 
In the 145,546 people with T2D 169,349 oral medications prescriptions were identified. Of these 76,593 were 
initiated before 1st January 2016 and continued beyond this date. These prescription events were therefore 
eligible for inclusion in the adherence analysis. Of these 58,024 (75.6%) had no prescriptions of indeterminate 
duration during 2016. The proportion of indeterminate prescriptions varied between medications and classes 
(Table 17). 
Of those with T2D, 27,422 (18.8%) had a prescription for one or more diabetes medications initiated before 1st 
January 2016 and continued beyond this date in an EMIS WEB practice. In this T2D cohort the mean age was 
66.0 (SD 13.1) years, and 11,460 (41.8%) were female (Table 18). 
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Medication/Class Number of new 
prescriptions 
N 
Number starting prior to 2016 
and continuing into 2016 
N (%) 
Number with no indeterminate 
prescriptions during 2016 
N (%) 
Metformin 85,912 45,379 (52.8) 30,447 (67.1) 
Acarbose 970 85 (8.8) 65 (76.5) 
Glibenclamide 2,009 101 (5.0) 89 (88.1) 
Gliclazide 44,721 17,097 (38.2) 14,568 (85.2) 
Glimepiride 3,295 798 (24.2) 716 (89.7) 
Glipizide 1,370 280 (20.4) 246 (87.9) 
All Sulphonylureas 51,395 18,276 (35.6) 15,619 (85.5) 
Pioglitazone 9,128 1,937 (21.2) 1,796 (92.7) 
Nateglinide 343 37 (10.8) 29 (78.4) 
Repaglinide 1,023 137 (13.4) 70 (51.1) 
All Meglitinides 1,366 174 (12.7) 99 (56.9) 
Alogliptin 630 493 (78.3) 471 (95.5) 
Linagliptin 2,911 1,688 (58.0) 1,599 (94.7) 
Saxagliptin 1,324 564 (42.6) 546 (96.8) 
Sitagliptin 12,557 5,913 (47.1) 5,493 (92.9) 
Vildagliptin 299 75 (25.1) 74 (98.7) 
All DPP4 inhibitors 17,721 8,733 (49.3) 8,183 (93.7) 
Canagliflozin 633 473 (74.7) 450 (95.1) 
Dapagliflozin 1,912 1,290 (67.5) 1,136 (88.1) 
Empagliflozin 312 246 (78.8) 229 (93.1) 
All SGLT2 inhibitors 2,857 2,009 (70.3) 1,815 (90.3) 
All medications 169,349 76,593 (45.2) 58,024 (75.8) 
Table 17. The number of new prescription events examined for the level of medication adherence by drug and class. 
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Figure 18. The directions processing algorithm used to determine the length of a prescription. 
The algorithm determines the daily frequency and number of tablets (items) per dose e.g. 2 BD is two tablets per dose, twice per day.   
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Characteristic n (%) or mean (sd) Characteristic n (%) or mean (sd) 
Age 66.03 (13.11) HbA1c (mmol/mol) 
Female 11,460 (41.8)    x<42 8,085 (29.5) 
Ethnicity 
 
   42≤x<50 3,845 (14.0) 
   White 19,128 (69.8)    50≤x<60 1,929 (7.0) 
   Asian 3,133 (11.4)    60≤x<70 2,245 (8.2) 
   Black 1498 (5.5)    70≤x<100 74 (0.3) 
   Mixed 263 (1.0)    ≥100 11,244 (41.0) 
   Other 285 (1.0) Body mass index 
   Missing 3,115 (11.4)    Underweight 140 (0.5) 
IMD quintile    Normal weight 3,946 (14.4) 
   1 (most deprived) 5,558 (20.3)    Overweight 9,065 (33.1) 
   2 5,006 (18.3)    Class I obesity 7,714 (28.1) 
   3 5,154 (18.8)    Class II obesity 3,854 (14.1) 
   4 5,672 (20.7)    Class III obesity 2,450 (8.9) 
   5 (least deprived) 5,977 (21.8)    Missing 253 (0.9) 
   Missing 55 (0.2) Duration of diabetes (years) 
Smoking status    0-5 5,705 (20.8) 
   Never smoked 7,484 (27.3)    6-10 8,036 (29.3) 
   Active smoker 3,938 (14.4)    11-15 7,603 (27.7) 
   Ex-smoker 15,977 (58.3)    16-20 3,822 (13.9) 
   Not recorded 23 (0.1)    20+ 2,256 (8.2) 
Alcohol intake Comorbidities and complications 
   None 7,503 (27.4) Angina 2,695 (9.8) 
   Within recommended limits 8,096 (29.5) Atrial fibrillation 2,434 (8.9) 
   Over recommended limits 10,340 (37.7) Congestive cardiac failure 1,346 (4.9) 
   Alcoholic 1,191 (4.3) Hypertension 17,710 (64.6) 
   Not Recorded 292 (1.1) Stroke or TIA 2,235 (8.2) 
  Peripheral arterial disease 1,262 (4.6) 
  CKD stages 3-5 6,355 (23.2) 
  Amputation 359 (1.3)  
Table 18. The characteristics of people with T2D suitable for analysis of medication adherence (n=27,422).  
The average level of adherence (PDC) to 58,024 medications in the T2D adherence cohort was mean; 84.7% (SD 
22.3%), median 95.1% (IQR: 78.9-100.0%). As suggested by the differences between the mean and median 
average values the distribution of adherence was heavily negatively skewed (Figure 19). There was considerable 
variation in the crude levels of adherence between medications and medication classes (Table 19 and Figure 20). 
 
 
 
 
 
 
Figure 19. The distribution of medication 
adherence (PDC) for all oral diabetes 
medications during 2016. 
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Medication/Class Number of prescription 
events analysed 
N 
PDC 
Mean (SD) 
PDC 
Median (IQR) 
Metformin 30,447 83.7 (22.6) 93.7 (76.7-99.7) 
Acarbose 65 85.9 (19.1) 93.2 (82.2-100.0) 
Glibenclamide 89 83.0 (23.0) 92.9 (76.4-99.7) 
Gliclazide 14,568 84.7 (23.0) 95.9 (78.9-100.0) 
Glimepiride 716 89.3 (19.0) 97.8 (88.8-100.0) 
Glipizide 246 82.0 (25.9) 96.2 (76.0-100.0) 
All Sulphonylureas 15,619 84.9 (22.9) 96.2 (79.5-100.0) 
Pioglitazone 1,796 89.4 (18.8) 98.1 (88.5-100.0) 
Nateglinide 29 91.0 (12.3) 97.0 (92.1-98.9) 
Repaglinide 70 83.9 (23.0) 95.8 (74.9-100.0) 
All Meglitinides 99 86.0 (20.6) 95.9 (79.3-100.0) 
Alogliptin 471 89.2 (17.9) 97.5 (87.0-100.0) 
Linagliptin 1,599 88.6 (19.6) 97.8 (87.9-100.0) 
Saxagliptin 546 89.7 (16.9) 97.8 (87.1-100.0) 
Sitagliptin 5,493 86.2 (22.0) 96.4 (83.3-100.0) 
Vildagliptin 74 87.1 (19.7) 95.9 (83.4-100.0) 
All DPP4 inhibitors 8,183 87.1 (21.0) 97.0 (84.4-100.0) 
Canagliflozin 450 89.2 (17.6) 98.1 (86.7-100.0) 
Dapagliflozin 1,136 86.4 (20.9) 96.4 (82.1-100.0) 
Empagliflozin 229 83.3 (22.5) 93.4 (75.1-99.5) 
All SGLT2 inhibitors 1,815 86.7 (20.4) 96.4 (82.5-100.0) 
All medications 58,024 84.7 (22.3) 95.1 (78.9-100.0) 
Table 19. A comparison of crude medication adherence (PDC) across different medications and medication classes during 2016. 
PDC is reported as the percentage of days covered during 2016 (365 days). 
  
 
Figure 20. A comparison of the crude medication adherence (PDC) across different medications and medication classes during 2016. 
PDC is shown as the median percentage of days covered during 2016 (365 days) with the error bars representing the upper and lower 
quartiles of PDC. 
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In linear regression analyses, after stepwise elimination of non-significant variables, factors associated with 
improved medication adherence include older age, male gender, white ethnicity, less socioeconomic 
deprivation, previous smoking, lower HbA1c, presence of hypertension or CKD, and fewer previous glucose 
lowering medications (Table 20). Factors associated with non-adherence include the presence of alcohol related 
disease, history of myocardial infarction, and stroke/TIA. All medication classes were associated with better 
adherence than metformin except meglitinides and AGIs. Variables not associated with adherence (and 
therefore removed from the model) were BMI, diabetes complications, atrial fibrillation, angina, and use of renal 
replacement therapy. The logistic regression model showed similar trends for all predictors (Table 20). 
 
Characteristic Linear regression model Logistic regression model 
Estimate (95% CI) P value OR (95% CI) P value 
Age 
  ≤ 40 years 0.0 [reference] 
 
1.00 [reference] 
 
  41 to 50 years 6.2 (4.9 to 7.4) <0.001 1.44 (1.28 to 1.62) <0.001 
  51 to 60 years 9.3 (8.2 to 10.5) <0.001 1.89 (1.69 to 2.11) <0.001 
  61 to 75 years 11.0 (9.8 to 12.1) <0.001 2.21 (1.98 to 2.48) <0.001 
  > 75 years 11.9 (10.7 to 13.1) <0.001 2.63 (2.34 to 2.96) <0.001 
Female -0.8 (-1.2 to -0.4) <0.001 0.95 (0.91 to 0.99) 0.021 
Ethnicity 
  White 0.0 [reference] 
 
1.00 [reference] 
 
  Asian -5.3 (-5.9 to -4.7) <0.001 0.59 (0.56 to 0.63) <0.001 
  Black -9.2 (-10.0 to -8.3) <0.001 0.43 (0.39 to 0.46) <0.001 
  Mixed -6.3 (-8.2 to -4.4) <0.001 0.53 (0.44 to 0.64) <0.001 
  Other -7.5 (-9.3 to -5.7) <0.001 0.49 (0.41 to 0.58) <0.001 
  Not Recorded -0.3 (-0.8 to 0.2) 0.280 0.97 (0.91 to 1.03) 0.291 
IMD quintile 
  1 (most deprived) 0.0 [reference] 
 
1.00 [reference] 
 
  2 0.8 (0.3 to 1.4) 0.005 1.05 (0.99 to 1.12) 0.080 
  3 1.1 (0.5 to 1.7) <0.001 1.14 (1.08 to 1.22) <0.001 
  4 1.3 (0.8 to 1.9) <0.001 1.12 (1.06 to 1.19) <0.001 
  5 (least deprived) 1.1 (0.5 to 1.7) <0.001 1.15 (1.08 to 1.22) <0.001 
  Not Recorded 4.0 (0.4 to 7.6) 0.029 1.62 (1.04 to 2.52) 0.034 
Smoking status 
  Never smoked 0.0 [reference] 
 
1.00 [reference] 
 
  Active smoker -0.9 (-1.5 to -0.3) 0.003 0.92 (0.87 to 0.98) 0.014 
  Ex-smoker 0.7 (0.3 to 1.1) 0.002 1.11 (1.06 to 1.16) <0.001 
  Not Recorded 3.7 (-4.5 to 11.9) 0.372 1.12 (0.48 to 2.60) 0.799 
Alcohol intake 
  None 0.0 [reference] 
 
1.00 [reference] 
 
  Within recommended limits 0.1 (-0.3 to 0.6) 0.560 1.05 (1.00 to 1.11) 0.062 
  Over recommended limits -0.3 (-0.7 to 0.2) 0.248 0.99 (0.94 to 1.04) 0.798 
  Alcoholic -1.7 (-2.7 to -0.8) <0.001 0.81 (0.73 to 0.89) <0.001 
  Not Recorded -1.8 (-3.8 to 0.1) 0.067 0.92 (0.75 to 1.13) 0.426 
HbA1c (mmol/mol) 
  x<53 1.1 (0.6 to 1.5) <0.001 1.13 (1.08 to 1.19) <0.001 
  53≤x<64 0.0 [reference] 
 
1.00 [reference] 
 
  64≤x<74 -2.3 (-2.8 to -1.7) <0.001 0.82 (0.77 to 0.87) <0.001 
  74≤x<85 -4.2 (-4.9 to -3.5) <0.001 0.66 (0.61 to 0.71) <0.001 
  ≥85 -7.3 (-7.9 to -6.6) <0.001 0.52 (0.49 to 0.56) <0.001 
  Not recorded -13.3 (-17.3 to -9.4) <0.001 0.54 (0.37 to 0.79) 0.002 
Duration of diabetes 
  0-5 years 0.0 [reference] 
 
1.00 [reference] 
 
  6-10 years -0.8 (-1.4 to -0.2) 0.005 0.93 (0.88 to 0.99) 0.017 
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  11-15 years -1.2 (-1.8 to -0.6) <0.001 0.87 (0.82 to 0.93) <0.001 
  16-20 years -0.3 (-1.0 to 0.4) 0.407 0.96 (0.89 to 1.03) 0.287 
  >20 years 0.7 (-0.1 to 1.5) 0.094 1.06 (0.97 to 1.16) 0.179 
Comorbidities 
  Hypertension 1.5 (1.1 to 1.9) <0.001 1.16 (1.11 to 1.21) <0.001 
  Myocardial infarction -1.1 (-1.8 to -0.4) 0.001 0.90 (0.84 to 0.97) 0.007 
  Stroke or TIA -0.8 (-1.5 to -0.2) 0.013 0.90 (0.83 to 0.96) 0.003 
  CKD stages 3-5 0.8 (0.3 to 1.2) 0.001 1.08 (1.02 to 1.14) 0.004 
Number of previous oral glucose lowering medications 
  None 0.0 [reference] 
 
1.00 [reference] 
 
  One -1.1 (-1.6 to -0.6) <0.001 0.89 (0.85 to 0.94) <0.001 
  Two -1.7 (-2.5 to -1.0) <0.001 0.85 (0.78 to 0.92) <0.001 
  Three or more -3.2 (-4.3 to -2.1) <0.001 0.80 (0.70 to 0.90) <0.001 
Number of concurrent oral glucose lowering medications 
  None 0.0 [reference] 
 
1.00 [reference] 
 
  One 0.2 (-0.3 to 0.8) 0.405 1.03 (0.97 to 1.09) 0.301 
  Two or more 1.4 (0.8 to 2.0) <0.001 1.19 (1.11 to 1.28) <0.001 
Medication class 
  Metformin 0.0 [reference] 
 
1.00 [reference] 
 
  Thiazolidinediones 4.4 (3.3 to 5.4) <0.001 1.65 (1.44 to 1.88) <0.001 
  Sulfonylureas 1.3 (0.9 to 1.8) <0.001 1.15 (1.09 to 1.21) <0.001 
  Meglitinides 2.1 (-2.2 to 6.4) 0.338 1.05 (0.66 to 1.66) 0.846 
  Alpha-glucosidase inhibitors 2.7 (-2.6 to 7.9) 0.319 1.32 (0.73 to 2.38) 0.358 
  DPP4 inhibitors 3.4 (2.8 to 4.0) <0.001 1.43 (1.34 to 1.52) <0.001 
  SGLT2 inhibitors 4.8 (3.7 to 5.8) <0.001 1.47 (1.31 to 1.66) <0.001 
Table 20. Linear and logistic regression analysis of factors associated with medications adherence. 
For the regression model the impact on the PDC (%) is shown as the parameter estimate (the increase in PDC per unit of the predictor 
variable). For the logistic regression model the odd ratio (OR) for adherence (PDC>80%) is reported. Linear regression model R2 = 0.065. 
Logistic regression model area under the ROC curve = 0.652. 
 
The linear model failed multiple model diagnostic tests demonstrating a substantial association between the 
model residuals and predictor variables, heteroskedasticity, and a non-normal distribution of residuals. Various 
transformations of the outcome variable were attempted but they did not resolve these issues. The results of 
the linear regression model should therefore be treated with extreme caution and it is presented for comparison 
only. There were no such problems with the logistic regression model. 
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4 DISCUSSION 
4.1  SYSTEMATIC REVIEW OF COMPARITIVE MEDICATIONS PERSISTENCE AND ADHERENCE 
The systematic review identified many studies which compare adherence across different medication classes in 
people with T2D. When measured as the adherence proportion (MPR or PDC) sulfonylureas and TZDs had better 
adherence than metformin and TZDs marginally better than sulfonylureas. When measured as OR for non-
adherence there were no significant differences. DPP4 inhibitors generally had better adherence and persistence 
than sulfonylureas and TZDs. Data on meglitinides and AGIs was limited, although adherence appears lower than 
other therapies. Data on SGLT2 inhibitors were also limited but appears to indicate good persistence. Compared 
to oral therapies GLP1 receptor agonists had lower adherence than DPP4 inhibitors and SGLT2 inhibitors, and 
shorter persistence than sulfonylureas and DPP4 inhibitors. They also had shorter persistence than long acting 
analogue insulins. Long acting insulin analogues had better persistence than human insulins. Methods for 
defining adherence and persistence were highly variable and all meta-analyses demonstrated a high degree of 
heterogeneity. 
The differing results when pooling adherence reported as a percent and adherence reported as an odds ratio 
are difficult to interpret. It is plausible that measuring adherence as a percentage (MPR or PDC) provides a more 
precise way to gauge differences in medication adherence. Whilst there was a high degree of heterogeneity in 
the mean difference in adherence where studies compared metformin, sulphonylureas, and TZDs, the overall 
trends were broadly consistent. 
4.1.1  LIMITATIONS OF THE EXISTING DATA 
The primary limitation of existing adherence and persistence research is the ongoing lack of a universal 
definitions of adherence and persistence. The majority of studies in this area use prescription records to infer 
medication use and yet there is a huge variety in the methods used to calculate these measures. This limits the 
comparability of studies and increases the risk of selective reporting. 
The use of MPR and PDC by most studies is also a limitation, with few studies providing a direct measure of 
medication use. However, where both indirect and direct measures were used to make the same comparison, 
results were generally consistent. 
Several important comparisons were not found: Very few studies compared adherence across different 
injectable therapies. This may be because adherence is difficult to calculate from prescription records. Most 
insulin and GLP1 receptor analogue studies only considered treatment persistence. There was also limited data 
available on comparative adherence to SGLT2 inhibitors. This is likely to become available in time and has been 
presented in the real-world analysis here. Given the heterogeneity between studies of this type no firm 
conclusions can be derived from any one study.  
The vast majority of studies were funded by pharmaceutical companies. This may increase the risk of bias 
towards results favouring newer pharmacotherapies, although we were not able to assess this in any meta-
analysis other than for comparison of persistence between GLP1 receptor agonists and long acting insulin 
analogues. For this comparison no evidence of publication bias was identified. 
4.1.2  RESEARCH RECOMMENDATIONS 
One important implication for future research is the current lack of consistent definitions of medication 
adherence and persistence. The real-world data presented here demonstrate that the mean value of adherence 
is not an appropriate measure and therefore all study should report the median value. As PDC has been 
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recommended as more appropriate measure than MPR for reporting adherence this measure should be used in 
all future research.76 We suggest that where an adjusted measure of adherence is used the associated 
unadjusted values should also be reported for comparison. Other factors important to report are method used 
to account for medication switching within classes, and the method used to identify the duration of each 
prescription. 
4.2 REAL-WORLD DATA ANALYSIS OF MEDICATIONS PERSISTENCE 
The real-world data analysis concurred with the systematic review in that it demonstrated that medication 
persistence with glucose lowering agents differs considerably between classes; persistence with metformin was 
significantly longer than with all other medication classes except SGLT2 inhibitors. Only metformin, 
sulfonylureas, and SGLT2 inhibitors had more than 50% persistence at two years. AGIs have the highest rates of 
non-persistence in clinical practice. Younger people and people of non-white ethnicity had the lowest 
medication persistence. 
The effect size for influence on medication persistence was largest for medication class. This suggests that the 
class of medication used is a major factor influencing the duration of a selected treatment in T2D. Whilst this 
finding may be unsurprising it has important implications. Careful selection of second line therapy after 
metformin, with preference for therapies which have longer treatment persistence, may facilitate better long 
term diabetes control. However, medication persistence is not uniformly positive. For instance, extended 
duration of sulphonylureas may not be beneficial as the effects of treatment wane over time when compared 
to those of an insulin independent therapy.243 244 Similarly, reduced persistence in those with HbA1c less than 
42mmol/mol suggests appropriate discontinuation in those at risk of hypoglycaemia. 
4.2.1  COMPARISON WITH THE LITERATURE 
The findings concurred with previous analyses that demonstrated reduced medication adherence in women.108 
109 245 246  This correlation with reduced duration of mediation persistence remained after adjustment for other 
factors. The identified differences in medication persistence between people of different ethnicities should be 
cause for concern. It has previously been reported that ethnic minorities have reduced medication adherence,108 
112 113 but no previous study has adjusted for socioeconomic status. The finding that these differences are still 
substantial in a healthcare system free at the point of delivery, and after adjusting for socioeconomic status, is 
an important finding. This is particularly so, given that a number of the ethnic groups with shorter medication 
persistence have a higher prevalence of diabetes and diabetes related complications.247 These observed 
differences merit further investigation. In particular, identification of possible causes for this disparity. 
The findings also concurred with previous studies which found that the presence of depression and other 
comorbidities was associated with reduced medication adherence.110 120 123 129 However, we found that 
hypertension was associated with slightly longer persistence which has not been previously reported. The 
reasons for this association are unclear. The findings also concurred with others which have demonstrated 
reduced adherence and persistence in younger people with T2D.108 109 245 246 248 We have extended these previous 
analyses to demonstrate that the association with persistence is non-linear; there is substantially reduced 
medication persistence under 30 years old when compared to the other age groups. This may represent lifestyle 
factors, or be due to early beta-cell failure or misdiagnosis of diabetes aetiology (e.g. misdiagnosed type 1 
diabetes with a need for early escalation of therapy).249 
No comparison of medication persistence across all groups of diabetes medications has previously been 
performed. Our data suggest that medication class is the major influencing factor on medication persistence, 
which is readily identifiable from the EPR. 
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4.2.2  STRENGTHS AND LIMITATIONS 
The large population size, long duration of follow-up and completeness of the patient record are the main 
strengths of this analysis. In particular, the availability of a recognised measure of socioeconomic status and of 
previous and concurrent medication numbers add validity to the conclusion that medication class is the major 
influencing factor in medication persistence. 
Non-persistence is defined retrospectively with a non-persistence event only identified 90 days after the last 
medication prescription. This may have artificially inflated the apparent persistence for medications which have 
not been available for a long time period such as the SGLT2 inhibitors. Re-evaluation of persistence rates with 
these medications is needed as more data becomes available. Our inclusion of drug switching within a class as a 
non-persistence event may mean our data shows lower persistence rates than others who have not included 
this. In the absence of a formal definition we have chosen this method to fit best with previous 
recommendations.69 
We were unable to adjust for some factors which have been shown to be associated with medication adherence 
or persistence such as proximity to pharmacy, continuity of care, and level of trust in healthcare provider.130 131 
133  However, it is unlikely that the inclusion of these factors would substantially alter the associations identified 
here. 
4.3 REAL-WORLD DATA ANALYSIS OF MEDICATIONS ADHERENCE 
The median adherence levels with diabetes medications which have been established was surprisingly good with 
a median PDC of 95.1% (IQR: 78.9-100.0%). After adjustment for identified confounders adherence was better 
than metformin with TZDs, sulfonylureas, DPP4 inhibitors, and SGLT2 inhibitors. No significant difference 
between metformin adherence and meglitinides or AGIs was identified. The highest levels of adherence were 
seen with TZDs, DPP4 inhibitors, and SGLT2 inhibitors. Age was the strongest predictor of medication adherence 
followed by medication class. 
4.3.1  COMPARISON WITH THE LITERATURE 
Most of the published adherence literature reports a lower level of medications adherence with oral medications 
in T2D than identified here.85 86 There are several possible reasons for this discrepancy. Firstly, most studies 
report adherence within the first year of medication use in contrast to the cross-sectional approach used here. 
It is likely that a large proportion of people with poor initial adherence within the first year will have the 
medication switched or discontinued and therefore those who continue to take the medication for a longer 
period are more likely to have a greater level of adherence. Secondly, a large number of medication adherence 
studies are undertaken in the USA using health claims databases.85 86 These databases predominantly include 
people under the age of 65 who have lower levels of adherence. Analysis of medication adherence for the 
complete T2D population with therefore demonstrate a higher median adherence level. Medication costs, and 
other healthcare access barriers outside the UK may also contribute to differing levels of reported adherence.82 
114 Finally, the use of medication prescriptions used here may overestimate the level of medication adherence 
when compared to medication dispensing records used in some studies. The levels of adherence we reported 
however are consistent with those reported in a very similar large study in Sweden.199 
4.3.2  STRENGHTS AND LIMITATIONS 
As with the medication persistence analysis the major strengths of this analysis are the large population size and 
the completeness of the dataset. Again the ability to adjust for socioeconomic status and ethnicity in the 
majority of the cohort is another major strength as these have been previously identified a major predictors of 
medication adherence.108 109 112 113 118  
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As already discussed the use of medication prescriptions to estimate medication adherence may lead to an 
overestimate of medication use. It is likely that this overestimate is a systematic error which applies equally to 
all medication classes and should therefore not invalidate the comparison between medication classes. We have 
not been able to formally test this assertion however as no medication dispensing data were available. 
Additional limitations include the relatively small number of people taking meglitinides, AGIs, and SGLT2 
inhibitors; the inability to determine medication adherence from older prescribing data; and the differential 
ability to identify prescription durations for different medication classes. 
The small number of people taking meglitinides, AGIs, and SGLT2 inhibitors means the parameter estimates for 
these medications have wide confidence intervals. Despite these it is still apparent that SGLT2 inhibitors have a 
higher level of adherence than metformin. 
Due to the difficulties in correctly determining prescription durations from older prescribing data (described in 
section 2.2.8) robustly determining a PDC for data predating 2015 was not reliably possible. This meant the 
planned analysis of measuring adherence for each medication class over the first year of use, was not possible. 
This may mean that there are some residual confounding effects relating to the duration of medication use or 
the stage at which it has been prescribed in the disease process which are not captured by counting the number 
of preceding and concurrent diabetes medications. The advantage of this approach is that it provides a 
contemporary overview of medication adherence and comparative adherence across classes which would not 
be captured using the analysis originally planned. 
The ability to determine all prescription durations (during 2016) for varied by medication class (Table 17) from 
56.9% of people taking meglitinides to 93.7% for sulphonylureas. The reasons for the inability of the duration 
calculating algorithm to determine the duration of a prescription varied by medication class. For metformin a 
large proportion of these were caused by directions describing dosing changes e.g. “1 DAILY, INCREASE AS 
DIRECTED BY DIABETES SPECIALIST NURSE; OD WITH MAIN MEAL”. With meglitinides there were several 
common reasons for the inability of the algorithm to determine the duration of prescriptions: inclusion of the 
number of minutes before a meal that the medication should be taken (this was counted a number-frequency 
mismatch at the final step of the algorithm) e.g. “1 THREE TIMES A DAY TAKE 1/2 HOUR BEFORE MAIN MEALS”, 
unclear directions e.g. “1 WITH EACH MAIN MEAL 2 DAILY” and the lack of a described frequency e.g. “ONE 30 
MINS BEFORE FOOD”. It is unclear what impact these differences in the proportions of patients with a calculable 
PDC may have had on the comparisons between medication classes. It is plausible that those with more 
complicated (and therefore not processed) directions may have lower medication adherence. If this conjecture 
is true then the adherence to metformin, meglitinides, and AGIs is lower than reported. 
4.4 COMBINING THE LITERATURE AND REAL-WORLD DATA 
Results from the systematic review and the real-world observational cohorts were broadly consistent for 
comparisons of adherence to oral medications. Adherence was found to vary by medication class with 
metformin, AGIs, and meglitinides having low adherence, sulphonylureas intermediate, and TZDs, DPP4 
inhibitors, and SGLT2 inhibitors high (Figure 21). The only notable discrepancy between the systematic review 
and the real-world observational data was that the review found DPP4 inhibitor adherence to be higher than 
that of TZDs whereas the real-world analysis found them to have similar adherence. No paper reporting 
comparative SGLT2 adherence was found during the systematic review. 
The systematic review found few papers reporting persistence with oral medications except for comparisons 
between metformin and sulphonylureas, and sulphonylureas and DPP4 inhibitors. Three of four identified 
studies comparing persistence between metformin and sulphonylureas reported longer persistence with 
metformin197 201 205 which was consistent with our real world data. Most studies identified in the review which 
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compared persistence in sulphonylureas and DPP4 inhibitors found longer persistence with DPP4 inhibitors179 
193 207-210 which was also consistent with the real-world analysis. The real-world analysis provided additional 
comparisons not available in the existing literature. An overview of relative persistence for oral medications 
(summarising the review and real-world data) is shown in Figure 22. 
 
 
Figure 21. The approximate relative adherence for all major classes of oral medications. 
 
 
Figure 22. The approximate relative persistence for all major classes of oral medications. 
 
Comparing both persistence and adherence across classes; AGIs and meglitinides have both poor adherence and 
persistence, DPP4 inhibitors and SGLT2 inhibitors have good adherence and persistence, and sulphonylureas 
have modest adherence and persistence. Metformin has low adherence but long persistence and conversely 
TZDs have short persistence but good adherence. The reasons for these trends are likely to be multifactorial. 
Limited adherence and persistence with AGIs and meglitinides is likely to be due to the frequent dosing schedule 
required (often with each meal) and high frequency of adverse effects in these classes. Meglitinides can cause 
hypoglycaemia and weight gain and AGIs commonly cause gastrointestinal disturbance (flatulence and 
diarrhoea).176 By contrast SGLT2 inhibitor and DPP4 inhibitors require only once daily dosing and are relatively 
well tolerated. DPP4 inhibitors also have very few commonly reported side effects which may also be a reason 
for good and adherence and long persistence.250 251 They are generally considered to be weight neutral and do 
not cause hypoglycaemia.252 SGLT2 inhibitors can cause genital candidiasis and polyuria.253-256 However, the 
genital infections are readily treated with standard antifungals and these adverse effects have been shown to 
be relatively well tolerated by patients and do not generally cause discontinuation.256 SGLT2 inhibitors also do 
not cause hypoglycaemia.252 Furthermore, SGLT2 inhibitors tend to result in modest weight loss253-255 257 which 
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as a tangible effect to the patient may lead to improved medication adherence. It is also plausible that patients 
currently using SGLT2 inhibitors are early adopters (as this is the newest therapy class) and therefore have 
slightly different characteristics to others with T2D. The increased adherence to this class may therefore 
represent the characteristics of the patient users rather than the medication. 
Adherence to sulphonylureas may be limited by the need for multiple daily dosing in some cases and by a higher 
frequency of adverse events than seen with DPP4 inhibitors.258 Sulphonylureas can cause weight gain and 
hypoglycaemic episodes.176 252 259 Additionally the glycaemic efficacy of sulphonylureas deteriorates more rapidly 
than with other oral therapies,243 260 which may in part explain their slightly shorter persistence duration. 
The high level of adherence to TZDs (pioglitazone) is surprising. TZDs tend to cause weight gain and peripheral 
oedema, although they have fewer gastrointestinal side effects than metformin and lower hypoglycaemia risk 
than sulphonylureas.260 Following concerns around a possible increased cardiovascular risk with rosiglitazone 
and it’s withdrawal from several global markets this medication class has lost favour.261 262 These and other 
concerns around the risk of heart failure, fractures, and bladder cancer may be the reason for a shorter duration 
of persistence than would be expected given the high level of medication adherence.262 
The disparities between the long duration of persistence with metformin and the relatively low level of 
adherence is perhaps less surprising. Metformin is advocated in most guidelines internationally as the first 
choice for first line therapy in most people with T2D.176 263 It is also highly regarded given the demonstration in 
the UKPDS trial of possible long-term cardiovascular benefits.13 Furthermore metformin is the most widely 
prescribed diabetes medication and therefore will have a high level of widespread clinical experience.176 262 A 
combination of these factors is probably likely to explain the long duration of prescribing persistence despite 
relatively low adherence. Low adherence may be attributable to the common requirement for multiple daily 
dosing and the high frequency of gastrointestinal symptoms.176 260 
The real-world proportion of the analysis did not investigate injectable therapies and therefore a comparison 
with the data from the systematic review is not possible. Papers identified by the systematic review almost 
universally only investigated medication persistence or discontinuation with injectable therapies. This is 
probably due to the difficulties in calculating a reliable measure of medication adherence to injectable therapies 
from prescription records as already described. With variable dosing being widely used with insulin it is not 
possible accurately determine the appropriate coverage of any insulin prescription. Given the discrepancies 
identified between persistence and adherence with oral therapies is should not be considered appropriate to 
make any assumptions about adherence to injectable therapies from persistence data. The persistence data 
from paper identified in the systematic review fairly consistently report that long acting analogue insulins have 
longer persistence than GLP1 receptor agonists and medium acting human insulins. 
4.4.1  IMPLICATIONS FOR CLINICAL PRACTICE 
These findings have several immediate implications for clinical practice. The data suggest that medication class 
selection in people with type 2 diabetes could facilitate improved medication adherence. Whilst this assertion 
should be tested directly before it can be confirmed, these data are supportive of this approach, especially where 
there is otherwise clinical equipoise in class selection. 
For oral medication selection, these data would favour the use of TZDs, DPP4 inhibitors, or SGLT2 inhibitors 
where medication adherence is an important concern. The regression models also support previous research in 
identifying younger people with diabetes to be at the highest risk of non-adherence. In addition, people of non-
white ethnicity, people from lower socioeconomic backgrounds, and people with a history of medication non-
persistence are also more likely to be non-adherent. Pre-emptively selecting medications which facilitate 
adherence in these groups may be advantageous and lead to improved glycaemic outcomes. 
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The data also suggest that metformin is continually prescribed (as demonstrated by the long persistence) despite 
relatively low adherence. It is possible that this long duration of use is inappropriate for some metformin users 
who will not be achieving the glycaemic benefits of the medication given their suboptimal use. In these people 
there may be scope to improve glycaemic control by switching metformin for another medication class. 
For injectable medication selection the data favour the use of insulin analogues over human insulin or GLP1 
receptor agonists where a long duration of use is required. There are not enough data to make inferences about 
the impact that injectable class section might have on adherence levels. 
4.4.2  FURTHER RESEARCH 
Many avenues for future research could be suggested from these data however there two key areas which are 
worth outlining briefly. If class switching as a possible means of improving medication adherence is to be 
confirmed then further data are needed. Ideally an interventional study, with randomisation to class switching 
or continuation of people with T2D and low medication adherence would be undertaken. Failing this additional 
observational evidence could be provided in the form of a case control analysis comparing adherence in people 
with pre-existing low adherence levels in those who continued the low adherence medication compared with 
those who were switched. Whilst the latter of these investigations would be easier to undertake it would be 
extremely difficult to exclude confounders and even with careful study design residual confounding could not 
be completed excluded. 
A second area for future investigation is the influence of ethnicity on adherence and persistence. With both 
adherence and persistence ethnicity appears to be a major influencing factor. People of non-white ethnicities 
have substantially lower adherence rates and shorter persistence than those of white ethnicities. These 
differences persist after adjustment for socioeconomic status. The reasons for these differences should be 
identified. Whilst additional observational analysis may provide some clues as to the underlying reasons for 
these discrepancies, a qualitative research programme would be an appropriate next step. 
 
5 CONCLUSIONS 
Adherence and persistence vary considerably across the different medication classes used for treatment of T2D. 
Of the oral therapies, AGIs and meglitinides have low adherence and persistence, DPP4 inhibitors and SGLT2 
inhibitors have good adherence and persistence, and sulphonylureas have modest adherence and persistence. 
Metformin has low adherence but long persistence and conversely TZDs have short persistence but good 
adherence. Of the injectable therapies, analogue insulins have longer persistence than human insulins and GLP1 
receptor analogues. The reasons for these trends are likely to include the adverse effect profiles of each 
medication class, and daily dosing frequencies. There is little available data comparing adherence across classes 
of injectable therapies and the existing data are limited by the lack of a clear definition of adherence and 
persistence. Other than medication class important factors associated with reduced medication persistence and 
adherence are female gender, younger age, and non-white ethnicity. 
Medication class selection or switching is a promising approach to improving adherence in people with T2D. 
Switching to medications which facilitate a higher level of adherence such as TZDs, DPP4 inhibitors, or SGLT2 
inhibitors may lead to improved adherence and improved glycaemic control. Pre-emptive selection of these 
agents in people with a higher risk for non-adherence such as younger patients and those of non-white ethnicity 
may also improve adherence although further investigation is required to confirm this assertion. 
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7 APPENDICIES 
7.1 APPENDIX 1: SEARCH STRATEGY FOR SYSTEMATIC REVIEW 
The search strategy which will be used to search the MEDLINE database. This strategy will be adapted to apply 
to the other included databases. 
Type 2 diabetes 
1. Diabetes Mellitus, Type 2 [MeSH, all subheadings and categories included]  
2. (type* ADJ3 ("2" OR "II" OR two*) ADJ3 (diabete* OR diabetic*)).ti,ab 
3. ((non-insulin* OR (non ADJ1 insulin*) OR noninsulin*) ADJ3 depend* ADJ3 (diabete* OR 
diabetic*)).ti,ab 
4. ((maturit* OR adult* OR slow*) ADJ3 onset* ADJ3 (diabete* OR diabetic*)).ti,ab 
5. ((ketosis-resistant* OR stable*) ADJ3 (diabete* OR diabetic*)).ti,ab 
6. NIDDM.ti,ab 
7. 1 OR 2 OR 3 OR 4 OR 5 OR 6 
Medication adherence OR persistence 
8. Medication Adherence [MeSH, all subheadings and categories included]  
9. Patient Dropouts [MeSH, all subheadings and categories included]  
10. Patient Compliance [MeSH, all subheadings and categories included]  
11. Patient Participation [MeSH, all subheadings and categories included] 
12. Patient Preference [MeSH, all subheadings and categories included]  
13. Treatment Refusal [MeSH, all subheadings and categories included]  
14. ((complianc* OR  non-complianc* OR noncomplianc*) ADJ6 (treatment* OR medication* OR 
therapy* OR therapies OR regimen)).ti,ab 
15. ((complianc* OR  non-complianc* OR noncomplianc*) ADJ3 patient*).ti,ab 
16. ((adherenc* OR non-adherenc* OR nonadherec*) ADJ6 (treatment* OR medication* OR therapy* 
OR therapies OR regimen)).ti,ab 
17. ((adherenc* OR non-adherenc* OR nonadherec*) ADJ3 patient*).ti,ab 
18. ((persistenc* OR cooperat* OR co-operat* OR concordanc*) ADJ6 (treatment* OR medication* OR 
therapy* OR therapies OR regimen)).ti,ab 
19. ((persistenc* OR cooperat* OR co-operat* OR concordanc*) ADJ3 patient*).ti,ab 
20. ((refusal OR withdrawal OR discontinu*) ADJ3 (treatment* OR medication* OR therapy* OR 
therapies OR regimen)).ti,ab 
21. ((dropout* OR (drop* ADJ1 out*)) ADJ3 patient*).ti,ab 
22. 8 OR 9 OR 10 OR 11 OR OR 12 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 
Study types 
23. Clinical Trial [MeSH, all subheadings and categories included]  
24. Case-control Studies [MeSH, all subheadings and categories included]  
25. Retrospective Studies [MeSH, all subheadings and categories included]  
26. Cohort Studies [MeSH, all subheadings and categories included]  
27. Longitudinal Studies [MeSH, all subheadings and categories included]  
28. Follow-up Studies [MeSH, all subheadings and categories included]  
29. Prospective Studies [MeSH, all subheadings and categories included]  
30. (clinical ADJ3 trial).ti,ab 
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31. cohort.ti,ab 
32. longitudinal.ti,ab 
33. (“follow up” OR followup OR follow-up).ti,ab 
34. prospective.ti,ab 
35. retrospective.ti,ab 
36. “comparison group”.ti,ab 
37. “control group”.ti,ab 
38. observational.ti,ab 
39. nonrandom*.ti,ab 
40. random*.ti,ab 
41. 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37 OR 
38 OR 39 OR 40 
Final Medline list for analysis 
42. 7 AND 22 AND 41 
43. 42 excluding non-English language studies 
44. 43 excluding results prior to 2006 
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7.2 APPENDIX 2: THE NEWCASTLE-OTTAWA QUALITY ASSESSMENT SCALE FOR COHORT STUDIES 
The Newcastle – Ottawa quality assessment scale for cohort studies – adapted to assess the quality of studies 
comparing medication adherence or persistence in people with type 2 diabetes. 
 
Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Outcome 
categories. A maximum of two stars can be given for Comparability 
 
Selection 
1) Representativeness of the exposed cohort 
a) truly representative of the average person with type 2 diabetes in the community   
b) somewhat representative of the average person with type 2 diabetes in the community  
c) selected group of users e.g. nurses, volunteers 
d) no description of the derivation of the cohort 
2) Selection of the comparator cohort (comparator medication class users) 
a) all drawn from the same community 
b) drawn from a different source 
c) no description of the derivation of the non-exposed cohort  
3) Ascertainment of medication use 
a) secure record (eg primary care records)  
b) structured interview  
c) self-report 
d) no description 
4) Measurement of outcome from first prescription 
a) yes  
b) no 
Comparability 
1) Comparability of cohorts on the basis of the design or analysis (maximum two stars) 
a) study controls for patient demographics  
b) study controls for any additional factor   
Outcome 
1) Assessment of outcome  
a) direct measurement (e.g. medication adherence monitoring device)   
b) indirect measurement (e.g. prescription refills)  
c) self-report  
d) no description 
2) Was follow-up long enough for outcomes to occur 
a) yes (12 months or longer)  
b) no 
3) Adequacy of follow up of cohorts 
a) complete follow up - all subjects accounted for   
b) subjects lost to follow up unlikely to introduce bias - small number lost - > 10% follow up, or description 
provided of those lost)  
c) follow up rate < 90% (select an adequate %) and no description of those lost 
d) no statement 
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7.3 APPENDIX 3: PUBLICATIONS I 
Publications and other research outputs produced during the research tenure with direct applicability to the 
research question. 
Manuscripts in preparation/peer review 
McGovern A, Hinton W, Calderara S, Munro N, Whyte M, de Lusignan S. A class comparison of medication 
persistence in people with type 2 diabetes: A retrospective cohort study. (under peer review [Dec 2017]) 
Peer reviewed publications  
McGovern AP, Tippu Z, Hinton W, Munro N, Whyte M, de Lusignan S. A comparison of adherence and persistence 
by medication class in type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2017 Nov 
14. doi: 10.1111/dom.13160. [Epub ahead of print] 
 Tippu, Z., Correa, A., Liyanage, H., Burleigh, D., McGovern, A., Van Vlymen, J., Jones, S., & de Lusignan, S. (2017). 
Ethnicity Recording in Primary Care Computerised Medical Record Systems: An Ontological Approach. J Innov 
Health Inform, 23(4), 799–806. doi:10.14236/jhi.v23i4.920 
McGovern AP, Hinton W, Correa A, Munro N, Whyte M, de Lusignan S. Real-world evidence studies into 
treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in 
the UK. BMJ Open (2016). 6(11):e012801 doi:10.1136/bmjopen-2016-012801. PMID: 27884846 
Correa A, Hinton W, McGovern AP, van Vlymen J, Yonova I, Jones, S. de Lusignan S. Royal College of General 
Practitioners Research and Surveillance Centre (RCGP RSC) sentinel network: a cohort profile. BMJ Open (2016). 
6(4):e011092. doi:10.1136/bmjopen-2016-011092. PMID: 27098827 
McGovern AP, Tippu Z, Hinton W, Munro N, Whyte M, de Lusignan S. A systematic review of adherence rates by 
medication class in type 2 diabetes: Study protocol. BMJ Open (2016). 6(2):e010469 doi:10.1136/bmjopen-
2015-010469. PMID: 26928029 
Published letters 
McGovern A, Hinchliffe R, Munro N, de Lusignan S. Basing approval of drugs for type 2 diabetes on real world 
evidence. BMJ (2015). 3;351:h5829. doi: 10.1136/bmj.h5829. PMID: 26530057 
Oral presentations 
McGovern A, Hinton W, Tippu Z, Whyte M, de Lusignan S. Ethnic disparities in medication persistence in type 2 
diabetes: Non-whites have reduced persistence [Presentation]. American Diabetes Association's 76th Scientific 
Sessions. New Orleans, USA. June 11th, 2016. 
Poster presentations 
McGovern A, Hinton W, Curtis BH, van Brunt K, Calderara S, de Lusignan S. Differences in persistence by class of 
oral therapy for the treatment of type 2 diabetes [Poster]. 52nd EASD Annual Meeting, Munich, Germany, 12–
16th September, 2016. 
McGovern A, Hinton W, van Vlymen J, Munro N, Whyte M, de Lusignan S. Real world evidence on the prescribing 
trends in sodium glucose co-transporter 2 inhibitors in UK primary care [Poster]. Diabetes UK Professional 
Conference. Glasgow, UK. March 2-4th, 2016. 
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Hinton W, McGovern A, van Vlymen J, Munro N, Whyte M, de Lusignan S. Real world evidence on the prescribing 
trends of glucagon-like peptide-1 agonists in UK primary care [Poster]. Diabetes UK Professional Conference. 
Glasgow, UK. March 2-4th, 2016. 
Tippu Z, Liyanage H, Correa A, Burleigh D, McGovern A, Jones S, de Lusignan S. Ontologies to improve the 
identification of ethnicity in people with type 2 diabetes [Poster]. Diabetes UK Professional Conference. Glasgow, 
UK. March 2-4th, 2016. 
McGovern A, Hinton W, van Vlymen J, Munro N, Whyte M, de Lusignan S. Real world evidence on the disparities 
of prescribing of dipeptidyl peptidase-4 inhibitors in UK primary care [Poster]. Diabetes UK Professional 
Conference. Glasgow, UK. March 2-4th, 2016. 
 
7.4 APPENDIX 4: PUBLICATIONS II 
Additional publications and other research outputs achieved during the tenure of the MD but not directly 
relevant to the research question. These projects have been indirectly important in improving the quality of the 
data extracted from the research database, and in developing my personal research skills (including skills in 
project development, management, and supervision). 
Manuscripts in preparation/peer review/in press 
Hayward N, McGovern A, Arrowsmith B, Cole N, Hinton W, de Lusignan S, Jones S. Low, high, and high-normal 
serum phosphate predict cardiac events: An observational study. PLOS ONE (accepted: in press [Dec 2017]). 
Rayner LH, McGovern A, Sherlock J, Gatenby P, Correa A, Creagh-Brown B, de Lusignan S. The impact of therapy 
on the risk of asthma in type 2 diabetes: A retrospective nested case control study over eight years. (under peer 
review [Dec 2017]) 
Rayner LH, McGovern A, Creagh-Brown B, Woodmansey C, de Lusignan S. Type 2 diabetes and asthma: 
systematic review of the bidirectional relationship. (under peer review [Dec 2017]) 
Ansari AS, de Lusignan S, Hinton W, Munro N, McGovern A. Understanding the relationship between diabetes, 
retinopathy, glycaemic control, acute uveitis, and scleritis: A cohort database study. (under peer review [Dec 
2017]) 
Kumar S, de Lusignan S, McGovern A, Correa C, Van Vlymen J, Hriskova M, Gatenby P, Jones S, Goldsmith D. 
Ischaemic stroke, haemorrhage and mortality in elderly patients with chronic kidney disease receiving 
anticoagulation for atrial fibrillation: a population-based study from UK primary care. (under peer review [Dec 
2017]) 
Rayner LH, McGovern A, Sherlock J, Gatenby P, Correa A, Creagh-Brown B, de Lusignan S. Type 2 Diabetes: A 
Protective Factor for COPD?. (under peer review [Dec 2017]) 
Peer reviewed publications 
Woodmansey C, McGovern AP, McCullough KA, Whyte MB, Munro N, Correa AC, Gatenby PAC, Jones SA, de 
Lusignan S. Incidence, Demographics, and Clinical Characteristics of Diabetes of the Exocrine Pancreas (Type 3c): 
A Retrospective Cohort Study. Diabetes Care (2017) [ahead of print]. doi; 10.2337/dc17-0542. 
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10.1016/j.pcd.2017.05.009. PMID: 28648963 
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